UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~FORM 10-Q~~

☒

FORM 10-Q

�� QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2023

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission file number: 333-232426

Crown Electrokinetics Corp.

(Exact name of registrant as specified in its charter)

Delaware		47-5423944
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1110 NE Circle Blvd., Corvallis, Oregon 97330

(Address of principal executive offices) (Zip Code)

213.660.4250

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of common stock, $0.0001 par value per share, outstanding as of ~~August 22,~~November 13, 2023 was ~~3,018,533.~~12,636,555.

Common Stock, $0.0001 par value

CRKN

The Nasdaq Capital Market

CROWN ELECTROKINETICS CORP.

		Page
PART I - FINANCIAL INFORMATION

Item 1.	Consolidated Financial Statements (Unaudited)	1

	Condensed Consolidated Balance Sheets as of ~~June~~September 30, 2023 (Unaudited) and December 31, 2022	1

	Condensed Consolidated Statements of Operations for the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2023 and 2022 (Unaudited)	2

	Condensed Consolidated Statements of Stockholders’ Equity for the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2023 and 2022 (Unaudited)	3

	Condensed Consolidated Statements of Cash Flows for the ~~Six~~Nine Months Ended ~~June~~September 30, 2023 and 2022 (Unaudited)	7

	Notes to the Condensed Consolidated Financial Statements (Unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	37	29

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	5037

Item 4.	Controls and Procedures	5037

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	51	38

Item 1A.	Risk Factors	51	38

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	51	38

Item 3.	Defaults Upon Senior Securities	51	38

Item 4.	Mine Safety Disclosures	51	38

Item 5.	Other Information	51	38

Item 6.	Exhibits	51	39

	~~Signatures~~	52Signatures		40

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties.

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements.

CROWN ELECTROKINETICS CORP.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

June 30,
2023 December 31,
2022
(Unaudited)
ASSETS
Current assets:
Cash $ 36 $ 821
Prepaid and other current assets 756 590
Total current assets 792 1,411
Property and equipment, net 2,366 1,409
Intangible assets, net 1,688 1,598
Right of use asset 797 1,842
Goodwill 652 -
Deferred debt issuance costs 5,819 150
Other assets 33 180
TOTAL ASSETS $ 12,147 $ 6,590

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable $ 1,822 $ 865
Accrued expenses 408 621
Lease liability - current portion 484 574
Warrant liability 2,721 972
Notes payable at fair value 1,470 1,654
Notes payable 330 8
Total current liabilities 7,235 4,694
Lease liability - non-current portion 355 1,366
Total liabilities 7,590 6,060

Commitments and Contingencies (Note 14)

STOCKHOLDERS’ EQUITY:
Preferred stock, par value $0.0001; 50,000,000 shares authorized, no shares outstanding - -
Series A preferred stock, par value $0.0001; 300 shares authorized, 251 shares outstanding as of June 30, 2023 and December 31, 2022; liquidation preference $260 as of June 30, 2023 and 0 as of December 31, 2022 - -
Series B preferred stock, par value $0.0001; 1,500 shares authorized, 1,443 shares outstanding as of June 30, 2023 and December 31, 2022; liquidation preference $1,492 as of June 30, 2023 and 0 as of December 31, 2022 - -
Series C preferred stock, par value $0.0001; 600,000 shares authorized, 500,756 shares outstanding as of June 30, 2023 and December 31, 2022; liquidation preference $511 as of June 30, 2023 and 0 as of December 31, 2022 - -
Series D preferred stock, par value $0.0001; 7,000 shares authorized, 0 shares issued and outstanding as of June 30, 2023 and 1,058 as of December 31, 2022; liquidation preference 0 as of June 30, 2023 and $1,113 as of December 31, 2022 - -
Series E preferred stock, par value $0.0001; 77,000 shares authorized, 21,000 shares committed pending shareholder approval as of June 30, 2023 and no shares outstanding as of December 31, 2022 - -
Series F preferred stock, par value $0.0001; 9,073 shares authorized, 5,251 shares outstanding as of June 30, 2023 and no shares outstanding as of December 31, 2022 -
Series F-1 preferred stock, par value $0.0001; 9,052 shares authorized, 3,583 shares outstanding as of June 30, 2023 and no shares outstanding as of December 31, 2022. -
Series F-2 preferred stock, par value $0.0001; 9,052 shares authorized, 1,153 shares outstanding as of June 30, 2023 and no shares outstanding as of December 31, 2022. -
Common stock, par value $0.0001; 800,000,000 shares authorized; 1,067,341 and 337,392 shares outstanding as of June 30, 2023 and December 31, 2022, respectively 6 2
Additional paid-in capital 109,381 88,533
Accumulated deficit (104,830 ) (88,005 )
Total stockholders’ equity 4,557 530
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 12,147 $ 6,590

	September 30, 2023			December 31, 2022
	(Unaudited)
ASSETS
Current assets:
Cash	$	2,056		$	821
Prepaid and other current assets		606			590
Total current assets		2,662			1,411
Property and equipment, net		2,638			1,409
Intangible assets, net		1,633			1,598
Right-of-use assets		701			1,842
Goodwill		652			-
Deferred debt issuance costs		3,847			150
Other assets		33			180
TOTAL ASSETS	$	12,166		$	6,590

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	1,855		$	865
Accrued expenses		175			621
Lease liabilities - current portion		385			574
Warrant liability		34			972
Notes payable at fair value		-			1,654
Notes payable		88			8
Total current liabilities		2,537			4,694
Lease liabilities - non-current portion		355			1,366
Total liabilities		2,892			6,060

Commitments and Contingencies (Note 14)

STOCKHOLDERS’ EQUITY:
Preferred stock, par value $0.0001; 50,000,000 shares authorized, no shares outstanding		-			-
Series A preferred stock, par value $0.0001; 300 shares authorized, 251 shares outstanding as of September 30, 2023 and December 31, 2022; liquidation preference $256 as of September 30, 2023 and zero as of December 31, 2022		-			-
Series B preferred stock, par value $0.0001; 1,500 shares authorized, 1,443 shares outstanding as of September 30, 2023 and December 31, 2022; liquidation preference $1,472 as of September 30, 2023 and zero as of December 31, 2022		-			-
Series C preferred stock, par value $0.0001; 600,000 shares authorized, 500,756 shares outstanding as of September 30, 2023 and December 31, 2022; liquidation preference $521 as of September 30, 2023 and zero as of December 31, 2022		-			-
Series D preferred stock, par value $0.0001; 7,000 shares authorized, 0 shares issued and outstanding as of September 30, 2023 and 1,058 as of December 31, 2022; liquidation preference zero as of September 30, 2023 and $1,113 as of December 31, 2022		-			-
Series E preferred stock, par value $0.0001; 77,000 shares authorized, 0 shares issued and outstanding as of September 30, 2023 and December 31, 2022.		-			-
Series F preferred stock, par value $0.0001; 9,073 shares authorized, 4,448 shares outstanding as of September 30, 2023 and no shares outstanding as of December 31, 2022; liquidation preference $4,620 as of September 30, 2023 and zero as of December 31, 2022.		-
Series F-1 preferred stock, par value $0.0001; 9,052 shares authorized, 653 shares outstanding as of September 30, 2023 and no shares outstanding as of December 31, 2022; liquidation preference $1,578 as of September 30, 2023 and zero as of December 31, 2022.		-
Series F-2 preferred stock, par value $0.0001; 9,052 shares authorized, 1,153 shares outstanding as of September 30, 2023 and no shares outstanding as of December 31, 2022; liquidation preference $1,198 as of September 30, 2023 and zero as of December 31, 2022.		-
Common stock, par value $0.0001; 800,000,000 shares authorized; 6,880,049 and 338,033 shares outstanding as of September 30, 2023 and December 31, 2022, respectively		7			2
Additional paid-in capital		116,956			88,533
Accumulated deficit		(107,689	)		(88,005	)
Total stockholders’ equity		9,274			530
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	12,166		$	6,590

The accompanying notes are an integral part of these condensed consolidated financial statements.

CROWN ELECTROKINETICS CORP.

Condensed Consolidated Statements of Operations

(Unaudited)

~~(in thousands, except share and per share amounts)~~

Three Months Ended
June 30, Six months ended
June 30,
2023 2022 2023 2022
Revenue $ 37 $ - $ 59 $ -
Cost of revenue 23 - 54 -
Gross profit 14 - 5 -

Operating expenses:
Research and development 490 1,473 1,031 2,568
Selling, general and administrative 4,409 3,002 7,985 6,474
Total operating expenses 4,899 4,475 9,016 9,042

Loss from operations (4,885 ) (4,475 ) (9,011 ) (9,042 )

Other income (expense):
Interest expense (2,508 ) (2 ) (4,525 ) (5 )
Loss on extinguishment of warrant liability - - (504 ) -
Loss on extinguishment of debt (2,345 ) - (2,345 )
Gain on issuance of convertible notes - - 64 -
Change in fair value of warrants 2,130 - 7,736 -
Change in fair value of notes (6,883 ) - (7,000 ) -
Other expense (28 ) - (1,234 ) -
Total other income (expense) (9,634 ) (2 ) (7,808 ) (5 )

Loss before income taxes (14,519 ) (4,477 ) (16,819 ) (9,047 )

Income tax expense - - - -

Net loss (14,519 ) (4,477 ) (16,819 ) (9,047 )
Deemed dividend on Series D preferred stock - - (6 ) -
Cumulative dividends on Series A preferred stock (5 ) - (9 ) -
Cumulative dividends on Series B preferred stock (29 ) - (49 ) -
Cumulative dividends on Series C preferred stock (10 ) - (10 ) -
Cumulative dividends on Series D preferred stock (53 ) - (84 ) -
Net loss attributable to common stockholders $ (14,616 ) $ (4,477 ) $ (16,997 ) $ (9,047 )

Net loss per share attributable to common stockholders $ (18.02 ) $ (16.35 ) $ (25.96 ) $ (33.62 )

Weighted average shares outstanding, basic and diluted: 810,983 273,767 653,848 269,094
~~The accompanying notes are an integral part of these condensed consolidated financial statements.~~

~~CROWN ELECTROKINETICS CORP.~~
~~Condensed Consolidated Statements of Stockholders’ Equity~~
~~(Unaudited)~~
~~(in thousands, except share and per share amounts)~~
Series A
Preferred Stock Series B
Preferred Stock Series C
Preferred Stock Series D
Preferred Stock Series E
Preferred Stock Series F
Preferred Stock Series F-1
Preferred Stock Series F-2
Preferred Stock Common Stock Additional Paid-in Accumulated Total Stockholders’
Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Capital Deficit Equity
Balance as of December 31, 2022 251 $         - 1,443 $        - 500,756 $        - 1,058 $        - - $        - - $        - - $        - - $        - 338,033 $        2 $ 88,533 $ (88,005 ) $ 530
Exercise of common stock warrants - - - - - - - - - - - - - - - - 109,257 1 2,061 - 2,062
Issuance of common stock in connection with conversion of notes - - - - - - - - - - - - - - - - 31,466 - 516 - 516
Issuance of common stock/At-the-market offering, net of offering costs - - - - - - - - - - - - - - - - 211,667 1 2,106 - 2,107
Issuance of Series E preferred stock in connection with LOC - - - - - - - - 5,000 - - - - - - - - - 4,350 - 4,350
Deemed dividend for repricing of Series D preferred stock - - - - - - - - - - - - - - - - - - 6 (6 ) -
Commitment to issue shares of common stock in connection with March waiver agreement - - - - - - - - - - - - - - - - - - 298 - 298
Issuance of common stock in connection with Series A and Series B Dividends - - - - - - - - - - - - - - - - 6,921 - - - -
Issuance of common stock upon the conversion of Series E preferred stock - - - - - - - - (5,000 ) - - - - - - - 83,334 1 - - 1
Issuance of common stock in connection with conversion of October Notes - - - - - - - - - - - - - - - - 248,984 1 2,165 - 2,166
Dividends paid in shares of Series D preferred stock - - - - - - 139 - - - - - - - - - - - - - -
Series D preferred stock exchanged for Series F preferred stock in connection with Exchange Agreements - - - - - - (1,197 ) - - - 1,847 - - - - - - - (450 ) - (450 )
Conversion of Demand Notes and October Notes into Series F preferred stock in connection with Exchange Agreements - - - - - - - - - - 3,198 - - - - - - - 1,276 - 1,276
Conversion of January Notes into Series F preferred stock in connection with Exchange Agreements - - - - - - - - - - 206 - - - - - - - 82 - 82
Issuance of Series F-1 preferred stock - - - - - - - - - - - - 3,583 - - - - - 1,372 - 1,372
Issuance of Series F-2 preferred stock - - - - - - - - - - - - - - 1,153 - - - 464 - 464
Commitment to issue shares of common stock in connection with January Notes - - - - - - - - - - - - - - - - - - 2,410 - 2,410
Commitment to issue shares of common stock in connection with LOC Notes - - - - - - - - - - - - - - - - - - 230 - 230
Commitment to issue shares of Series E preferred stock in connection with LOC Notes - - - - - - - - - - - - - - - - - - 3,363 - 3,363
Commitment to issue shares of common stock in connection with Demand Notes - - - - - - - - - - - - - - - - - - 286 - 286
Stock-based compensation - - - - - - - - - - - - - - - - 38,335 - 313 - 313
Net loss - - - - - - - - - - - - - - - - - - - (16,819 ) (16,819 )
Balance as of June 30, 2023 (unaudited) 251 - 1,443 - 500,756 - - - - - 5,251 - 3,583 - 1,153 - 1,067,997 6 $ 109,381 $ (104,830 ) $ 4,557
~~The accompanying notes are an integral part of these condensed consolidated financial statements.~~

~~CROWN ELECTROKINETICS CORP.~~
~~Condensed Consolidated Statements of Stockholders’ Equity (Continued)~~
~~(Unaudited)~~
(in thousands, except share and per share amounts)

Series A
Preferred Stock Series B
Preferred Stock Series C
Preferred Stock Common Stock Additional
Paid-in Accumulated Total
Stockholders’ Equity
Number Amount Number Amount Number Amount Number Amount Capital Deficit (Deficit)
Balance as of December 31, 2021 251 $         - 1,443 $         - 500,756 $         - 242,808 $         1 $ 82,677 $ (73,690 ) $       8,988
Issuance of common stock/At-the-market offering, net of offering costs - - - - - - 853 - 58 - 58
Delivery of restricted common stock - - - - - - 556 - - - -
Issuance of common stock warrants in connection with SLOC - - - - - - - - 223 - 223
Stock-based compensation - - - - - - - - 2,531 - 2,531
Net loss - - - - - - - - - (9,047 ) (9,047 )
Balance as of June 30, 2022 (Unaudited) 251 $ - 1,443 $ - 500,756 $ - 244,217 $ 1 $ 85,489 $ (82,737 ) $ 2,753
Three Months Ended
September 30, Nine months ended
September 30,
2023 2022 2023 2022
Revenue $ - $ - $ 59 $ -
Cost of revenue - - 54 -
Gross profit - - 5 -

Operating expenses:
Research and development 492 955 1,523 3,523
Selling, general and administrative 2,941 2,160 10,926 8,634
Total operating expenses 3,433 3,115 12,449 12,157

Loss from operations (3,433 ) (3,115 ) (12,444 ) (12,157 )

Other income (expense):
Interest expense (2,445 ) (1 ) (6,970 ) (6 )
Loss on extinguishment of warrant liability - - (504 ) -
Loss on extinguishment of debt - - (2,345 )
Gain on issuance of convertible notes - - 64 -
Change in fair value of warrants 2,688 - 10,424 -
Change in fair value of notes (40 ) - (7,040 ) -
Change in fair value of derivative liability 401 401
Other expense (30 ) - (1,264 ) -
Total other income (expense) 574 (1 ) (7,234 ) (6 )

Loss before income taxes (2,859 ) (3,116 ) (19,678 ) (12,163 )

Income tax expense - - - -

Net loss (2,859 ) (3,116 ) (19,678 ) (12,163 )
Deemed dividend on Series D preferred stock - - (6 ) -
Cumulative dividends on Series A preferred stock (5 ) - (14 ) -
Cumulative dividends on Series B preferred stock (29 ) - (78 ) -
Cumulative dividends on Series C preferred stock (10 ) - (20 ) -
Cumulative dividends on Series D preferred stock - (23 ) (53 ) (23 )
Cumulative dividends on Series F preferred stock (144 ) (190 )
Cumulative dividends on Series F-1 preferred stock (51 ) (71 )
Cumulative dividends on Series F-2 preferred stock (44 ) (44 )
Net loss attributable to common stockholders $ (3,142 ) $ (3,139 ) $ (20,154 ) $ (12,186 )

Net loss per share attributable to common stockholders $ (0.94 ) $ (11.76 ) $ (12.96 ) $ (48.58 )

Weighted average shares outstanding, basic and diluted: 3,349,195 266,872 1,554,554 250,832

The accompanying notes are an integral part of these condensed consolidated financial statements.

CROWN ELECTROKINETICS CORP.
Condensed Consolidated Statements of Stockholders’ Equity ~~(Continued)~~
(Unaudited)
(in thousands, except share and per share amounts)

Series A
Preferred Stock Series B
Preferred Stock Series C
Preferred Stock Series D
Preferred Stock Series E
Preferred Stock Series F
Preferred Stock Series F-1
Preferred Stock Series F-2
Preferred Stock Common Stock Additional Paid-in Accumulated Total Stockholders’
Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Capital Deficit Equity
Balance as of March 31, 2023 (Unaudited) 251 $          - 1,443 $          - 500,756 $          - 1,058 $          - 5,000 $          - - $ - - $          - - $          - 728,758 $ 4 $ 98,051 $ (90,311 ) $ 7,744
Issuance of common stock in connection with Series A and Series B Dividends - - - - - - - - - - - - - - - - 6,921 - - - -
Issuance of common stock upon the conversion of Series E preferred stock - - - - - - - - (5,000 ) - - - - - - - 83,334 1 - - 1
Issuance of common stock in connection with conversion of October Notes - - - - - - - - - - - - - - - - 248,984 1 2,165 - 2,166
Dividends paid in shares of Series D preferred stock - - - - - - 139 - - - - - - - - - - - - - -
Series D preferred stock exchanged for Series F preferred stock in connection with Exchange Agreements - - - - - - (1,197 ) - - - 1,847 - - - - - - - (450 ) - (450 )
Conversion of Demand Notes and October Notes into Series F preferred stock in connection with Exchange Agreements - - - - - - - - - - 3,198 - - - - - - - 1,276 - 1,276
Conversion of January Notes into Series F preferred stock in connection with Exchange Agreements - - - - - - - - - - 206 - - - - - - - 82 - 82
Issuance of Series F-1 preferred stock - - - - - - - - - - - - 3,583 - - - - - 1,372 - 1,372
Issuance of Series F-2 preferred stock - - - - - - - - - - - - - - 1,153 - - - 464 - 464
Commitment to issue shares of common stock in connection with January Notes - - - - - - - - - - - - - - - - - - 2,410 - 2,410
Commitment to issue shares of common stock in connection with LOC Notes - - - - - - - - - - - - - - - - - - 230 - 230
Commitment to issue shares of Series E preferred stock in connection with LOC Notes - - - - - - - - - - - - - - - - - - 3,363 - 3,363
Commitment to issue shares of common stock in connection with Demand Notes - - - - - - - - - - - - - - - - - - 286 - 286
Stock-based compensation - - - - - - - - - - - - - - - - - - 132 - 132
Net loss - - - - - - - - - - - - - - - - -        - - (14,519 ) (14,519 )
Balance as of June 30, 2023 (Unaudited) 251 - 1,443 - 500,756 - - - - - 5,251 - 3,583 - 1,153 - 1,067,997 6 $ 109,381 $ (104,830 ) $ 4,557
Series A
Preferred Stock Series B
Preferred Stock Series C
Preferred Stock Series D
Preferred Stock Series E
Preferred Stock Series F
Preferred Stock Series F-1
Preferred Stock Series F-2
Preferred Stock Common Stock Additional Paid-in Accumulated Total Stockholders’
Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Capital Deficit Equity
Balance as of December 31, 2022 251 $ - 1,443 $         - 500,756 $ - 1,058 $       - - $      - - $      - - $     - - $           - 338,033 $ 2 $ 88,533 $ (88,005 ) $ 530
Exercise of common stock warrants - - - - - - - - - - - - - - - - 109,257 1 2,061 - 2,062
Issuance of common stock in connection with conversion of notes - - - - - - - - - - - - - - - - 31,466 - 516 - 516
Issuance of common stock in connection with equity line of credit - - - - - - - - - - - - - - - - 3,986,991 - 4,489 - 4,489
Issuance of common stock/at-the-market offering, net of offering costs - - - - - - - - - - - - - - - - 794,689 1 3,786 - 3,787
Issuance of Series E preferred stock in connection with LOC - - - - - - - - 5,000 - - - - - - - - - 4,350 - 4,350
Deemed dividend for repricing of Series D preferred stock - - - - - - - - - - - - - - - - - - 6 (6 ) -
Commitment to issue shares of common stock in connection with March waiver agreement - - - - - - - - - - - - - - - - - - 298 - 298
Issuance of common stock in connection with Series A and Series B Dividends - - - - - - - - - - - - - - - - 6,921 - - - -
Issuance of common stock upon the conversion of Series E preferred stock - - - - - - - - (5,000 ) - - - - - - - 83,334 1 - - 1
Issuance of common stock in connection with conversion of 2022 Notes - - - - - - - - - - - - - - - - 248,984 1 2,165 - 2,166
Dividends paid in shares of Series D preferred stock - - - - - - 139 - - - - - - - - - - - - - -
Series D preferred stock exchanged for Series F preferred stock in connection with Exchange Agreements - - - - - - (1,197 ) - - - 1,847 - - - - - - - (450 ) - (450 )
Conversion of Demand Notes and 2022 Notes into Series F preferred stock in connection with Exchange Agreements - - - - - - - - - - 3,198 - - - - - - - 1,276 - 1,276
Conversion of Senior Secured Notes into Series F preferred stock in connection with Exchange Agreements - - - - - - - - - - 206 - - - - - - - 82 - 82
Issuance of Series F-1 preferred stock - - - - - - - - - - - - 3,583 - - - - - 1,372 - 1,372
Issuance of Series F-2 preferred stock - - - - - - - - - - - - - - 1,153 - - - 464 - 464
Conversion of Series F preferred stock into common stock - - - - - - - - - - (803 ) - - - - - 103,234 - - - -
Conversion of Series F-1 preferred stock into common stock - - - - - - - - - - - - (2,930 ) - - - 325,737 - - - -
Commitment to issue shares of common stock in connection with Senior Secured Notes - - - - - - - - - - - - - - - - - - 2,410 - 2,410
Commitment to issue shares of common stock in connection with line of credit notes - - - - - - - - - - - - - - - - - - 230 - 230
Commitment to issue shares of Series E preferred stock in connection with line of credit notes - - - - - - - - - - - - - - - - - - 3,363 - 3,363
Commitment to issue shares of common stock in connection with Demand Notes - - - - - - - - - - - - - - - - - - 286 - 286
Issuance of common stock to settle commitment shares - - - - - - - - - - - - - - - - 570,916 1 (1 ) - -
Issuance of common stock in connection with Senior Secured Notes settlement - - - - - - - - - - - - - - - - 189,602 - 1,160 - 1,160
Issuance of common stock in connection with equity line of credit - - - - - - - - - - - - - - - - 21,841 - 114 - 114
Reverse stock split rounding - - - - - - - - - - - - - - - - 30,709 - - - -
Stock-based compensation - - - - - - - - - - - - - - - - 38,335 - 446 - 446
Net loss - - - - - - - - - - - - - - - - -          - - (19,678 ) (19,678 )
Balance as of September 30, 2023 (unaudited) 251 $ - 1,443 $ - 500,756 $ - - $ - - $ - 4,448 $ - 653 $ - 1,153 $ - 6,880,049 $ 7 $ 116,956 $ (107,689 ) $ 9,274

The accompanying notes are an integral part of these condensed consolidated financial statements.

CROWN ELECTROKINETICS CORP.
Condensed Consolidated Statements of Stockholders’ Equity (Continued)
(Unaudited)
(in thousands, except share and per share amounts)
Series A
Preferred Stock Series B
Preferred Stock Series C
Preferred Stock Common Stock Additional
Paid-in Accumulated Total Stockholders’
Number Amount Number Amount Number Amount Number Amount Capital Deficit Equity
Balance as of March 31, 2022 (Unaudited) 251 $         - 1,443 $         - 500,756 $         - 243,364 $         1 $ 83,983 $ (78,260 ) $ 5,724
Issuance of common stock/At-the-market offering, net of offering costs - - - - - - 853 - 58 - 58
Stock-based compensation - - - - - - - - 1,448 - 1,448
Net loss - - - - - - - - - (4,477 ) (4,477 )
Balance as of June 30, 2022 (Unaudited) 251 $ - 1,443 $ - 500,756 $ - 244,217 $ 1 $ 85,489 $ (82,737 ) $ 2,753
Series A
Preferred Stock Series B
Preferred Stock Series C
Preferred Stock Series D
Preferred Stock Common Stock Additional Paid-in Accumulated Total Stockholders’ Equity
Number Amount Number Amount Number Amount Number Amount Number Amount Capital Deficit (Deficit)
Balance as of December 31, 2021 251 $       - 1,443 $       - 500,756 $       - - $     - 242,808 $ 1 $ 82,677 $ (73,690 ) $ 8,988
Delivery of restricted common stock - - - - - - - - 18,255 1 - - 1
Issuance of common stock and warrants, net of fees - - - - - - - - 20,834 - 855 - 855
Issuance of common stock warrants in connection with SLOC - - - - - - - - - - 223 - 223
Issuance of Series D preferred stock and warrants, net of fees - - - - - - 1,058 - - - 1,039 - 1,039
Issuance of common stock/at-the-market offering, net of offering costs - - - - - - - - 27,462 - 706 - 706
Issuance of common stock warrants in connection with consideration payable - - - - - - - - - - 86 - 86
Stock-based compensation - - - - - - - - - - 3,011 - 3,011
Net loss - - - - - - - - - - - (12,163 ) (12,163 )
Balance as of September 30, 2022 (Unaudited) 251 $ - 1,443 $ - 500,756 $ - 1,058 $ - 309,359 $ 2 $ 88,597 $ (85,853 ) $ 2,746

The accompanying notes are an integral part of these condensed consolidated financial statements.

CROWN ELECTROKINETICS CORP.
Condensed Consolidated Statements of ~~Cash Flows~~Stockholders’ Equity (Continued)
(Unaudited)
(in ~~thousands)~~thousands, except share and per share amounts)
Series A
Preferred Stock Series B
Preferred Stock Series C
Preferred Stock Series D
Preferred Stock Series E
Preferred Stock Series F
Preferred Stock Series F-1
Preferred Stock Series F-2
Preferred Stock Common Stock Additional Paid-in Accumulated Total Stockholders’
Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Number Amount Capital Deficit Equity
Balance as of June 30, 2023 (Unaudited) 251 $      - 1,443 $       - 500,756 $       - - $      -     - $        - 5,251 $ - 3,583 $ - 1,153 $      - 1,067,997 $ 6 $ 109,381 $ (104,830 ) $ 4,557
Issuance of common stock to settle commitment shares - - - - - - - - - - - - - - - - 570,916 1 (1 ) - -
Issuance of common stock in connection with Senior Secured Notes settlement - - - - - - - - - - - - - - - - 189,602 - 1,160 - 1,160
Issuance of common stock in connection with equity line of credit - - - - - - - - - - - - - - - - 21,841 - 114 - 114
Issuance of common stock/equity line of credit, net of offering costs - - - - - - - - - - - - - - - - 3,986,991 - 4,489 - 4,489
Issuance of common stock/at-the-market offering, net of offering costs - - - - - - - - - - - - - - - - 583,022 - 1,680 - 1,680
Conversion of Series F preferred stock into common stock - - - - - - - - - - (803 ) - - - - - 103,234 - - - -
Conversion of Series F-1 preferred stock into common stock - - - - - - - - - - - - (2,930 ) - - 325,737 - - - -
Reverse stock split rounding - - - - - - - - - - - - - - - - 30,709 - - - -
Stock-based compensation - - - - - - - - - - - - - - - - - - 133 - 133
Net loss - - - - - - - - - - - - - - - - - - - (2,859 ) (2,859 )
Balance as of September 30, 2023 (Unaudited) 251 $ - 1,443 $ - 500,756 $ - - $ - - $ - 4,448 $ - 653 $ - 1,153 $ - 6,880,049 $ 7 $ 116,956 $ (107,689 ) $ 9,274

Six months ended
June 30,
2023 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss $ (16,819 ) $ (9,047 )
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation 313 2,531
Depreciation and amortization 372 234
Loss on extinguishment of warrant liability 504 -
Change in fair value of warrant liability (7,736 ) -
Loss on extinguishment of debt 2,345
Change in fair value of notes 7,000 -
Amortization of deferred debt issuance costs 4,049 -
Amortization of right of use assets 1,045 239
Other expenses 1,275 -
Loss on disposal of equipment 235 52
Changes in operating assets and liabilities:
Prepaid and other assets (14 ) 3
Accounts payable 886 370
Accrued expenses (742 ) (182 )
Lease liability (1,101 ) (143 )
Net cash used in operating activities (8,388 ) (5,943 )
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for acquisition of Amerigen 7 (644 ) -
Purchase of equipment (707 ) (258 )
Purchase of patents - (61 )
Net cash used in investing activities (1,351 ) (319 )
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the exercise of warrants 2,061 -
Proceeds from the issuance of common stock / At-the-market offering 2,198 60
Proceeds from the issuance of notes in connection with Line of Credit 2,350 -
Offering costs for the issuance of common stock / At-the-market offering (91 ) (2 )
Proceeds from a deposit for Series D preferred stock (shares liability) - 1,058
Proceeds from issuance of  Series F-1 preferred stock 2,328 -
Proceeds from issuance of  Series F-2 preferred stock 748 -
Proceeds from issuance of January promissory notes, net of fees paid 1,357 -
Repayment of notes payable (1,997 ) -
Net cash provided by financing activities 8,954 1,116

Net increase / decrease in cash (785 ) (5,146 )
Cash — beginning of period 821 6,130
Cash — end of period $ 36 $ 984

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of Series E preferred stock in connection with LOC $ 9,943 $ -
Issuance of Series F preferred stock in connection with exchange of Series D preferred stock $ 450 $ -
Issuance of common stock in connection with conversion of notes $ 516 $ -
Issuance of common stock warrants in connection with SLOC $ - $ 223
Deemed dividend for repricing of Series D preferred stock $ 6 $ -
Commitment to issue shares of common stock in connection with Demand Notes $ 286 $ -
Unpaid equipment included in accounts payable $ 92 $ 112
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for interest $ 8 $ 3
The accompanying notes are an integral part of these condensed consolidated financial statements.

CROWN ELECTROKINETICS CORP.
Condensed Consolidated Statements of Stockholders’ Equity (Continued)
(Unaudited)
(in thousands, except share and per share amounts)
Series A
Preferred Stock Series B
Preferred Stock Series C
Preferred Stock Series D
Preferred Stock Common Stock Additional
Paid-in Accumulated Total
Stockholders’
Number Amount Number Amount Number Amount Number Amount Number Amount Capital Deficit Equity
Balance as of July 1, 2022 (Unaudited) 251 $        - 1,443 $        - 500,756 $       - - $           - 244,217 $          1 $ 85,489 $ (82,737 ) $ 2,753
Delivery of restricted common stock - - - - - - - - 17,699 1 - - 1
Issuance of common stock and warrants, net - - - - - - - - 20,834 - 855 - 855
Issuance of Series D preferred stock and warrants, net of fees - - - - - - 1,058 - - - 1,039 - 1,039
Issuance of common stock/at-the-market offering, net of offering costs - - - �� - - - - - 26,609 - 648 - 648
Issuance of common stock warrants in connection with consideration payable - - - - - - - - - - 86 - 86
Stock-based compensation - - - - - - - - - - 480 - 480
Net loss - - - - - - - - - - - (3,116 ) (3,116 )
Balance as of September 30, 2022 (Unaudited) 251 $ - 1,443 $ - 500,756 $ - 1,058 $ - 309,359 $ 2 $ 88,597 $ (85,853 ) $ 2,746
The accompanying notes are an integral part of these condensed consolidated financial statements.

CROWN ELECTROKINETICS CORP.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
Nine months ended
September 30,
2023 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss $ (19,678 ) $ (12,163 )
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation 446 3,011
Depreciation and amortization 542 360
Loss on extinguishment of warrant liability 504 -
Change in fair value of warrant liability (10,424 ) -
Change in fair value of derivative liability (401 ) -
Gain on issuance of convertible note (64 )
Loss on extinguishment of debt 2,345 -
Change in fair value of notes 7,040 -
Amortization of deferred debt issuance costs 6,800 -
Amortization of right-of-use assets 1,141 365
Other expenses 467 -
Loss on disposal of equipment 380 52
Changes in operating assets and liabilities:
Prepaid and other assets 136 392
Accounts payable 732 367
Accrued expenses (575 ) (165 )
Lease liabilities (1,200 ) (268 )
Net cash used in operating activities (11,809 ) (8,049 )
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for acquisition of Amerigen 7 (645 ) -
Purchase of equipment (1,084 ) (278 )
Purchase of patents - (61 )
Net cash used in investing activities (1,729 ) (339 )
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the exercise of warrants 2,062 -
Proceeds from the issuance of common stock and warrants, net of fees - 855
Proceeds from the issuance of common stock / at-the-market offering 3,957 732
Proceeds from the issuance of notes in connection with line of credit 2,350 -
Offering costs for the issuance of common stock / at-the-market offering (170 ) (26 )
Proceeds from a deposit for Series D preferred stock (shares liability) - 1,039
Proceeds from issuance of Series F-1 preferred stock 2,328 -
Proceeds from issuance of Series F-2 preferred stock 748 -
Proceeds from issuance of Senior Secured Notes, net of fees paid 1,357 -
Repayment of notes payable (2,348 ) -
Proceeds from the issuance of common stock in connection with equity line of credit, net of offering costs 4,489 -
Net cash provided by financing activities 14,773 2,600

Net increase / decrease in cash 1,235 (5,788 )
Cash — beginning of period 821 6,130
Cash — end of period $ 2,056 $ 342
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of Series E preferred stock in connection with line of credit $ 4,350 $ -
Issuance of common stock in connection with equity line of credit $ 114 $ -
Issuance of Series F preferred stock in connection with exchange of Series D preferred stock $ 450 $ -
Issuance of common stock in connection with conversion of notes $ 2,681 $ -
Issuance of common stock in connection with Senior Secured Notes settlement $ 1,160 $ -
Issuance of common stock warrants in connection with SLOC $ - $ 223
Conversion of Senior Secured Notes into Series F preferred stock in connection with Exchange Agreements $ 82 $ -
Commitment to issue shares of common stock in connection with Demand Notes $ 286 $ -
Unpaid equipment included in accounts payable $ 23 $ 486
Issuance of common stock warrants in connection with consideration payable $ - $ 86
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for interest $ 9 $ 3
The accompanying notes are an integral part of these condensed consolidated financial statements.

Notes to the Condensed Consolidated Financial Statements
(Unaudited)
Note 1 ~~- Organization and Description~~– Nature of Business ~~Operations~~and Liquidity
Organization
Crown Electrokinetics Corp. (the “Company”) was incorporated in the State of Delaware on April 20, 2015. Effective October 6, 2017, the Company’s name was changed to Crown Electrokinetics Corp. from 3D Nanocolor Corp. (“3D Nanocolor”).
~~On January 26, 2021, the Company completed its public offering, and its common stock began trading on the Nasdaq Capital Market (Nasdaq) under the symbol CRKN.~~
The Company is commercializing technology for smart or dynamic glass. The Company’s electrokinetic glass technology is an advancement on microfluidic technology that was originally developed by HP Inc.
On December 20, 2022, the Company incorporated Crown Fiber Optics Corp., a Delaware based entity, to own and operate its acquired business from the acquisition of Amerigen 7, LLC (“Amerigen 7”) in January 2023. Crown Fiber Optics Corp. is accounted for as a ~~wholly- owned~~wholly-owned subsidiary of Crown Electrokinetics, Corp.
~~Preferred Stock~~
Initial Public Offering
~~Subsequent to December 31, 2022,~~
On January 26, 2021, the Company ~~filed the first amendment to~~completed its ~~Series D preferred stock, which modifies the conversion price of the Series D preferred stock from $78.00 to $30.00 per share (See Note 12).~~
On February 1, 2023, the Company’s Board of Directors authorized 77,000 shares of Series E preferred stock with a par value of $0.0001 per share. Each share of Series E Preferred Stock is convertible into 1,000 shares of the Company’spublic offering, and its common stock atbegan trading on the ~~option of~~Nasdaq Capital Market (“Nasdaq”) under the ~~holders (See Note 12).~~
On June 4, 2023, the Company’s Board of Directors authorized 9,073 shares of Series F preferred stock with a par value of $0.0001 per share. Each share of Series F Preferred Stock has a stated value of $1,000 and is convertible at the option of the holders into shares of the Company’s common stock at an initial conversion price of $8.868 (See Note 12).
On June 13, 2023, the Company’s Board of Directors authorized 9,052 shares of Series F-1 preferred stock with a par value of $0.0001 per share. Each share of Series F-1 Preferred Stock has a stated value of $1,000 and is convertible at the option of the holders into shares of the Company’s common stock at an initial conversion price of $8.994 (See Note 12).
On June 14, 2023, the Company’s Board of Directors authorized 9,052 shares of Series F-2 preferred stock with a par value of $0.0001 per share. Each share of Series F-2 Preferred Stock has a stated value of $1,000 and is convertible at the option of the holders into shares of the Company’s common stock at an initial conversion price of $9.228 (See Note 12).
symbol CRKN.
~~Business Combination~~
On January 3, 2023, the Company acquired certain assets related to the construction of 5G fiber optics infrastructure and distributed antenna systems from Amerigen 7 (the “Business Combination”), for cash consideration of approximately $0.65 million (See Note 4).
Reverse Stock Split
On August 11, 2023, the Company’s ~~Board~~board of ~~Directors~~directors authorized a reverse stock split (‘Reverse Stock Split”) at an exchange ratio of ~~one (1) share of common stock for every sixty (60) shares of common stock.~~one-for-60 basis. The Reverse Stock Split was effective on August 15, 2023, such that every ~~sixty (60)~~60 shares of common stock have been automatically converted into one ~~(1)~~ share of common stock. The Company did not issue fractional certificates for post-reverse split shares in connection with the Reverse Stock Split. Rather, all shares of common stock that were held by a stockholder were aggregated and each stockholder was entitled to receive the number of whole shares resulting from the combination of the shares so aggregated. Any fractions resulting from the Reverse Stock Split computation were rounded up to the next whole share.
The number of authorized shares and the par value of the common stock was not adjusted as a result of the Reverse Stock Split. In connection with the Reverse Stock Split, the conversion ratio for the Company’s outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. All references to common stock and options to purchase common stock share ~~and~~data, per share data and related information contained in ~~these~~the condensed consolidated financial statements have been ~~retrospectively~~ adjusted to reflect the effect of the Reverse Stock Split for all periods presented. The shares of common stock retain a par value of $0.0001 per share. Accordingly, an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split was reclassified from common stock to additional paid-in capital.Split.

~~Note 2 –~~ Liquidity ~~Financial Condition,~~ and Going Concern
The Company has incurred substantial operating losses since its inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As reflected in the condensed consolidated financial statements, the Company had an accumulated deficit of approximately ~~$104.8~~$107.7 million and ~~negative working capital~~cash of approximately ~~$6.4~~$2.1 million ~~at June~~as of September 30, 2023, a net loss of approximately ~~$17.0~~$19.7 million, and approximately ~~$8.4~~$11.8 million of net cash used in operating activities for the ~~six~~nine months ended ~~June~~September 30, 2023. ~~The Company expects to continue to incur ongoing administrative and other expenses, including public company expenses.~~

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

The Company ~~will seek to obtain~~has obtained additional capital through the sale of debt or equity financings or other arrangements to fund operations including through its existing ~~At-The-Market~~at-the-market offering, ~~$10~~$10.0 million Standing Letter of Credit (“SLOC”), ~~the $100~~$100.0 million ~~Line~~line of ~~Credit,~~credit, and ~~the $50~~$50.0 million ~~Equity Line~~equity line of ~~Credit (Note 15 Subsequent Event);~~credit; however, there can be no assurance that the Company will be able to raise needed capital under acceptable terms, if at all. The sale of additional equity may dilute existing stockholders and newly issued shares may contain senior rights and preferences compared to currently outstanding shares of common stock. Issued debt securities may contain covenants and limit the Company’s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued. Due to the uncertainty in the Company’s ability to raise capital, management believes that there is substantial doubt in the Company’s ability to continue as a going concern for twelve months from the issuance of these condensed consolidated financial statements.
Note 2 – Basis of Presentation and Significant Accounting Policies
~~At-the-Market Offerings~~
Basis of Presentation
The ~~Company entered into a Sales Agreement~~Company’s condensed consolidated financial statements have been prepared in conformity with ~~A.G.P./Alliance Global Partners (the “Sales Agents”~~accounting principles generally accepted in the United States of America (“GAAP”) ~~dated March 30, 2022 (the “Sales Agreement”), pursuant to which~~and include all adjustments necessary for the ~~Company may, from time to time, sell up to $5.0 million in shares (the “Placement Shares”)~~fair presentation of the Company’s ~~common stock through~~financial position for the ~~Sales Agents, acting~~periods presented.
The condensed consolidated balance sheet as of September 30, 2023, the condensed consolidated statements of operations, stockholders’ equity for the three and nine months ended September 30, 2023 and 2022 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s ~~sales agent and/or principal,~~consolidated financial position, results of operations and cash flows for the interim period presented. The financial data and the other financial information contained in ~~a continuous at-the-market offering (the “ATM Offering”).~~these notes to the condensed consolidated financial statements related to the three and nine month periods are also unaudited. The ~~Company will pay~~results of operations for the ~~Sales Agents a commission of up to 3.0%~~three and nine months ended September 30, 2023 are not necessarily indicative of the ~~aggregate gross proceeds~~results to be expected for the ~~Company receives~~year ending December 31, 2023 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2022 included herein was derived from ~~all sales~~the audited financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s common stock under the Sales Agreement. The Placement Shares will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (Registration No. 333- 262122) and the related base prospectusCompany's audited consolidated financial statements included in the ~~registration statement, as supplemented by~~Company’s Annual Report on Form 10-K for the ~~prospectus supplement dated~~year ended December 31, 2022, filed with the SEC on March ~~30, 2022.~~31, 2023.
During the six months ended June 30, 2023, the Company received net proceeds on sales of shares of common stock under the Sales Agreement of approximately $2.1 million (after deducting $0.1 million in commissions and expenses) at a weighted average price of $10.38 per share.
On July 5, 2023, the Company and the Sales Agents filed the second amendment to the Sales Agreement (the “Second Amendment to the Sales Agreement”). Pursuant to the First Amendment to the Sales Agreement, the Company may from time to time, sell up to $5.1 million in Placement Shares of the Company’s common stock through the Sales Agents in a continuous At-the-Market Offering (the Amended ATM Offering”). According to the First Amendment to the Sales Agreement, the Company will pay the Sales Agents a commission of up to 3.0% of the aggregate gross proceeds the Company receives from all sales of its common stock in the Amended ATM Offering.
Subsequent to June 30, 2023, the Company received net proceeds on sales of 545,100 shares of common stock of approximately $1.59 million (after deducting $0.76 million in commissions and expenses) at a weighted average price of $3.05 per share.

~~Line of Credit~~
Use of Estimates
~~On February 2, 2023,~~
The preparation of condensed financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the ~~Company entered into a line~~reported amounts of ~~credit agreement (the “Line~~assets and liabilities, disclosure of Credit”) securing a line of credit up to $100.0 million. The Line of Credit will be used to fund expenses related to the fulfillment of contracts with customers of the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation (See Note 1). The Line of Credit expires February 2, 2024, unless the Line of Credit is extended for one or two additional years in accordance with its terms. On February 2, 2023, the Company drew down $2.0 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company issued a Secured Promissory Note (the “2023 Note”) which is duecontingent assets and ~~payable 60 days from the issuance date (See Note 11).~~
~~On May 16, 2023, the Company made a second draw of $0.2 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company issued a second Secured Promissory Note (the “2~~^nd ~~2023 Note”) which is due and payable July 16, 2023. The 2~~^nd ~~2023 Note shall accrue interest~~liabilities at the ~~fifteen percent (15%) per annum from the original funding~~ date of the 2^nd ~~2023 Note.~~
~~On May 26, 2023,~~condensed financial statements and the ~~Company made a third draw~~reported amounts of ~~$0.15 million~~revenue and expenses during the reporting periods. Accounting estimates and assumptions are inherently uncertain. Management bases its estimates and assumptions on current facts, historical experience and various other factors believed to be reasonable under the ~~Line of Credit. Upon drawing down on the Line of Credit, the Company issued a third Secured Promissory Note (the “3~~^rd ~~2023 Note”) which is due~~circumstances. Actual results could differ materially and ~~payable June 2, 2023. The 3~~^rd ~~2023 Note included a $200,000 Commitment fee~~adversely from these estimates. Significant estimates and ~~does not bear interest.~~
~~On June 13, 2023, the Company partially redeemed the principal amount of the 2023 Note and fully redeemed the principal amount of the 2~~^nd ~~2023 Note and 3~~^rd ~~2023 Note in addition to all accrued interest and commitment fees owing for approximately $2.1 million.~~
~~Demand Notes~~
Between May 17, 2023 and May 18, 2023, the Company issued secured demand promissory notes (the “Demand Notes”) to certain investors (the “Demand Holders”) in an aggregate principal amount equal to $229,877. The Demand Notes are due and payable at any time upon demand by a Demand Holder after the earlier of (i) the consummation of the Company’s first securities offering after the issuance of the Demand Notes and (ii) July 16, 2023. The Demand Notes do not bear interest. In connection with the issuance of the Demand Notes, the Company agreed to issue, pending shareholder approval, to the Demand Holders an aggregate of 76,626 shares of the Company’s common stock.
~~On May 30, 2023, the Company issued secured demand promissory notes (the “2~~^nd ~~Demand Notes”) to certain investors (the “2~~^nd ~~Demand Holders”) in an aggregate principal amount equal to $140,804. The 2~~^nd ~~Demand Notes are due and payable at any time upon demand by a 2~~^nd ~~Demand Holder after the earlier of (i) the consummation of the Company’s first securities offering after the issuance of the 2~~^nd ~~Demand Notes and (ii) July 16, 2023. The 2~~^nd ~~Demand Notes do not bear interest. In connection with the issuance of the 2~~^nd ~~Demand Notes, the Company agreed to issue, pending shareholder approval, to the 2~~^nd ~~Demand Holders an aggregate of 46,935 shares of the Company’s common stock.~~
~~Exchange Agreements~~
~~On June 4, 2023, the Company entered into Exchange Agreements (the “Exchange Agreements”): (i) with the October Investors for the exchange of October Notes~~assumptions made in the ~~aggregate principal amount~~accompanying condensed consolidated financial statements include, but not limited to, valuation of $2.6 million for 2,622 shares of the Company’s newly created Series F Convertible Preferred Stock (“Series F Preferred Stock”), in the aggregate; (ii) with the January Investors for the exchange of January Notes in the aggregate principal amount of $0.2 million for 206 shares of Series F Preferred Stock, in the aggregate; (iii) with the Demand Noteholders for the exchange of Demand Notes in the principal amount of $0.6 million for 576 shares of Series F Preferred Stock, in the aggregate; and (iv) with the purchasers of the Company’s Series D Preferred Stock for the exchange of 1,197 shares of Series D Preferred Stock for 1,847 shares of Series F Preferred Stock, in the aggregate.

In addition, in connection with the Exchange Agreements, the Company issued new five-year warrants to purchase an aggregate of 592,129 shares of Common Stock (the “Exchange Warrants”) to the October Investors, the January Investors, and the purchasers of the Company’s Series D Preferred Stock. The Exchange Warrants are exercisable at an exercise price of $8.868 per share of Common Stock, subject to certain adjustments as set forth in the Exchange Warrants. The holders may exercise the Exchange Warrants on a cashless basis if the shares of our Common Stock underlying the Exchange Warrants are not then registered pursuant to an effective registration statement. The Company concluded that the Exchange Warrants are liability classified.
~~For the October Investors, the total~~its business combination, estimated fair value of ~~Series F Preferred Stock and Warrant Liability issued was $1.7 million ($1.1 million for Series F Preferred Stock and $0.6 million for Warrant Liability). For the January Investors, the total~~convertible notes, estimated fair value of warrant lability, Series ~~F Preferred Stock~~F/F-1/F-2 preferred stock, stock option awards for stock-based compensation and ~~Warrant Liability issued was $0.13 million ($0.1 million for Series F Preferred Stock~~operating lease right-of-use assets and $0.03 million for the Warrant Liability). For the Demand Note holders, the total fair value of Series F Preferred Stock and Warrant Liability issued was $0.4 million ($0.2 million for Series F Preferred Stock and $0.2 million for the Warrant Liability). For the purchasers of the Company’s Series D Preferred Stock, the Company accounted for the exchange as an extinguishment of the Series D Preferred Stock. The Company recorded the total fair value of Series F Preferred Stock and Warrant Liability of $1.2 million ($0.7 million for Series F Preferred Stock and $0.5 million for the Warrant Liability) and the difference of $0.5 million with the $0.7 million carrying value of the Series D Preferred Stock as a deemed dividend and reduction to additional-paid-in-capital.
liabilities.
~~Series F-1 Preferred Stock Offering~~
On June 13, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which, at the closing of the transactions contemplated by the Purchase Agreement (the “Closing”) the Purchasers agreed to purchase an aggregate of 3,583 shares of the Company’s newly created Series F-1 Convertible Preferred Stock (“Series F-1 Preferred Stock”) for an aggregate purchase price of approximately $2.3 million .. In addition, in connection with the issuance of the Series F-1 Preferred Stock, the Purchasers will receive five-year warrants to purchase an aggregate of 398,377 shares of Common Stock (defined below) (the “Series F-1 Warrants”). The Series F-1 Warrants will be exercisable at an exercise price of $8.994 per share of the Company’s common stock, subject to certain adjustments as set forth in the Warrants. The holders may exercise the Warrants on a cashless basis if the shares of our Common Stock underlying the Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the Purchasers to consummate the transactions contemplated by the Purchase Agreement are subject to the satisfaction on or prior to the Closing of customary closing conditions.
~~Series F-2 Preferred Stock Offering~~
On June 14, 2023, the Company entered into a Securities Purchase Agreement (the “F-2 Purchase Agreement”) with certain accredited investors (the “F-2 Purchasers”), pursuant to which, at the closing of the transactions contemplated by the Purchase Agreement (the “F-2 Closing”) the F-2 Purchasers agreed to purchase an aggregate of 1,153 shares of the Company’s newly created Series F-2 Convertible Preferred Stock (“Series F-2 Preferred Stock”) for an aggregate purchase price of approximately $0.7 million. In addition, in connection with the issuance of the Series F-2 Preferred Stock, the F-2 Purchasers will receive five-year warrants to purchase an aggregate of 124,946 shares of Common Stock (defined below) (the “F-2 Warrants”). The F-2 Warrants will be exercisable at an exercise price of $9.228 per share of Common Stock, subject to certain adjustments as set forth in the F-2 Warrants. The holders may exercise the F-2 Warrants on a cashless basis if the shares of our Common Stock underlying the F-2 Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the F-2 Purchasers to consummate the transactions contemplated by the F-2 Purchase Agreement are subject to the satisfaction on or prior to the F-2 Closing of customary closing conditions.
Risks and Uncertainties
The Company is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. The Company’s financial condition and results of operations may be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in Ukraine or any other geopolitical tensions.
The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~Note 3 - Significant Accounting Policies~~
~~Basis~~Summary of ~~Presentation~~
The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The condensed consolidated results of operations for the six months ended June 30, 2023 are not necessarily indicative of the results for the full year or the results for any future periods. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes for the fiscal year ended December 31, 2022 included in the Company’s Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2023.
~~Use of Estimates~~
The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the valuation of its business combination, senior secured convertible notes and warrants, Series F/F-1/F-2 Preferred Stock, warrants, and equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Significant Accounting Policies
~~For~~Reference is made to Note 3 Basis of Presentation and Significant Accounting Policies in our 2022 Form 10-K filed on March 31, 2023 for a detailed ~~discussion about the Company’s~~description of significant accounting policies. There have been no significant changes to our accounting policies ~~see the Company’s December 31,~~as disclosed in our 2022 ~~financial statements included in its 2022 Annual Report.~~Form 10-K.
Revenue Recognition

The Company ~~adopted the new~~recognizes revenue standard, ASC 606, on March 31, 2019 using the full retrospective approach. The adoption did not have an effect on 2021 or 2020 revenue recognition or a cumulative effect on opening equity, as the timing and measurement of revenue recognition is materially the same as under ASC 605. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer ofwhen promised goods or services are transferred to customers in an amount that reflects the consideration to which the ~~company~~Company expects to be entitled in exchange for those goods or ~~services. The~~services by following ~~five steps are applied to achieve that core principle:~~a five-step process:
● Step 1: Identify the contract with the customer
● Step 2: Identify the performance obligations in the contract
● Step 3: Determine the transaction price
● Step 4: Allocate the transaction price to the performance obligations in the contract
● Step 5: Recognize revenue when the company satisfies a performance obligation

~~For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the~~The Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing ~~component.~~component when the time between the goods or service being transferred to the customer and the customer pays is one year or less,
The ~~Company’s performance obligation is to provide~~Company generates revenue from providing fiber splicing services as required based on short-term work orders ~~as work is~~ assigned by ~~the Customer.~~customers. The Company is required to complete the description of work described in the work order and test the service provided prior to any recognition of revenue and invoicing. The short-term work orders are ~~for very specific performance obligations which are performed from start to finish~~generally completed within two ~~weeks or less, and more often, within one week.~~weeks. The Company is required to adhere to the rules and regulations that are outlined in the Agreement between the Company and the Customer.
Cost ~~for the work performed~~of revenue is ~~outlined in the~~based on individual work orders ~~based on the~~and detailed description of work to be performed. All of the revenue is recognized immediately upon completion of ~~the work in~~ each work order. A 5% retainage will be withheld by the Customer upon payment of invoices and will be paid to the Company within one year after termination of the contract. The retainage can be utilized by Customer for any claims that may arise after work is completed up through one year after completion.
Revenue recognized during the ~~six~~nine months ended ~~June~~September 30, 2023 was generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was immaterial. No revenue was recognized by the Company during the ~~six~~nine months ended ~~June~~September 30, 2022.

Financial Instruments – Credit Losses

~~Measurements~~In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (“Topic 326”): Measurement of Credit Losses on Financial ~~Instruments (“ASC 326”), which replaces~~Instruments. The amendments in ASU No. 2016-13 introduce an approach based on expected losses to estimated credit losses on certain types of financial instruments, modify the existing incurred loss model with a current expected credit loss (“CECL”) model that requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company would be required to use a forward-looking CECLimpairment model for ~~accounts receivables, guarantees~~available-for-sale debt securities and ~~other~~provide for a simplified accounting model for purchased financial ~~instruments.~~assets with credit deterioration since their origination. The new standard requires financial assets measured at amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. The standard is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. The Company adopted ~~ASC 326 on~~ASU No. 2016-13 and related updates as of January 1, ~~2023 and ASC 326 did not have a~~2023. The adoption of this guidance had no material impact on ~~its~~the Company’s condensed consolidated financial ~~statements.~~
statements

Segment and Reporting Unit Information
Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is determined to be the CODM. On January 3, 2023, the Company acquired Crown Fiber Optics, Corp. (see Note 1) and is currently in the process of integrating this new business line including identifying leadership, and aligning management reporting and allocation methodologies. The Company ~~is assessing its current segment structure in conjunction with~~has two operating segments and two reportable segments as of September 30, 2023, which includes film group and fiber optics group. Revenue recognized during the ~~integration efforts.~~nine months ended September 30, 2023 relates to the fiber optics group.
Business Combinations
The Company accounts for business combinations using ~~the guidance provided by Accounting Standards Codification (“ASC”) 805,~~ ~~Business Combinations~~~~. ASC 805 requires the Company to use~~ the acquisition method of accounting by recognizing the identifiable tangible and intangible assets acquired and liabilities assumed, and any non-controlling interest in the acquired business, measured at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the aforementioned amounts.
Accounting for business combinations requires management to make significant estimates and assumptions, especially at the acquisition date, including estimates for intangible assets. Although the Company believes the assumptions and estimates made have been reasonable and appropriate, they are based in part on historical experience and information obtained from management of the acquired companies and are inherently uncertain. Critical estimates in valuing certain intangible assets we have acquired include future expected cash flows from customer contracts. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates, or actual results. The initial purchase price may be adjusted as needed per the terms of the arrangement agreement. The allocation of purchase price, including any fair value of the assets acquired and liabilities assumed as of the acquisition date has not been completed.
Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.

Deferred Debt Issuance Costs
The Company accounts for debt issuance costs related to its ~~Line~~line of ~~Credit~~credit and equity line of credit as a deferred asset on the condensed consolidated balance sheets, which is amortized over the life of the ~~Line~~line of ~~Credit.~~credit and equity line of credit. Since the Company has elected the fair value option for its convertible notes (see ~~below)~~Note 9), upon a draw down, a portion of the deferred asset balance will be amortized toand recognized as other ~~expense.~~income (expense) on the condensed consolidated statements of operations. On the issuance date of the Company’s ~~Line~~line of ~~Credit,~~credit, the cost related to issuance of the Series E preferred shares and the warrant to purchase Series E preferred shares was recorded as a deferred asset. On the issuance date of the Company’s equity line of credit, the cost related to issuance of common stock was recorded as a deferred asset.

Goodwill
The Company performs a goodwill impairment analysis on October 1^st of each year. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation to determine if it is more likely than not that the fair value of its reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a two-step goodwill impairment test.

~~Convertible Notes and~~ Notes Payable at Fair Value
~~In accordance with Accounting Standards Codification 825,~~ ~~Financial Instruments~~ ~~(“ASC 825”), the~~The Company has elected the fair value option for the recognition of its convertible notes and notes ~~payable. In accordance with ASC 825, the Company recognizes these notes at fair value~~payable, with changes in fair value recognized in the statements of operations. ~~The fair value option may be applied instrument by instrument, but it is irrevocable.~~ As a result of applying the fair value option, direct costs and fees related to the convertible notes and notes payable ~~were~~are recognized in other ~~expense.~~income (expense) in the condensed consolidated statements of operations. The Company ~~will include~~includes the interest expense as a component of the notes fair value.

Warrants
The Company ~~accounted~~accounts for certain common stock warrants outstanding as a liability at fair value and ~~adjusted~~adjusts the ~~instruments to~~ fair value of the instruments at each reporting period. ~~This~~The liability is subject to ~~re-measurement~~remeasurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s condensed consolidated statements of operations. The fair value of the warrants issued by the Company ~~have been~~was estimated using the ~~Black Scholes Methodology.~~Black-Scholes model.
SLOC
The Company accounts for its warrants related to the SLOC ~~in accordance with ASC 815-40,~~ ~~Contracts in Entity’s Own Equity.~~ ~~The warrants to purchase the Company’s common stock meet the criteria in ASC 815-40 to be classified within~~as stockholders’ equity, and therefore, the warrants are not revalued after issuance. The Company uses athe Black-Scholes model to value the warrants at issuance.
~~Under the guidance~~As of ~~ASU 2015-15,~~ ~~Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements~~~~, the Company concluded the warrants should be recorded as a deferred asset. At issuance and as of June~~September 30, 2023, since no loan amounts were drawn down, the SLOC warrant is recorded as a deferred asset on the condensed consolidated balance sheets at fair value and will be amortized over the life of the SLOC. Upon a draw down, the remaining balance of the deferred asset would be reclassified to debt discount and amortized under the effective interest method over the one-year term of the loan.
Purchase Order Warrants

The Company accounts for its warrants issued in connection with purchase orders in accordance with ASC 606~~Revenue Recognition.~~. With respect to the warrant, the Company accounts for it as consideration payable to a customer under ASC 606, as it relates to the future ~~purchase of the Company’s Smart Window Inserts™. Pursuant to ASC 718~~ ~~Compensation - Stock Compensation (“~~~~ASC 718~~”)~~, the~~purchases. The Company measured the fair value of the warrant using the Black-Scholes ~~valuation~~ model on the issuance date, with the value being recognized as a prepaid asset in the condensed consolidated balance sheets, up to the recoverable value represented by the value of the contract.

Net Loss per Share Attributable to Common Stockholders
~~ASC 260,~~ ~~Earnings Per Share~~, requires dual presentation of basic and diluted earnings per share (“EPS”) with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.
Basic net loss per share ofattributable to common ~~stock excludes dilution and~~stockholders is computed ~~by dividing net loss by~~using the ~~weighted average~~weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to common stockholders is computed using the sum of the weighted-average number of shares of common stock ~~reflects~~outstanding during the ~~potential dilution that could occur if~~period and the effect of dilutive securities.
As the Company was in a net loss position for the three and nine months ended September 30, 2023 and 2022, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders because the effects of potentially dilutive securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive.are antidilutive.
Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at ~~June~~September 30, 2023 and 2022 are as follows:
June 30,
2023 2022

Series A preferred stock 3,146 3,146
Series B preferred stock 33,883 33,883
Series C preferred stock 9,346 9,346
Series F preferred stock 592,130 -
Series F-1 preferred stock 398,377 -
Series F-2 preferred stock 124,946 -
Convertible notes 11,667 -
Warrants to purchase common stock (excluding penny warrants) 1,760,095 78,787
Warrants to purchase Series E preferred stock 750,000 -
Options to purchase common stock 157,779 151,892
Unvested restricted stock units 7,139 8,613
Commitment shares 783,806 -
4,632,314 285,667
~~Emerging Growth Company~~
The Company is considered to be an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (JOBS Act). The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Securities and Exchange Act of 1934.
September 30,
2023 2022

Series A preferred stock 3,146 3,146
Series B preferred stock 33,883 33,883
Series C preferred stock 9,346 9,346
Series D preferred stock - 35,278
Series F preferred stock 501,579 -
Series F-1 preferred stock 72,631 -
Series F-2 preferred stock 124,946 -
Warrants to purchase common stock (excluding penny warrants) 1,760,095 98,402
Warrants to purchase Series E preferred stock 750,000 -
Options to purchase common stock 157,779 164,996
Unvested restricted stock units 7,139 14,796
Commitment shares 200,205 -
Total 3,620,749 359,847

~~Note 4 – Acquisitions~~
On January 3, 2023, the Company completed its Business Combination as described in Note 1. In accordance with the terms of the Business Combination, the Company paid cash consideration of approximately $0.65 million. The Business Combination included approximately 12 employees, customer contracts, and certain operating liabilities. The initial purchase price may be adjusted as needed per the terms of the agreement. The measurement period for the Business Combination will be up to one year from the acquisition date.

Note 3 – Acquisitions
On January 3, 2023, the Company acquired certain assets and assumed liabilities from Amerigen 7, which was accounted for as a business combination as the Company concluded that the transferred set of activities and assets related to the acquisition constituted a business. The Company paid cash consideration of approximately $0.7 million which included approximately 12 employees, customer contracts, and certain operating liabilities.
The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed for the Amerigen 7 acquisition (in thousands):
Property and equipment $ 655
Intangible assets 200
Security deposits 5
Accrued expenses (529 )
Notes payable (338 )
Total identifiable assets and liabilities acquired (7 )
Goodwill 652
Total purchase consideration $ 645
The Company engaged an independent valuation specialist to conduct a valuation analysis of the identifiable intangible assets acquired by the Company with the objective of estimating the fair value of such assets as of January 3, 2023. The valuation specialist utilized the ~~Income Approach,~~income approach, specifically the ~~Multi-Period Excess Earnings Method,~~multi-period excess earnings method, to value the existing customer relationship.
Note ~~5 -~~4 – Prepaid and Other Current Assets
Prepaid and other current assets consist of the following (in thousands):
June 30,
2023 December 31,
2022 September 30,
2023 December 31,
2022

License fees $ 215 $ 300 $ 176 $ 300
Notes receivable - - - -
Professional fees 385 - 189 -
Insurance 34 142 59 142
Hudson warrant * 86 85 86 85
Other 36 63 96 63
Total $ 756 $ 590 $ 606 $ 590
* Fair value of warrant issued to Hudson Pacific Properties, L.P. (See Note ~~13)~~12)
Note ~~6 -~~5 – Property & Equipment, Net
Property and equipment, net, consists of the following (in thousands):
June 30, December 31,
2023 2022

Equipment $ 2,456 $ 1,457
Leasehold improvements 362 362
Vehicles 159 -
Computers 55 52
Other 44 -
Total 3,076 1,871
Less accumulated depreciation and amortization (710 ) (462 )
Property and equipment, net $ 2,366 $ 1,409
September 30, December 31,
2023 2022

Equipment $ 2,204 $ 1,457
Leasehold improvements 362 362
Vehicles - -
Computers 57 52
Construction-in-progress 854 -
Total 3,477 1,871
Less: accumulated depreciation (839 ) (462 )
Property and equipment, net $ 2,638 $ 1,409
Depreciation expense for the three months ended ~~June~~September 30, 2023 and 2022 was $0.1 million and $0.1 million, respectively. Depreciation expense for the ~~six~~nine months ended ~~June~~September 30, 2023 and 2022 was $0.3 million and ~~$0.1~~$0.2 million, respectively.

Note ~~7 -~~6 – Intangible Assets, Net
Intangible assets, net, consists of the following (in thousands):
June 30, December 31,
2023 2022

Patents $ 1,800 $ 1,800
Research license 375 375
Customer relationships 200 -
Total 2,375 2,175
Accumulated amortization (687 ) (577 )
Intangible assets, net $ 1,688 $ 1,598
September 30, December 31,
2023 2022

Patents $ 1,800 $ 1,800
Research license 375 375
Customer relationships 200 -
Total 2,375 2,175
Less: accumulated amortization
(742 ) (577 )
Intangible assets, net $ 1,633 $ 1,598
The following table represents the total estimated amortization of intangible assets for the five succeeding years and thereafter as of ~~June~~September 30, 2023 (in thousands):
Estimated
Amortization
Expense Estimated
Amortization
Expense

Six months ended December 31, 2023 $ 121
Nine months ended December 31, 2023 $ 66
Year ended December 31, 2024 235 235
Year ended December 31, 2025 234 234
Year ended December 31, 2026 197 197
Year ended December 31, 2027 and thereafter 901 901
Total $ 1,688 $ 1,633
For the three months ended ~~June~~September 30, 2023 and 2022, amortization expense was approximately $0.1 million and $0.1 million, respectively. For the ~~six~~nine months ended ~~June~~September 30, 2023 and 2022, amortization expense was approximately ~~$0.1~~$0.2 million and ~~$0.1~~$0.2 million, respectively.
Note 87 – Deferred Debt Issuance Costs
Deferred debt issuance costs consist of the following (in thousands):
June 30,
2023 December 31,
2022
SLOC $ 150 $ 223
Line of Credit $ 9,943              -
Total 10,093 223
Accumulated amortization (4,274 ) (73 )
Deferred debt issuance costs, net $ 5,819 $ 150
September 30,
2023 December 31,
2022
Standing letter of credit $ 150 $ 223
Equity letter of credit 555
Line of credit $ 9,943 -
Total 10,648 223
Accumulated amortization (6,801 ) (73 )
Deferred debt issuance costs $ 3,847 $ 150

SLOC
For the three months ended September 30, 2023 and 2022, the Company recognized amortization expense of approximately $0.1 million and $23,000, respectively. For the nine months ended September 30, 2023 and 2022, the Company recognized amortization expense of approximately $0.2 million and $0.1 million, respectively.
Equity line of credit
In July 2023, the Company entered into the equity line of credit (“ELOC”) for the right to sell common stock shares to an investor and recorded deferred debt issuance costs of approximately $0.6 million. For the three and nine months ended September 30, 2023, the Company recognized amortization expense of approximately $0.1 million and $0.1 million, respectively.
Line of Credit

OnIn February 2, 2023, the Company entered into its ~~Line~~line of ~~Credit~~credit and recorded deferred debt issuance costs of approximately $9.9 ~~million (See Note 2).~~million. During the ~~six~~three and nine months ended ~~June~~September 30, 2023, the Company recognized amortization expense of approximately ~~of $4.1~~$2.4 million ~~in connection with the Line of Credit, which is recorded as interest expense on the accompanying condensed consolidated statement of operations.~~and $6.5 million, respectively. During the ~~six~~nine months ended ~~June~~September 30, 2023, in connection with the $2.4 million draw down and issuance of the convertible promissory notes, the Company recognized amortization expense of approximately $0.2 million.
Note 8 – Accrued Expenses
Accrued expenses consisted of the following (in thousands):
September 30,
2023 December 31,
2022

Payroll and related expenses $ 115 $ -
Bonus - 510
Taxes 49 -
Insurance - 104
Other expenses 11 7
Total $ 175 $ 621
Note 9 – Notes Payable
Convertible Notes
2022 Notes
In October 2022, the Company issued convertible notes (the “2022 Notes”) with a principal balance of approximately $5.4 million and warrants to purchase 362,657 shares of the Company’s common stock for net proceeds of $3.5 million. The 2022 Notes is non-interest bearing and secured by the Company’s assets. The maturity date is the earlier of (i) twelve months from the date of issuance or (ii) the closing of a change of control transaction. The 2022 Notes are convertible into shares of the Company’s common stock at a conversion price of $29.70 per share. The warrants have an exercise price of $19.32 per share and expire five years from the issuance date.
In February 2023, the Company entered into waiver agreements with holders of the 2022 Notes which extended the maturity date of the 2022 Notes from October 19, 2023 to April 18, 2024. As consideration for this agreement, the Company issued 96,890 warrants to purchase shares of the Company’s common stock (See Note 10).

In March 2023, the Company entered into the waiver agreements with holders of the 2022 Notes to eliminate the minimum pricing covenant as it relates to Company’s at-the-market facility. As consideration for this agreement, the Company provided the holders with two options to choose from (i) to take an additional five percent original issue discount (“OID”) on their 2022 Note principal or (ii) to be issued shares of common stock with a value equal to the five percent OID, and to issue total shares of 31,724 as converted using the Nasdaq minimum price of $9.42. During the nine months ended September 30, 2023, six of the note holders elected option (i), and the Company increased the respective principal balance of the notes by approximately $0.2 million. The remaining noteholders elected option (ii), and as of September 30, 2023, no shares of common stock have been issued. The Company recorded expense of $0.3 million associated with the commitment to issue shares of the Company’s common stock.
In May 2023, the Company entered into an inducement agreements with the investors to reduce the conversion price of the 2022 Notes in an aggregate principal amount equal to $1.5 million, convertible into 161,603 shares of the Company’s common stock at $9.28 per share. The remaining investors agreed to reduce the conversion price of the 2022 Notes in an aggregate principal amount equal to $1.4 million, convertible into 127,393 shares of the Company’s common stock at $10.93 per share.
The Company elected to account for the 2022 Notes under the fair value option. For the inducement agreements that were entered into as described above, the Company accounted for the change in the terms through the fair value adjustment of $2.7 million, which is ~~recorded as interest expense~~included in the change in fair value of notes on the ~~accompanying condensed consolidated statement of operations (See Note 2).~~
~~SLOC~~
For the three months ended June 30, 2023 and 2022, in connection with its SLOC, the Company recognized amortization expense of approximately $28,000 and $26,000, respectively, which is recorded as interest expense on the accompanying condensed consolidated statements of ~~operations. For~~operations, upon the ~~six~~settlement of $0.2 million principal balance of the 2022 Notes as part of the exchange agreements, and $1.0 million principal balance of the 2022 Notes in June 2023 based on the issuance of 248,981 shares of the Company’s common stock.
Senior Secured Notes
In January 2023, the Company issued senior secured notes (“Senior Secured Notes”) with a principal balance of approximately $1.2 million and warrants to purchase 41,667 shares of the Company’s common stock for net proceeds of $1.0 million. The Senior Secured Notes do not bear interest, and mature three months ~~ended~~from the date of issuance. Pursuant to these terms, the Senior Secured Notes were subsequently extended to May 3, 2023, incurring an additional 10% on principal. The warrants are exercisable for five years at an exercise price of $19.32 per share.
In May 2023, the Company entered into several amendments to extend the Senior Secured Notes maturity date with the investors. In exchange, the Company issued a total of 203,500 shares of common stock to the investors.
The Company concluded that a troubled debt restructuring did not occur, but an extinguishment of the outstanding senior secured notes occurred. Subsequent to the extinguishment, the Company concluded to account for the Senior Secured Notes using the fair value option. The Company recorded an extinguishment loss of $2.2 million.
On June 4, 2023, $0.2 million of the outstanding Senior Secured Notes was settled. The Company accounted for the settlement as an extinguishment that resulted in a $0.1 million gain and resulted in $0.1 million being recorded as Series F convertible preferred stock and $0.1 million being recorded as part of the warrant liability.
On June 30, 2023, the Company and ~~2022,~~the remaining investors agreed to extend the maturity date of the 2023 Notes until July 31, 2023, in exchange for 41,667 shares of common stock. The Company recorded a change in fair value adjustment of $0.3 million based on the fair value of the 41,667 shares of common stock.
On July 10, 2023, the Company and the remaining investors entered into a forbearance agreement, which was subsequently amended on July 14, 2023. The forbearance agreement provides that the investor shall forbear the exercise of its rights and remedies due to certain events of defaults under the Senior Secured Notes, including payment, until December 31, 2023, in exchange for a non-refundable and indefeasible payment of $0.1 million in the form of a promissory note due December 31, 2023 (the “December 2023 Note). The December 2023 Note was never executed and the Senior Secured Notes investors fully settled the outstanding balance for a total of 189,602 shares of common stock during July and August 2023. The Company recorded a change in fair value adjustment of $39,000 at settlement of the Senior Secured Notes. As of September 30, 2023, there was no outstanding balance related to the Senior Secured Notes.

2023 Note
In February 2023, upon drawing down on the line of credit, the Company issued a Secured Promissory Note (the “2023 Note”) totaling $2.0 million, which is due and payable 60 days from the issuance date. The 2023 Note is non-interest bearing and secured by the Company’s assets. The 2023 Note is convertible into shares of the Company’s common stock at $30.00 per share.
In April 2023, the Company entered into a first amendment to the 2023 Note with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note balance until May 1, 2023 in exchange for 33,333 shares of the Company’s common stock. The 2023 Note was further amended to accrue interest at the 15% per annum from the original funding date of the 2023 Note. The Company recorded a change in fair value adjustment of $0.2 million related to the commitment to issue 33,333 shares of the Company’s common stock.
On May 1, 2023, the Company entered into a second amendment to the 2023 Note with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note balance until May 15, 2023
On May 15, 2023, the Company entered into a third amendment to the 2023 Note with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note until June 7, 2023 in exchange for 4,000 shares of the Company’s Series E preferred stock, which are convertible into 66,667 shares of the Company’s common stock. The Company recorded a change in fair value adjustment of $0.7 million related to the commitment to issue 4,000 shares of the Company’s Series E preferred stock.
On May 16, 2023, the Company made a second draw of $0.2 million under the line of credit. Upon drawing down on the line of credit, the Company issued a second Secured Promissory Note (the “2^nd 2023 Note”) which is due and payable on July 16, 2023. The 2^nd2023 Note shall accrue interest at the 15% per annum from the original funding date of the 2^nd 2023 Note.
On May 26, 2023, the Company made a third draw of $0.2 million under the line of credit. Upon drawing down on the line of credit, the Company issued a third Secured Promissory Note (the “3^rd 2023 Note”) which is due and payable on June 2, 2023. The 3^rd2023 Note included a $0.2 million commitment fee and does not bear interest. With the 3^rd 2023 Note, the Company recorded a change in fair value adjustment of $0.2 million related to the commitment fee.
On May 26, 2023, the Company entered into a fourth amendment to the 2023 Note, pursuant to which the Company will issue to the holder a convertible promissory note in the principal amount of $0.2 million due June 2, 2023 in exchange for 4,000 shares of the Company’s Series E preferred stock, which are convertible into 66,667 shares of the Company’s common stock. The Company recorded a change in fair value adjustment of $0.6 million related to the commitment to issue 4,000 shares of the Company’s Series E preferred stock.
On June 13, 2023, the Company partially redeemed the principal of the 2023 Note. In addition to the accrued interest and commitment fees, the total redeemed balance was approximately $2.1 million. With the settlement of the 2^nd 2023 and the 3^rd2023 Note, the Company recorded a change in fair value adjustment of $0.1 million.
On June 30, 2023, the Company and the line of credit lender agreed to amend the 2^nd 2023 Note and the 3^rd 2023 Note to extend the maturity dates of each until July 16, 2023. In connection with ~~its SLOC,~~the amendments, the Company ~~recognized amortization~~agreed to issue to the line of credit lender 5,000 shares of the Company’s Series E preferred stock, which is convertible into 83,333 shares of the Company’s common stock. Additionally, the Company agreed to issue an additional 8,000 shares of the Company’s Series E preferred stock, which is convertible into 133,333 shares of the Company’s common stock, to the line of credit lender for failure to comply with a covenant in the line of credit, as amended. The Company recorded a change in fair value adjustment of $2.0 million related to the commitment to issue 13,000 shares of the Company’s Series E preferred stock.
During July 2023, the Company repaid the outstanding balance of the 2^nd 2023 Note and 3^rd 2023 Note for cash of $0.4 million. As of September 30, 2023, there was no outstanding balance related to the 2^nd 2023 Note and 3^rd 2023 Note.

Demand Note
Between May 17 and May 18, 2023, the Company issued secured demand promissory notes (the “Demand Notes”) in an aggregate principal amount equal to $0.2 million. The Demand Notes are due and payable at any time upon demand by the noteholders after the earlier of (i) the consummation of the Company’s first securities offering after the issuance of the Demand Notes or (ii) July 16, 2023. The Demand Notes do not bear interest. In connection with the issuance of the Demand Notes, the Company agreed to issue an aggregate of 76,626 shares of the Company’s common stock to the Demand Note holders. The Company recorded expense of ~~approximately $69,000~~$0.2 million associated with the commitment to issue shares of the Company’s common stock.
On May 30, 2023, the Company issued secured demand promissory notes (the “2^nd Demand Notes”) in an aggregate principal amount equal to $0.1 million. The 2^nd Demand Notes are due and ~~$29,000, respectively.~~payable at any time upon demand by the noteholder after the earlier of (i) the consummation of the Company’s first securities offering after the issuance of the 2^nd Demand Notes or (ii) July 16, 2023. The 2^nd Demand Notes do not bear interest. In connection with the issuance of the 2^nd Demand Notes, the Company agreed to issue an aggregate of 46,935 shares of the Company’s common stock to the 2^nd Demand Notes holders. The Company recorded expense of $0.1 million associated with the commitment to issue shares of the Company’s common stock.
On July 25, 2023, the Company entered into the Demand Secured Promissory Note Agreement (“Q3 Demand Notes”) with two investors for a purchase price of $20,000 each and with an original issue discount of $12,000. Upon settlement, the Company is obligated to pay a total of $0.1 million in principal for the issuance of both notes. The Q3 Demand Notes are due and payable at any time upon demand by the holder after the earlier of (i) the consummation of the Company’s first securities offering after the issuance of the Q3 Demand Notes and (ii) January 25, 2024.
Note 910 - Fair Value Measurements
The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of ~~June~~September 30, 2023 and December 31, 2022:
Fair value measured at June 30, 2023 Fair value measured at September 30, 2023
Total
carrying
value at
June 30,
2023 Quoted
prices in
active
markets
(Level 1) Significant
other
observable
inputs
(Level 2) Significant
unobservable
inputs
(Level 3) Total
carrying
value Quoted
prices in
active
markets
(Level 1) Significant
other
observable
inputs
(Level 2) Significant
unobservable
inputs
(Level 3)
Liabilities:
Convertible notes $ 1,470 $           - $           - $ 1,470
Warrant liability $ 2,721 $ - $ - $ 2,721 $    34 $          - $                - $      34
Fair value measured at December 31, 2022 Fair value measured at December 31, 2022
Total
carrying
value at
December 31,
2022 Quoted
prices in
active
markets
(Level 1) Significant
other
observable
inputs
(Level 2) Significant
unobservable
inputs
(Level 3) Total
carrying
value Quoted
prices in
active
markets
(Level 1) Significant
other
observable
inputs
(Level 2) Significant
unobservable
inputs
(Level 3)
Liabilities:
Convertible notes $ 1,654 $             - $             - $ 1,654 $ 1,654 $             - $          - $    1,654
Warrant liability $ 972 $ - $ - $ 972 $ 972 $ - $ - $ 972

For the ~~six~~nine months ended ~~June~~September 30, 2023 there was ~~an increase~~a decrease of approximately ~~$1.6~~$2.6 million in Level 3 liabilities measured at fair value.
The fair value of the convertible notes may change significantly as additional data is obtained, impacting the Company’s assumptions used to estimate the fair value of the liabilities. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods.
The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2023. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to unobservable (e.g., changes in unobservable long-dated volatilities) inputs.
Convertible
Notes Warrant
Liability
Balance at December 31, 2022 $ 1,654 $ 972
Conversion of October convertible notes (516 )
Issuance of convertible note in connection with Line of Credit 2,000
Change in fair value of convertible notes in connection with March waiver agreement 368
Gain on issuance of  convertible note (64 )
January Notes - reclass to fair value option 1,117
Settlement in Connection with October Note (2,166 )
Conversion of October Notes (1,685 )
Settlement in Connection with LOC (5,893 )
LOC Note issuance 350
Warrants issued in connection with January promissory note 157
Warrants issued in connection with Line of Credit 5,593
Warrants issued in connection with inducement agreement 760
Warrants issued in connection with February waiver agreement 711
Fair value of warrants exercised (759 )
Other income (expense): 504
Warrants Issued in connection with Demand Notes Series F Exchange 140
Warrants Issued in connection with January Notes Series F Exchange 50
Warrants Issued in connection with October Notes Series F Exchange 639
Warrants Issued in connection with Series D to Series F Exchange 450
Warrants Issued in connection with Series F-1 956
Warrants Issued in connection with Series F-2 285
Change in fair value 6,305 (7,737 )
Balance at June 30, 2023 $ 1,470 $ 2,721
2022 Convertible Notes at Fair Value
~~During the year ended December 31, 2022, the Company issued convertible promissory notes (the “2022 Notes”).~~ The fair value of the 2022 Notes on the issuance dates, and as of ~~December 31, 2022~~September 30, 2023 were estimated using a Monte Carlo simulation to capture the path dependencies intrinsic to their terms. The significant unobservable inputs used in the fair value measurement of the Company’s convertible notes are the common stock price, volatility, and risk-free interest rates. ~~Significant changes in these inputs may result in significantly lower or higher fair value measurement.~~ The Company elected the fair value option when recording its 2022 Notes and the 2022 Notes were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other income (expense) on the statements of operations and disclosed in the condensed consolidated financial statements.

During the ~~six~~nine months ended ~~June~~September 30, 2023, seven noteholders converted a portion of their 2022 Notes into 248,981 shares of the Company’s commons stock (See Note ~~11)~~9). The fair value of the converted notes totaled $2.2 million.
In February ~~Waiver Agreement~~
~~On February 28,~~ 2023, the Company entered into waiver agreements with holders of the 2022 Notes (See Note ~~11)~~9). In connection with ~~this~~the waiver agreement, the 2022 Notes were revalued as of the amendment date.

~~March Waiver Agreement~~
OnIn March ~~24,~~ 2023, the Company entered into the second waiver agreements with holders of the 2022 Notes (See Note ~~11)~~9). A ~~select~~ number of holders elected to increase the principal balance of their notes. The Company revalued the respective notes on the date prior to the amendment date and again on the amendment date. The change in fair value related to the amendment of these 2022 Notes was approximately $0.4 million.
OnIn June 4,2023, the Company entered into an ~~Exchange Agreement where~~exchange agreement and $0.2 million fair value of the 2022 Notes ~~balance with a fair value of $0.2 million~~ was exchanged for 206 shares of Series F Preferred stock. As of ~~June~~September 30, 2023, there was no outstanding balance related to the 2022 Notes.
Line of Credit

OnIn February 3, 2023, the Company drew down $2.0 million from the ~~Line~~line of ~~Credit~~credit and ~~in accordance with the terms of the agreement~~ issued the 2023 ~~Note~~Notes of $2.0 million. The 2023 Note had fair value at issuance of $1.9 million and the Company recorded a gain on issuance of approximately $0.1 million, which is included in other income (expense) on the ~~accompanying~~ condensed consolidated statement of operations.
~~Between~~In May ~~17, 2023 and May 30,~~ 2023, the Company drew down $0.4 million from the ~~Line~~line of ~~Credit~~credit and in accordance with the terms of the agreement issued the 2^nd2023 Notes and 3^rd 2023 Notes. During July 2023, the Company repaid the outstanding balance of $0.4 million in cash.
As of ~~June~~September 30, 2023, there was no outstanding balance related to the 2023 Notes.
The following table provides the changes in fair value of the ~~2023 Note was approximately $0.3 million.~~2022 Notes and warrant liability (in thousands):
Convertible
Notes Warrant
Liability
Balance at December 31, 2022 $ 1,654 $ 972
Conversion of 2022 Notes (516 )
Issuance of 2023 Notes in connection with line of credit 2,000
Change in fair value of 2022 Notes in connection with March waiver agreement 368
Senior Secured Notes - reclass to fair value option 1,133
Conversion of 2022 Notes into Series F in connection with exchange agreements (243 )
Conversion of 2022 Notes (950 )
Settlement in connection with line of credit (1,747 )
Issuance of 2^nd 2023 Notes and 3^rd 2023 Notes 350
Repayment of line of credit, 2^nd 2023 Notes and 3^rd 2023 Notes (600 )
Settlement in connection with Senior Secured Notes (1,107 )
Warrants issued in connection with Senior Secured Notes 157
Warrants issued in connection with line of credit 5,593
Warrants issued in connection with inducement agreement 760
Warrants issued in connection with February waiver agreement 711
Fair value of warrants exercised (759 )
Loss on extinguishment of warrant liability 504
Warrants Issued in connection with Demand Notes to Series F exchange 140
Warrants Issued in connection with Senior Secured Notes to Series F exchange 50
Warrants Issued in connection with 2022 Notes to Series F exchange 639
Warrants Issued in connection with Series D to Series F exchange 450
Warrants Issued in connection with Series F-1 956
Warrants Issued in connection with Series F-2 285
Change in fair value (342 ) (10,424 )
Balance at September 30, 2023 $ - $ 34

Warrants
~~Senior Secured~~2022 Notes
In connection with the issuance of its senior secured notes on January 3, 2023 (See Note 11), the Company issued 41,667 warrants to purchase shares of the Company’s common stock. The warrants had a fair value at issuance of $157,000, and as of June 30, 2023 have a fair value of $35,000.
~~Line of Credit~~
On February 2, 2023, in connection with the issuance of its Line of Credit, the Company issued 45,000 warrants to purchase shares of its Series E preferred stock (See Note 13). The warrants had a fair value at issuance of approximately $5.6 million, and as of June 30, 2023 have a fair value of approximately $0.4 million.
~~Warrant Inducement and Exercise Agreement~~
~~During the year ended December 31, 2022, in~~ connection with the 2022 Notes, the Company issued 362,657 warrants to purchase shares of the Company’s common stock.
During the ~~six~~nine months ended ~~June~~September 30, 2023, ~~in connection with its 2022 Notes,~~ the Company entered into a warrant inducement and exercise agreement with certain holders. Under the terms of the agreement, the holders exercised 106,764 warrants with a fair value of approximately ~~$0.76~~$0.8 million and the Company issued 106,764 new warrants to purchase shares of its common stock with a fair value of ~~$1.26~~$1.3 million. The Company recognized a loss on extinguishment of the warrants of approximately $0.5 million which is included in other income (expense) on the ~~accompanying~~ condensed consolidated statement of operations.
February Waiver Agreement
~~As consideration for~~In connection with the February waiver agreement, the Company issued 96,890 warrants to purchase shares of the Company’s common stock with a fair value of $0.7 million on the issuance date.
As of ~~June~~September 30, 2023, there ~~are 459,547~~were 96,980 warrants outstanding ~~issued in~~with nominal fair value.
Series F Preferred Stock Exchange Agreements
In connection with the ~~2022 Notes,~~Series F preferred stock exchange agreements, the Company issued 592,137 warrants to purchase shares of the Company’s common stock. The Company concluded that the exchange warrants are liability classified with a fair value of $1.3 million as of the issuance date. As of September 30, 2023, the exchange warrants had a nominal fair value.
Senior Secured Notes
In connection with the issuance of the Senior Secured Notes in January 2023 (See Note 9), the Company issued 41,667 warrants to purchase shares of the Company’s common stock. The Company estimated the aggregate fair value of the warrants on the issuance date to be approximately ~~$0.4 million.~~$0.2 million, and nominal value as of September 30, 2023.
Line of Credit

In February 2023, in connection with the issuance of its line of credit, the Company issued 45,000 warrants to purchase shares of its Series E preferred stock (See Note 11). The Company estimated the aggregate fair value of the warrants on the issuance date to be approximately $5.6 million, and nominal value as of September 30, 2023.
Series F-1 and F-2 Issuances
As part of the Series F-1 and F-2 preferred stock issuances, the Company issued 523,323 warrants to purchase shares of the Company’s common stock. The Company concluded that the Series F-1 and Series F-2 warrants are liability classified with a fair value of $1.2 million as of the issuance date. As of September 30, 2023, the fair value of the Series F-1 and Series F-2 warrants were nominal.
The warrants were classified as liabilities and measured at fair value on the grant date, with changes in fair value recognized as other income (expense) on the condensed consolidated statements of ~~operations and disclosed in the condensed consolidated financial statements.~~operations.

~~Exchange Agreements~~
As part of the Exchange Agreements, the Company issued 592,129 warrants to purchase shares of the Company’s common stock. The Company concluded that the Exchange Warrants are liability classified with a fair value of $1.3 million as of June 4, 2023 issuance date. As of June 30, 2023, the fair value of the Exchange Warrants is $1.0 million.
~~Series F-1 and F-2 Issuances~~
As part of the Series F-1 and F-2 Preferred Stock issuances, the Company issued 523,323 warrants to purchase shares of the Company’s common stock. The Company concluded that the Series F-1 and Series F-2 Warrants are liability classified with a fair value of $1.2 million as of the issuance date. As of June 30, 2023, the fair value of the Series F-1 and Series F-2 Warrants is $0.9 million.
A summary of significant unobservable inputs (Level 3 inputs) used in measuring warrants on the issuance dates and as of ~~June~~September 30, 2023 and December 31, 2022 is as follows:
Series F / F-1 / F-2 2022 Notes Warrants -
January
Note Warrants -
Series E -
LOC December 31,
2022
Date 6/4/2023 6/30/2023 6/30/2023 6/30/2023 12/31/2022
Dividend yield 0.0% 0.0% 0.0% 0.0% 0%
Expected price volatility 50.0% 50.0% 50.0% 50.0% 48.7%
Risk free interest rate 3.8% - 4.1% 4.19% - 4.26% 4.22% 4.20% 4.74%
Expected term (in years) 5.0 4.3 - 4.7 4.5 4.6 0.8
~~Significant changes in the expected price volatility and expected term would result in significantly lower or higher fair value measurement of the warrants, respectively.~~
~~Note 10 - Accrued Expenses~~
~~As of June 30, 2023 and December 31, 2022, the Company’s accrued expenses consisted of the following (in thousands):~~
June 30,
2023
December 31,
2022

Payroll and related expenses $ 274 $ -
Bonus - 510
Taxes 32 -
Insurance - 104
Other expenses 103 7
Total $ 409 $ 621

~~Note 11 - Notes Payable~~
~~Convertible Notes~~
~~2022 Notes~~
On October 19, 2022, the Company issued its 2022 Notes with a principal balance of approximately $5.4 million and warrants to purchase 362,657 shares of the Company’s common stock for net proceeds of $3.5 million. The 2022 Notes were issued with a conversion price at a 54% premium to the most recent closing price, an original issue discount (“OID”) of 35%, do not bear interest, and mature upon the earlier of twelve months from the date of issuance or the closing of a change of control transaction (as defined in the 2022 Notes). The 2022 Notes are convertible into shares of the Company’s common stock at a conversion price of $29.7 per share, subject to adjustment under certain circumstances described in the notes. The 2022 Notes are secured by all of the Company’s assets (subject to exceptions for certain strategic transactions). The warrants have an exercise price of $19.32 per share and expire five years from the issuance date (subject to adjustment under certain circumstances described in the warrants).
During the six months ended June 30, 2023, in connection with its 2022 Notes, the Company entered into a warrant inducement and exercise agreement with certain holders of the 2022 Notes (See Notes 7 and 13).
On February 28, 2023, the Company entered into waiver agreements with holders of the 2022 Notes which extended the maturity date of the 2022 Notes from October 19, 2023 to April 18, 2024. As consideration for this agreement, the Company issued 96,890 warrants to purchase shares of the Company’s common stock (See Note 7 and 13).
On March 24, 2023, the Company entered into the waiver agreements with holders of the 2022 Notes to eliminate the minimum pricing covenant as it relates to Company’s At-The-Market facility. As consideration for this agreement, the Company provided the holders with two options to choose from i) to take an additional 5% OID on their October note principal or ii) pending shareholder approval, to be issued shares of common stock with a value equal to the 5% OID, and to issue total shares of 31,724 as converted using the Nasdaq minimum price of $9.42. During the six months ended June 30, 2023, six of the note holders elected option i), and the Company increased the respective principal balance of the notes by approximately $0.15 million. The remaining noteholders elected option ii), and as of the date of this report, no shares of common stock have been issued. The Company recorded expense of $0.3 million associated with the commitment to issue shares of the Company’s common stock.
On May 12, 2023, the Company entered into letter agreements (the “Inducement Agreements”) with certain of the October Investors, pursuant to which such October Investors agreed to reduce the conversion price of October Notes in an aggregate principal amount equal to $1,500,000, to $9.42 per share, which are now convertible into 161,561 shares of the Company’s common stock, representing an increase of 83,849 shares in excess of the number of shares into which such October Notes were convertible prior to the Company’s entry into the Inducement Agreements.
On May 17, 2023, the Company entered into Inducement Agreements with the remaining October Investors, pursuant to which such October Investors agreed to reduce the conversion price of October Notes in an aggregate principal amount equal to $1,392,657, to $10.932 per share, which are now convertible into 127,393 shares of the Company’s common stock, representing an increase of 55,242 shares in excess of the number of shares into which such October Notes were convertible prior to the Company’s entry into the Inducement Agreements.
The Company elected to account for the October Notes under the fair value option. For the Inducement Agreements that were entered into as described in Note 2, the Company accounted for the change in the terms through the fair value adjustment of $2.7 million, which is included in the $6.9 million Change in FV of Notes on the Income Statement, upon the settlement of $0.2 million principal balance of the October Notes on June 4, 2023 as part of the Exchange Agreements and $1.0 million principal balance of October Notes on June 21, 2023 based on the issuance of 248,981 shares of the Company’s Common Stock.

Series F / F-1 / F-2 2022 Notes Warrants -
Senior Secured
Note Warrants -
Series E -
Line of Credit December 31,
2022
Date 9/30/2023 9/30/2023 9/30/2023 9/30/2023 12/31/2022
Dividend yield 0.0% 0.0% 0.0% 0.0% 0.0%
Expected price volatility 70.0% 65.0% 65.0% 65.0% 48.7%
Risk free interest rate 4.63% 4.69% 4.22% 4.67% 4.74%
Expected term (in years) 4.7 4.1 4.3 4.3 0.8
~~2023 Note~~
On February 3, 2023, upon drawing down on the Line of Credit, the Company issued its 2023 Note totaling $2.0 million, which is due and payable 60 days from the issuance date. The 2023 Note is non-interest bearing and secured by the Company’s assets. The 2023 Note issued with the initial $2.0 million drawdown is convertible into shares of the Company’s common stock, at a conversion price per share of $30.00 per share, subject to adjustment under certain circumstances described in the 2023 Note. Notes evidencing future withdrawals, if any, will be convertible into common stock only upon the declaration of an event of default under such promissory note.
On April 14, 2023, the Company entered into a First Amendment to the 2023 Note with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note balance until May 1, 2023 in exchange for 33,333 shares of the Company’s common stock pending shareholder approval. The 2023 Note was further amended to accrue interest at the fifteen percent (15%) per annum from the original funding date of the 2023 Note. The Company recorded a change in fair value adjustment of $0.2 million related to the commitment to issue 33,333 shares of the Company’s common stock.
On May 1, 2023, the Company entered into a Second Amendment to the 2023 Note with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note balance until May 15, 2023
On May 15, 2023, the Company entered into a Third Amendment to the 2023 Note with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note until June 7, 2023 in exchange for 4,000 shares of the Company’s Series E Preferred Stock, which are convertible into 66,667 shares of the Company’s common stock pending shareholder approval. The Company recorded a change in fair value adjustment of $0.7 million related to the commitment to issue 4,000 shares of the Company’s Series E Preferred Stock.
~~On May 16, 2023, the Company made a second draw of $0.2 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company issued a second Secured Promissory Note (the “2~~^nd ~~2023 Note”) which is due and payable July 16, 2023. The 2~~^nd ~~2023 Note shall accrue interest at the fifteen percent (15%) per annum from the original funding date of the 2~~^nd ~~2023 Note.~~
~~On May 26, 2023, the Company made a third draw of $0.15 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company issued a third Secured Promissory Note (the “3~~^rd ~~2023 Note”) which is due and payable June 2, 2023. The 3~~^rd ~~2023 Note included a $200,000 Commitment fee and does not bear interest. With the 3~~^rd ~~2023 Note, the Company recorded a change in fair value adjustment of $0.2 million related to the Commitment fee.~~
On May 26, 2023, the Company entered into that certain Fourth Amendment to the 2023 Note with the lender, pursuant to which the Company will issue to Holder a convertible promissory note in the principal amount of $0.15 million due June 2, 2023 in exchange for 4,000 shares of the Company’s Series E Preferred Stock, which are convertible into 66,667 shares of the Company’s common stock pending shareholder approval. The Company recorded a change in fair value adjustment of $0.6 million related to the commitment to issue 4,000 shares of the Company’s Series E Preferred Stock.
~~On June 13, 2023, the Company partially redeemed the principal of the 2023 Note and fully redeemed the principal of the 2~~^nd ~~2023 Note and the 3~~^rd ~~2023 Notes in addition to all accrued interest and commitment fees owing for approximately $2.1 million. With the settlement of the 2~~^nd ~~2023 and the 3~~^rd~~2023 Note, the Company recorded a change in fair value adjustment of $0.1 million.~~
~~On June 30, 2023, the Company and the LOC Lender agreed to amend the 2~~^nd ~~2023 Note and the 3~~^rd 2023 Note to extend the maturity dates of each until July 16, 2023. In connection with the amendments, the Company agreed to issue to the LOC Lender: 5,000 shares of the Company’s Series E Preferred Stock, which is convertible into 83,333 shares of the Company’s Common Stock. Additionally, the Company agreed to issue an additional 8,000 shares of the Company’s Series E Preferred Stock, which is convertible into 133,333 shares of the Company’s Common Stock, to the LOC Lender for failure to comply with a covenant in the Line of Credit, as amended. The Company recorded a change in fair value adjustment of $2.0 million related to the commitment to issue 13,000 shares of the Company’s Series E Preferred Stock pending shareholder approval.

~~Senior Secured Notes~~
On January 3, 2023, the Company issued senior secured notes with a principal balance of approximately $1.2 million and warrants to purchase 41,667 shares of the Company’s common stock for net proceeds of $1.0 million. The senior secured notes were issued with an original issue discount of 16.7%, do not bear interest, and mature three months from the date of issuance (unless extended pursuant to the terms of the notes). Pursuant to these terms, the Notes were subsequently extended to May 3, 2023 incurring an additional 10% on Principal or $120,000. The warrants are exercisable for five years at an exercise price of $19.32, subject to adjustment under certain circumstances described in the warrants.
On May 8, 2023, the Company entered into a letter agreement (the “Extension Letter”) with the lead noteholder and collateral agent for the January Notes (the “Agent”), pursuant to which we agreed to issue an aggregate of 11,833 shares of Common Stock to the holders of January Notes in exchange for the extension of the maturity date thereof until May 15, 2023.
On May 15, 2023, the Agent agreed to grant us an additional extension of the maturity date thereof until May 23, 2023 in exchange for the issuance by us to the holders of January Notes, on a pro rata basis, of 66,667 shares of our Common Stock, pending shareholder approval.
Subsequently, on May 23, 2023, the Agent agreed to grant us an extension of the maturity date thereof until May 31, 2023 in exchange for the issuance by us to the January Investors, on a pro rata basis, of 25,000 shares of our Common Stock, pending shareholder approval.
Thereafter, on May 31, 2023, the Agent for the January Notes agreed to grant us an extension of the maturity date thereof until June 12, 2023 in exchange for the issuance by us to the January Investors, on a pro rata basis, of 100,000 shares of our Common Stock, pending shareholder approval.
With the completion of the Extension Letter and additional extensions, the Company concluded that a troubled debt restructuring did not occur, but an extinguishment of the outstanding senior secured notes occurred. Subsequent to the extinguishment, the Company concluded to account for the senior secured notes using the fair value option. The Company recorded an extinguishment loss of $2.2 million. The loss was comprised of the fair value of the shares of Common Stock on the dates issued to extend the maturity date as discussed above.
On June 4, 2023, $0.2 million of the outstanding senior secured notes was settled as part of the Exchange Agreements described below. The Company accounted for the settlement as an extinguishment that resulted in a gain being recognized of $0.1 million and resulted in $0.1 million being recorded as Series F convertible preferred stock and $0.1 million being recorded as part of the warrant liability.
On June 30, 2023, the Company and the remaining January Investors agreed to extend the maturity date of the January Notes until July 31, 2023, in exchange for 41,667 shares of our Common Stock pending approval by shareholders. The Company recorded a change in fair value adjustment of $0.3 million based on the fair value of the 41,667 shares of Common Stock. As of June 30, 2023, the fair value of the outstanding senior secured notes approximated the principal balance of $1.1 million.
The secured notes and warrants were not registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state and were offered and sold in reliance upon the exemption from registration afforded by Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering. The Investors are “accredited investors” as such term is defined in Regulation D promulgated under the Securities Act.
Note 1211 – Stockholders’ Equity
Preferred Stock
As of ~~June~~September 30, 2023, ~~and December 31, 2022,~~ there were 50,000,000 authorized shares of the Company’s preferred stock with par value of $0.0001.
Series A Preferred Sock
As of ~~June~~September 30, 2023 and December 31, 2022, 251 shares of Series A preferred stock are issued and outstanding.
Series B Preferred Stock
As of ~~June~~September 30, 2023 and December 31, 2022, 1,443 shares of Series B preferred stock are issued and outstanding.
Series C Preferred Stock
As of ~~June~~September 30, 2023 and December 31, 2022, 500,756 shares of Series C preferred stock are issued and outstanding.

Series D Preferred Stock
On July 8, 2022, the Company’s Board of Directors authorized 7,000 shares of Series D preferred stock with a par value of $0.0001 per share. Each preferred share of Series D preferred stock has a stated valued of $16.67 per share, is convertible into shares of the Company’s common stock at an initial conversion price of $78.00 per share, and is entitled to a dividend of 12% per annum. The cumulative dividends shall be paid in common stock based on the conversion price in effect on the applicable conversion date. All accrued but unpaid dividends on shares of Series D preferred stock shall increase the stated value of such shares. The Company may redeem all, but not less than all, of the Series D preferred stock for cash, at a price per share of Series D preferred stock equal to 125% of the stated value. The Series D preferred stock has no voting rights.
~~In July 2022, the Company issued 1,058 shares of Series D preferred stock for approximately $1.1 million.~~ As of ~~June~~September 30, 2023 and December 31, 2022, zero and 1,058 shares of Series D preferred stock are issued and outstanding. ~~1,058 shares of Series D preferred stock were exchanged for Series F Preferred Stock and Exchange Warrants as part of the Exchange Agreements during June 2023.~~
In connection with the issuance of the 1,058 shares of Series D preferred stock, the Company issued 13,568 equity-classified warrants to purchase shares of the Company’s common stock with an exercise price of $78.00 per share. The proceeds from the Series D preferred stock were allocated between the warrants and the Series D preferred stock based on their relative fair values.
The Company entered into a Registration Rights Agreement (“RRA”) with the holders of the Series D preferred stock, whereby the Company was to use its best efforts to file a registration statement registering the resale of the shares of common stock issuable upon conversion of the Series D preferred stock and upon exercise of the warrants within thirty (30) calendar days following the closing of the Series D preferred stock offering. The Company was to use its best efforts to have the registration statement declared “effective” within ninety (90) calendar days from closing, or one hundred and twenty (120) from closing in the event the registration statement is reviewed by the SEC. If the Company fails to meet these requirements, the RRA states that the Company shall pay to each holder an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate subscription amount paid by such holder pursuant to the purchase agreement, up to an aggregate of 10% of the aggregate subscription amount paid by such holder pursuant to the purchase agreement for all such liquidated damages.
Using the guidance provided by ASC 825-20 Financial Instruments, the Company determined that the RRA should be accounted for as a separate unit of account from the Series D preferred stock. Accordingly, under ASC 825-20, a financial instrument that is both within the scope of ASC 825-20 and subject to a registration payment arrangement shall be recognized and measured in accordance with ASC 825-20 without regard to the contingent obligation to transfer consideration pursuant to the registration payment arrangement.
The RRA called for the Company to file a registration statement by August 25, 2022 and declare it effective within 90 days of July 26, 2022. The Company filed its registration statement on November 17, 2022, and the holders of the Series D preferred stock waived the related registration rights penalty of approximately $2,400.
The Series D preferred stock and warrants sold were not registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state and were offered and sold in reliance on the exemption from registration afforded by Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering. The holders of Series D preferred stock are “accredited investors” as such term is defined in Regulation D promulgated under the Securities Act.
During the six months ended June 30, 2023, the Company filed the first amendment to its Series D preferred stock, which modifies the conversion price of the Series D preferred stock from $78.00 to $30.00 per share. The modification increased the fair value of the Series D preferred stock by approximately $6,000, which the Company recorded as a deemed dividend.

Series E Preferred Stock
On February 1, 2023, the Company’s Board of Directors authorized 77,000 shares of Series E preferred stock with a par value of $0.0001 per share, in connection with its ~~2023 Line~~line of ~~Credit.~~credit. Each share of Series E ~~Preferred Stock~~preferred stock is convertible into 1,000 shares of the Company’s common stock at the option of the holders. The holders of the Series E preferred stock shall receive dividends on an as converted basis together with the holders of the Company’ common stock. The Series E preferred stock has no voting rights and does not have a preference upon any liquidation, dissolution or winding-up of the Company.
Holders of Series E preferred stock are prohibited from converting shares of Series E preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be initially set at 4.99% and thereafter adjusted by the holder to a number between 4.99% and 9.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. In addition, in the event a conversion of Series E preferred stock would result in the holder owning more than 19.99% of the Company’s outstanding shares of common stock, the number of shares of common stock that may be issued upon such conversion of Series E preferred stock, shall be limited to 19.99% of the Company’s outstanding shares of common stock on that date, unless stockholder approval is obtained by the Company to issue a number of shares of common stock exceeding the limit.
On February 2, 2023, in connection with its ~~Line~~line of ~~Credit,~~credit, the Company issued 5,000 shares of Series E ~~Preferred Stock~~preferred stock as a commitment fee with a fair value of ~~$1.45~~$1.5 million. In addition, the Company agreed to issue an additional 5,000 shares of Series E preferred stock on both the first and second anniversary date of the ~~Line~~line of ~~Credit,~~credit, or 10,000 shares on the first anniversary, if the Company does not elect to extend the maturity date of the ~~Line~~line of ~~Credit.~~credit. The fair value of the additional 10,000 shares of Series E preferred stock on the issuance date totaled $2.9 million. The Company recorded the total fair value of ~~$4.35~~$4.4 million as additional paid-in capital with the offsetting increase to deferred debt issuance costs. ~~The deferred debt issuance costs will be amortized over the term of the Line of Credit.~~
As of ~~June~~September 30, 2023, following Series E preferred stock conversions, zero shares of Series E preferred stock are issued and outstanding. There were no shares of Series E preferred stock issued and outstanding as of December 31, 2022.

Series F Preferred Stock
On June 4, 2023, the Company entered into ~~Exchange Agreements:~~exchange agreements with (i) ~~with~~ the ~~October Investors~~2022 Notes investors for the exchange of ~~October~~2022 Notes in the aggregate principal amount of $2.6 million for 2,622 shares of the Company’s ~~newly created~~ Series F ~~Convertible Preferred Stock~~convertible preferred stock (“Series F ~~Preferred Stock”~~preferred stock”), ~~in the aggregate;~~ (ii) with the ~~January Investors~~Senior Secured Notes investors for the exchange of ~~January~~Senior Secured Notes in the aggregate principal amount of $0.2 million for 206 shares of Series F Preferred ~~Stock, in the aggregate;~~Stock; (iii) with the Demand Noteholders for the exchange of Demand Notes in the principal amount of $0.6 million for 576 shares of Series F Preferred Stock, ~~in the aggregate;~~ and (iv) with the purchasers of the Company’s Series D Preferred Stock for the exchange of 1,197 shares of Series D Preferred Stock for 1,847 shares of Series F Preferred ~~Stock, in the aggregate.~~Stock.
In addition, ~~in connection with the Exchange Agreements,~~ the Company issued new five-year warrants to purchase an aggregate of ~~592,129~~592,137 shares of ~~Common Stock~~common stock (the “Exchange Warrants”) to the ~~October Investors,~~2022 Note holders, the ~~January Investors,~~Senior Secured Note holders, and the purchasers of the Company’s Series D ~~Preferred Stock.~~preferred stock. The Exchange Warrants are exercisable at an exercise price of $8.868 per share of ~~Common Stock, subject to certain adjustments as set forth in the Exchange Warrants.~~common stock. The holders may exercise the Exchange Warrants on a cashless basis if the shares of ~~our Common Stock~~the Company’s common stock underlying the Exchange Warrants are not then registered pursuant to an effective registration statement. The Company concluded that the Exchange Warrants are liability classified.
For the ~~October Investors,~~2022 Note holders, the total fair value of Series F ~~Preferred Stock~~preferred stock and ~~Warrant Liability~~warrant liability issued ~~was $1.7~~were $1.1 million ~~($1.1 million for Series F Preferred Stock~~ and $0.6 million, ~~for Warrant Liability).~~respectively. For the ~~January Investors,~~Senior Secured Note holders, the total fair value of Series F ~~Preferred Stock~~preferred stock and ~~Warrant Liability~~warrant liability issued ~~was $0.13~~were $0.1 million ~~($0.1 million for Series F Preferred Stock~~ and ~~$0.03 million for the Warrant Liability).~~$30,000, respectively. For the Demand Note holders, the total fair value of Series F Preferred Stock and Warrant Liability issued ~~was $0.4~~were $0.2 million ~~($0.2 million for Series F Preferred Stock~~ and $0.2 million, ~~for the Warrant Liability).~~respectively. For the purchasers of the Company’s Series D ~~Preferred Stock,~~preferred stock, the Company accounted for the exchange as an extinguishment of the Series D ~~Preferred Stock. The Company~~preferred stock and recorded the total fair value of Series F ~~Preferred~~preferred Stock and ~~Warrant Liability~~warrant liability of ~~$1.2~~$0.7 million ~~($0.7 million for Series F Preferred Stock~~ and $0.5 million, ~~for the Warrant Liability) and the~~respectively. The difference of $0.5 million with the $0.7 million carrying value of the Series D ~~Preferred Stock~~preferred stock as a deemed dividend and reduction to additional-paid-in-capital.
In July 2023, the Company converted 803 shares of Series F preferred stock for 103,234 shares of common stock. As of September 30, 2023 and December 31, 2022, 4,448 and zero shares of Series F preferred stock are issued and outstanding.

Series F-1 Preferred Stock
On June 13, 2023, the Company ~~entered into the Purchase Agreement with the “Purchasers, pursuant to which, at the closing of the transactions contemplated by the Closing, the Purchasers agreed to purchase an aggregate of~~issued 3,583 shares of ~~the Company’s newly created~~ Series F-1 ~~Convertible Preferred Stock (“Series F-1 Preferred Stock”)~~preferred stock for an aggregate purchase price of ~~approximately~~ $2.3 million. In ~~addition, in~~ connection with the issuance of the Series F-1 ~~Preferred Stock,~~preferred stock, the ~~Purchasers~~holders will receive five-year warrants to purchase an aggregate of 398,377 shares of ~~Common Stock (defined below)~~common stock (the “Series F-1 Warrants”). The Series F-1 Warrants will be exercisable at an exercise price of $8.994 per share of the Company’s ~~Common Stock,~~common stock, subject to certain adjustments as set forth in the Series F-1 Warrants. The holders may exercise the Series F-1 Warrants on a cashless basis if the shares of our Common Stock underlying the Series F-1 Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the Purchasers to consummate the transactions contemplated by the Purchase Agreement are subject to the satisfaction on or prior to the Closing of customary closing ~~conditions.~~conditions..
The Company allocated the proceeds of $2.3 million to the liability classified ~~Warrants~~warrants with a fair value of $0.9 million and the remaining proceeds of $1.4 million to the Series F-1 ~~Preferred Stock.~~preferred stock.
In July 2023, the Company converted 2,930 shares of Series F-1 preferred stock for 325,737 shares of common stock. As of September 30, 2023 and December 31, 2022, 653 and zero shares of Series F-1 preferred stock are issued and outstanding.

Series F-2 Preferred Stock Offering
On June 14, 2023, the Company entered into a F-2 Purchase Agreement with the F-2 Purchasers pursuant to which, at the closing of the transactions contemplated by the F-2 Closing, the F-2 Purchasers agreed to purchase an aggregate ofissued 1,153 shares of ~~the Company’s newly created the~~its Series F-2 ~~Preferred Stock~~preferred stock for an aggregate purchase price of approximately $0.7 million. In ~~addition, in~~ connection with the issuance of the Series F-2 ~~Preferred Stock,~~preferred stock, the ~~F-2 Purchasers~~holders will receive five-year warrants to purchase an aggregate of 124,946 shares of ~~Common Stock (defined below)~~common stock (the “F-2 Warrants”). The F-2 Warrants will be exercisable at an exercise price of $9.228 per share of Common Stock, subject to certain adjustments as set forth in the F-2 Warrants. The holders may exercise the F-2 Warrants on a cashless basis if the shares of our Common Stock underlying the F-2 Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the F-2 Purchasers to consummate the transactions contemplated by the F-2 Purchase Agreement are subject to the satisfaction on or prior to the F-2 Closing of customary closing conditions.common stock.
The Company allocated the proceeds of $0.7 million to the liability classified ~~the F-2 Warrants~~warrants with a fair value of $0.3 million and the remaining proceeds of $0.4 million to the Series F-2 ~~Preferred Stock.~~preferred stock.
As of September 30, 2023 and December 31, 2022, 1,153 and zero shares of Series F-2 preferred stock are issued and outstanding.
Common Stock

~~Change in~~ Authorized Shares
~~On December 22, 2022, the Company’s Board~~As of ~~Directors approved increasing~~September 30, 2023, there were 800,000,000 shares of the Company’s authorized shares of common ~~stock from 200,000,000 to 800,000,000 shares.~~
stock.
~~Reverse Stock Split~~
On August 11, 2023, the Company’s Board of Directors authorized a reverse stock split (‘Reverse Stock Split”) at an exchange ratio of one (1) share of common stock for every sixty (60) shares of common stock. The Reverse Stock Split was effective on August 15, 2023, such that every sixty (60) shares of common stock have been automatically converted into one (1) share of common stock. The Company did not issue fractional certificates for post-reverse split shares in connection with the Reverse Stock Split. Rather, all shares of common stock that were held by a stockholder were aggregated and each stockholder was entitled to receive the number of whole shares resulting from the combination of the shares so aggregated. Any fractions resulting from the Reverse Stock Split computation were rounded up to the next whole share.

Warrant Exercises
During the ~~six~~nine months ended ~~June~~September 30, 2023, the Company issued 106,764 shares of its common stock in connection with the exercise of ~~106,764~~106,768 warrants, receiving net proceeds of approximately ~~$2.06~~$2.0 million at a ~~weighted average~~weighted-average price of $19.30 per share.
During the ~~six~~nine months ended ~~June~~September 30, 2023, the Company issued 2,493 shares of its common stock in connection with the exercise of 2,778 penny warrants.
~~ATM~~
At-the-Market Offering
As of ~~June~~September 30, 2023, the Company has received net proceeds on sales of ~~211,667~~794,689 shares of common stock under ~~its ATM Offering (See Note 2)~~the at-the-market offering of approximately ~~$2.1~~$3.8 million ~~(after~~after deducting $0.1 million in commissions and ~~expenses) at a weighted average~~expenses. The weighted-average price of ~~$10.38~~the common stocks were $4.98 per share.
~~Restricted Stock~~Equity Line of Credit
~~During the six months ended June 30,~~On July 20, 2023 (“Closing Date”), the Company ~~issued 500,000 shares of its common stock in connection~~entered into the ELOC with ~~vested restricted stock units.~~
~~Note 13 – Stock-Based Compensation, Stock Options, Restricted Stock Units and Warrants:~~
~~On December 22, 2022,~~a purchaser (“ELOC Purchaser”) whereby the Company ~~adopted its 2022 Long-Term Incentive Plan~~has the right to sell up to an aggregate of $50.0 million of newly issued shares (the ~~“2022 Plan”~~“ELOC Shares”)~~. Under the 2022 Plan, there are 70,000 shares~~ of the Company’s common stock. The aggregate number of shares that the Company can sell under the ELOC Purchase Agreement may not exceed 4.99% of the outstanding common stock, ~~available for issuance and the 2022 Plan has a termination date of October 31, 2032.~~
~~The available shares~~subject to certain exceptions set forth in the ~~2022 Plan~~ELOC Purchase Agreement.
The purchase price of the shares of common stock that the Company elects to sell to the pursuant to the ELOC Purchase Agreement will ~~automatically increase~~be equal to 97.0% of the lower of (i) the lowest intraday sale price of the common stock on the ~~first~~Company’s current trading ~~day in January~~market on the applicable purchase date or (ii) the arithmetic average of ~~each calendar year~~the three lowest closing sale prices during the ~~term~~ten trading days immediately preceding the applicable purchase date. There is no upper limit on the price per share that ELOC Purchase could be obligated to pay for the common stock under the ELOC Purchase Agreement.
On the Closing Date, the Company issued 21,841 shares of ~~2022 Plan, commencing with January~~common stock to the ELOC Purchase as an initial fee for commitment to purchase the Company’s common stock under the ELOC Purchase Agreement. On the date that is the earlier of (i) 30 calendar days after the Closing Date or (2) October 16, 2023, ~~by such number of~~the Company will issue an additional 87,417 shares of common stock as ~~are necessary so that the total number of shares reserved~~additional commitment shares. Liability for ~~issuance under the 2022 Plan shall be equal to 19.9% of the total number of outstanding shares of~~ common stock ~~determined on a fully diluted basis~~issued was $0.4 million as of the ~~applicable trading date (the “Stipulated Percentage”); (b) our Board of Directors may act prior~~closing date. The liability is subject to ~~January 1~~^st ~~of a given calendar year to provide that (i) there will be no such automatic annual increase~~remeasurement at each reporting period until issued, and any change in fair value is recognized and included as other income (expense) in the ~~number~~condensed consolidated statement of ~~shares reserved for issuance under the 2022 Plan or (ii) the increase~~operations. The change in ~~the number~~fair value of shares for such calendar year will be a lesser number of shares than necessary to maintain the Stipulated Percentage of shares reserved for issuance under the 2022 Plan; and (c) unless an increase in shares reserved for issuance under the 2022 Plan in excess of the Initial Share Limit has been approved by our shareholders, the maximum number of shares of common stock that may be delivered pursuant to incentive stock options shall not exceed the Initial Share Limit or, if greater, the number of shares of common stock subsequently approved by the requisite vote of our shareholders entitled to vote thereon.
On December 16, 2020, the Company adopted its 2020 Long-Term Incentive Plan (the “2020 Plan”). Under the 2020 Plan, there are 88,889 shares of the Company’s common stock available for issuance and the 2020 Plan has a term of 10 years. The available shares in the 2020 Plan will automatically increase on the first trading day in January of each calendar yearliability issued was approximately $0.4 million during the term of this Plan, commencing with January 2021, by an amount equal to the lesser of (i) five percent (5%) of the total number of shares of common stock issued and outstanding on December 31 of the immediately preceding calendar year, (ii) 16,667 shares of common stock or (iii) such number of shares of common stock as may be established by the Company’s Board of Directors.nine months ended September 30, 2023.

As of September 30, 2023, the Company received net proceeds on sales of 3,986,991 shares of common stock of approximately $4.5 million, after deducting commissions and expenses, at a weighted average price of $1.19 per share.
Note 12 – Stock-Based Compensation
Stock Options
The Company grants equity-based compensation under its 2020 Long-Term Incentive Plan (the “2020 Plan”) and its 2016 Equity Incentive Plan (the “2016 Plan”). The 2020 Plan and 2016 Plan allows the Company to grant incentive and nonqualified stock options, and shares of restricted stock to its employees, directors and consultants. On June 14, 2019, the Board of Directors of the Company approved increasing the number of shares allocated to the Company’s 2016 Equity Incentive Plan from 91,667 to 122,222.
On December 16, 2020, the Company adopted its 2020 Plan. Under the 2020 Plan, there are 88,889 shares of the Company’s common stock available for issuance and the 2020 Plan has a term of 10 years.
Under the 2016 Plan and the 2020 Plan, upon the exercise of stock options and issuance of fully vested restricted common stock, shares of common stock may be withheld to satisfy tax withholdings. The Company intends to net settle certain employee options to ensure adequate authorized shares under the Incentive Plan.
~~Stock-based compensation:~~
~~The~~On December 22, 2022, the Company ~~recognized total expenses~~adopted its 2022 Long-Term Incentive Plan (the “2022 Plan”). Under the 2022 Plan, there are 70,000 shares of the Company’s common stock available for ~~stock-based compensation during~~issuance and the ~~six months ended June 30, 2023 and~~ 2022 ~~which are included in the accompanying statements of operations, as follows (in thousands):~~
Three months ended
June 30, Six months ended
June 30,
2023 2022 2023 2022

Research and development expenses $ 45 $ 445 $ 104 $ 500
Selling, general and administrative expenses 87 1,003 209 2,031
Total stock-based compensation $ 132 $ 1,448 $ 313 $ 2,531
~~Stock Options:~~
~~The Company provides stock-based compensation to employees, directors and consultants under both the 2016 and 2020 Plans. The fair value of each stock option grant is estimated on the~~Plan has a termination date of grant using the Black-Scholes option pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The risk-free interest rate is determined by referencing the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.October 31, 2032.
A summary of activity under the ~~2016 and 2020~~ Plans for the ~~six~~nine months ended ~~June~~September 30, 2023 is as follows:
Shares
Underlying
Options Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term
(Years) Aggregate
Intrinsic
Value
Outstanding at December 31, 2021
Granted
Canceled
Forfeited
Outstanding at December 31, 2022 159,295 $ 153.35 6.5 $ 26,188
Forfeited (1,516 ) $ 196.86 -
Outstanding at June 30, 2023 157,779 $ 157.47 6.0 $ -

Exercisable at June 30, 2023 142,884 $ 167.85 5.7 $ -
Shares
Underlying
Options Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term
(Years) Aggregate
Intrinsic
Value
Outstanding at December 31, 2022 159,295 $ 153.35 6.5 $ 26,188
Forfeited (1,516 ) $ 196.86 - -
Outstanding at September 30, 2023 157,779 $ 157.47 5.8 $ -

Exercisable at September 30, 2023 143,325 $ 168.04 5.5 $ -
Stock-Based Compensation
The total stock-based compensation expense recognized was as follows (in thousands):
Three months ended
September 30, Nine months ended
September 30,
2023 2022 2023 2022

Research and development expenses $ 46 $ 136 $ 150 $ 636
Selling, general and administrative expenses 87 344 296 2,375
Total stock-based compensation $ 133 $ 480 $ 446 $ 3,011
As of September 30, 2023, the total unrecognized stock-based compensation cost related to outstanding unvested stock options that are expected to vest was $0.1 million, which the Company expects to recognize over an estimated weighted-average period of 2.5 years.

Restricted ~~stock units:~~Stock Units
A summary of the Company’s restricted stock activity ~~during the six months ended June 30, 2023~~and related information is as follows:
Number of
Shares Weighted
Average
Grant-Date
Fair Value
Unvested at December 21, 2022 10,483 $ 82.02
Vested (3,344 ) $ 104.04
Unvested at June 30, 2023 7,139 $ 71.68
~~Warrants:~~
Number of
Shares Weighted
Average
Grant-Date
Fair Value
Unvested at December 21, 2022 10,483 $ 82.02
Vested (3,344 ) $ 104.04
Unvested at September 30, 2023 7,139 $ 71.68
Note 13 – Warrants
A summary of the Company’s warrant (excluding penny warrants) activity ~~during the six months ended June 30, 2023~~and related information is as follows:
Shares
Underlying
Warrants Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term
(Years) Aggregate
Intrinsic
Value Shares
Underlying
Warrants Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term
(Years) Aggregate
Intrinsic
Value
Outstanding at December 31, 2022 461,066 $ 44.88 4.5 $     - 461,066 $ 44.88 4.5 $        -
Issued 1,405,797 $ 11.42 4.7 1,405,797 $ 11.42 4.6 -
Exercised (106,768 ) $ 19.20 - (106,768 ) $ 19.20 - -
Outstanding at June 30, 2023 1,760,095 $ 18.96 4.7 $ -
Outstanding at September 30, 2023 1,760,095 $ 18.96 4.4 $ -
~~2023~~ Liability Classified Warrants

Senior Secured Note
During the ~~six~~nine months ended ~~June~~September 30, 2023, ~~in connection with the issuance of its senior secured notes on January 3, 2023 (See Note 11),~~ the Company issued 41,667 warrants to purchase shares of the Company’s common stock with an exercise price of $19.30 per share. The warrants expire 5 years from the issuance date.
Line of Credit

During the ~~six~~nine months ended ~~June~~September 30, 2023, in connection with its ~~Line~~line of ~~Credit,~~credit, the Company issued 45,000 Series E warrants to purchase shares of its Series E preferred stock with an exercise price of ~~$30.00~~$0.50 per share ~~multiplied by 16.67, and subject to adjustment under certain circumstances described in the warrant.~~ (See Note ~~11)~~9). The warrants expire 5 years from the issuance date.

2022 Notes
~~During the year ended December 31, 2022, in~~In connection with the 2022 Notes, the Company issued 362,657 warrants to purchase shares of the Company’s common stock. The warrants have an exercise price of $19.30 per share and expire five years from the issuance date.
During the ~~six~~nine months ended ~~June~~September 30, 2023, ~~in connection with its 2022 Notes,~~ the Company entered into a warrant inducement and exercise agreement with certain holders. Under the terms of the agreement, the holders exercised 106,764 warrants, and the Company issued 106,764 new warrants to purchase shares of its common stock with an exercise price of $19.30 per share. The warrants expire 5 years from the issuance date.

On February 28, 2023, the Company entered into waiver agreements with holders of the 2022 Notes and issued 96,894 warrants to purchase shares of the Company’s common stock with an exercise price of $19.30 per share.
Exchange Warrants, F-1 Warrants, and F-2 Warrants
In connection with the ~~Exchange Agreements,~~exchange agreement, the Company issued new five-year warrants to purchase an aggregate of 592,137 shares of ~~Common Stock (the “Exchange Warrants”)~~common stock to the ~~October Investors, the January Investors,~~noteholders and the purchasers of the Company’s Series D ~~Preferred Stock.~~preferred stock. The Exchange Warrants are exercisable at an exercise price of $8.868 per share of ~~Common Stock, subject to certain adjustments as set forth in the Exchange Warrants.~~common stock. The holders may exercise the ~~Exchange Warrants~~warrants on a cashless basis if the shares of ~~our Common Stock~~the common stock underlying the ~~Exchange Warrants~~warrants are not then registered pursuant to an effective registration statement. The Company concluded that the Exchange Warrants are liability classified.
In connection with the issuance of the Series F-1 ~~Preferred Stock,~~preferred stock, the ~~Purchasers~~noteholders will receive five-year ~~Warrants~~warrants to purchase an aggregate of 398,379 shares of ~~Common Stock.~~common stock. The ~~Warrants~~warrants will be exercisable at an exercise price of $8.994 per share of the Company’s ~~Common Stock, $0.0001 par value per share, subject to certain adjustments as set forth in the Warrants.~~common stock. The ~~holders~~noteholders may exercise the ~~Warrants~~warrants on a cashless basis if the shares of ~~our Common Stock~~the common stock underlying the ~~Warrants~~warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the Purchasers to consummate the transactions contemplated by the Purchase Agreement are subject to the satisfaction on or prior to the Closing of customary closing conditions.
In connection with the issuance of the Series F-2 ~~Preferred Stock,~~preferred stock, the ~~F-2 Purchasers~~noteholders will receive five-year warrants to purchase an aggregate of 124,948 shares of ~~Common Stock.~~common stock. The F-2 ~~Warrants~~warrants will be exercisable at an exercise price of $9.228 per share of ~~Common Stock, subject to certain adjustments as set forth in the F-2 Warrants.~~common stock. The ~~holders~~noteholders may exercise the F-2 ~~Warrants~~warrants on a cashless basis if the shares of ~~our Common Stock~~the common stock underlying the F-2 ~~Warrants~~warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the F-2 Purchasers to consummate the transactions contemplated by the F-2 Purchase Agreement are subject to the satisfaction on or prior to the F-2 Closing of customary closing conditions.

~~2022 Equity Classified~~Purchase Order Warrants
~~Hudson Pacific Properties, L.P.~~
On August 12, 2022, the Company entered into two Purchase Orders (PO’s) with Hudson Pacific Properties, L.P. (“Hudson”) for the purchase of the Company’s Smart Window Inserts™ (“Inserts”). ~~Hudson is a unique provider of end-to-end real estate solutions for tech and media tenants.~~ The PO’s have a value of ~~$85,450~~$0.1 million and represent the first orders the Company has received prior to the launch of its Inserts. ~~Delivery and installation are expected to begin in the fourth quarter of 2023.~~

~~On August 12, 2022, as~~As additional consideration for the PO’s, the Company issued a warrant to Hudson to purchase 5,000 shares of the Company’s common stock at $45.00 per share. The warrant has a five-year life and expires on August 12, 2027.
Because Hudson is a customer, the Company accounts for the PO’s and warrants under ~~Accounting Standards Codification (“ASC”) 606~~ ~~Revenue Recognition~~ (“ASC ~~606”).~~606. As the performance obligations have not yet been satisfied, the Company has not recognized any revenue in connection with Hudson during the ~~three~~nine months ended ~~June~~September 30, 2023.
The ~~Company accounts for the equity-classified warrant as consideration payable to a customer under ASC 606, as it relates to the future purchase of the Inserts. Pursuant to ASC 718~~ ~~Compensation – Stock Compensation (“~~~~ASC 718~~”)~~, the~~ Company measured the fair value of the warrant using the Black-Scholes valuation model on the issuance date, with the value being recognized as a prepaid asset up to the recoverable value represented by the value of the contract. The fair value of the warrant on the issuance date totaled ~~$161,700,~~$0.2 million, and as of ~~June~~September 30, 2023, ~~and December 31, 2022,~~ the Company recorded a prepaid asset of ~~$85,450,~~$0.1 million, representing the recoverable value from the PO’s, which is included in prepaid and other current assets on the ~~accompanying~~condensed consolidated balance sheet.
~~SLOC~~
SLOC
In connection with the SLOC, on March 17, 2022 the Company issued a warrant for 3,333 shares of common stock with an exercise price of $120.00 per share, and a total fair value of approximately ~~$223,000.~~$0.2 million. This amount is included in the accompanying consolidated balance sheet as deferred debt issuance costs (See Note 8).

Note 14 – Commitments and Contingencies
Operating Leases
~~Oregon State University~~
~~On March 8, 2016,~~The Company leases laboratory spaces, warehouse and office facilities with lease terms ranging from three to five years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain operating leases also include renewal options at the election of the Company ~~entered into a~~to renew or extend the lease. The Company evaluates renewal options at lease ~~agreement with Oregon State University,~~inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease ~~office~~terms when classifying leases and ~~laboratory space located at HP Campus Building 11, 1110 NE Circle Blvd, Corvallis, Oregon, for approximately $400 monthly. On July 1, 2016, the Company entered into the first amendment to the~~measuring lease agreement which increased the monthly lease expense to approximately $1,200. On October 1, 2017, the Company entered into a sublease agreement, which provides for additional office space and the monthly lease payment increased to approximately $1,800. The lease expired on Juneliabilities.
As of September 30, 2018 and the Company extended the lease through June 30, 2019. The monthly lease payment increased to approximately $4,500 for the months ended June 30, 2018 through November 30, 2018, and increased to approximately $7,550 for the months ended December 31, 2018 through June 30, 2019.
On January 24, 2022, the Company entered into the eighth amendment to its lease with Oregon State University which expands the lease to now include approximately 703 square feet of lab space, 768 square feet of cubicle space, 2,088 square feet of Highbay lab space, and 376 square feet of High bay storage space in a building commonly known as Building 11. Effective January 24, 2022, the quarterly operating expense will be $44,252 covering all utility and facility tooling costs. The sublease expires June 30, 2025.
~~On January 20,~~ 2023, the Company ~~entered into~~had operating lease liabilities of approximately $0.7 million and right-of- use assets of approximately $0.7 million, which are included in the ~~ninth amendment~~condensed consolidated balance sheet.
��
The components of operating lease expense were as follows:
Three Months Ended
September 30, Nine months Ended
September 30,
2023 2022 2023 2022
Operating leases:
Operating lease cost $ 108 $ 190 $ 439 $ 570
Variable lease cost 25 17 74 33
Operating lease expense $ 133 $ 207 $ 513 $ 603
The following information represents supplemental disclosure for the condensed consolidated statement of cash flows related to ~~its~~operating leases (in thousands):
Nine months Ended
September 30,
2023 2022
Operating cash flows - operating leases $ 513 $ 570
Right-of-use assets obtained in exchange for operating lease liabilities $ - $ 2,336
The present value assumptions used in calculating the present value of the lease with Oregon State University which reduces the amount of cubicle space from 768 square feet to 288 square feet. Effective January 20, 2023 the quarterly operating expense is $41,323 covering all utility and facility tooling costs.payments were as follows:
September 30,
2023 2022

Weighted-average remaining lease term (years) 1.7 3.5
Weighted-average discount rate 12.0 % 12.0 %

~~Hudson 11601 Wilshire, LLC~~
On March 4, 2021, the Company entered into a lease agreement with Hudson 11601 Wilshire, LLC, to lease 3,500 square feet of office space located in Los Angeles, California. The lease term is 39 months and expires on June 30, 2024. The monthly lease expense is as follows:
● ~~Months 1-12~~ - ~~$18,375~~
● ~~Months 13-24~~ - ~~$19,018~~
● ~~Months 25-36~~ - ~~$19,683~~
● ~~Months 37-39~~ - ~~$20,372~~
~~The Company paid a security deposit totaling $20,373 at the lease inception date.~~
~~HP Inc.~~
On May 4, 2021, the Company entered into a lease agreement with HP Inc. to lease office and lab space located in Corvallis, Oregon. The lease term is 5 years, and the lease commencement date is April 1, 2021. The monthly lease expense is $7,388 and increases 3% on each anniversary of the lease commencement date. The Company paid a security deposit totaling $8,315. The Company has the option to extend the lease for an additional 5 years. On January 26, 2022, the Company entered into the first amendment to its lease with HP Inc., which amends the lease commencement date to January 26, 2022 and the lease expiration date to January 31, 2027.
~~Pacific N.W. Properties, LLC~~
On October 5, 2021, the Company entered into a lease agreement with Pacific N.W. Properties, LLC to lease 26,963 square feet of warehouse, manufacturing, production and office space located in Salem Oregon. The commencement date of the lease is October 1, 2021, the lease term is 62 months and expires on November 30, 2026.
On December 9, 2021, the Company entered into the first amendment to its lease agreement with Pacific N.W. Properties, LLC. The Company and the Lessor entered into the Lease Termination Agreement on April 7, 2023. The Lease Termination Agreement set forth a termination fee of $0.1 million as well as required the forfeiture of the security deposit of $0.15 million from the original lease agreement. The Company was required to vacate by April 30, 2023 as well as cover all utilities through that day.
As of ~~June 30, 2023, the Company had operating lease liabilities of approximately $0.8 million and right-of-use assets of approximately $0.8 million, which are included in the condensed balance sheet.~~
~~The components of lease expense were as follows:~~
Three Months Ended
June 30, Six Months Ended
June 30,
2023 2022 2023 2022
Operating leases:
Operating lease cost $ 126 $ 190 $ 316 $ 380
Variable lease cost (9 ) 11 49 16
Operating lease expense $ 117 $ 201 $ 365 $ 396

~~Supplemental cash flow information related to leases were as follows:~~
Three Months Ended
June 30, Six Months Ended
June 30,
2023 2022 2023 2022
Operating cash flows - operating leases $ 119 $ 189 $ 311 $ 341
Right-of-use assets obtained in exchange for operating lease liabilities $ - $ - $ - $ 2,336
Weighted-average remaining lease term – operating leases (in years) 1.7 3.7 1.7 3.7
Weighted-average discount rate – operating leases 12.0 % 12.0 % 12.0 % 12.0 %
~~As of June~~September 30, 2023, future minimum payments are as follows (in thousands):
Operating
Leases
Six months ended December 31, 2023 $ 392
Year ended December 31, 2024 405
Year ended December 31, 2025 194
Year ended December 31, 2026 100
Year ended December 31, 2027 9
Total 1,100
Less present value discount (261 )
Operating lease liabilities $ 839
During the three months ended June 30, 2023 and 2022, the Company recognized rent expense of approximately $0.2 million and $0.2 million, respectively. During the six months ended June 30, 2023 and 2022, the Company recognized rent expense of approximately $0.4 million and $0.2 million, respectively.
Operating
Leases
Three months ended December 31, 2023 $ 133
Year ended December 31, 2024 417
Year ended December 31, 2025 194
Year ended December 31, 2026 100
Year ended December 31, 2027 9
Total 853
Less present value discount (113 )
Operating lease liabilities $ 740
~~On April 27, 2023 the Company terminated the Pacific NW lease and exited the building on May 10~~^th, 2023. As part of the termination agreement, the Company agreed to pay fees to the landlord for rent in arrears and re-tenanting costs. The fees will be covered by forfeiting Crowns $150,000 security deposit and paying an additional $115,394 for Landlord re-tenanting costs to be paid in three monthly instalments beginning April 30, 2023. As of June 30,2023 these tenanting costs remained outstanding.
Litigation
From time to time, the Company is also involved in various other claims and legal actions that arise in the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, the Company does not believe that the ultimate resolution of these actions will have a material adverse effect on its financial position, results of operations, liquidity or capital resources.
Future litigation may be necessary to defend ourselves and our partners by determining the scope, enforceability and validity of third party proprietary rights or to establish the Company’s proprietary rights. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.

Note 15 – Subsequent Events
The Company has evaluated all subsequent events through the date of filing, ~~August 24,~~November 14, 2023, of this Quarterly Report on Form 10-Q with the SEC, to ensure that this filing includes appropriate disclosure of events both recognized in the condensed consolidated financial statements as of ~~June~~September 30, 2023, and events which occurred after ~~June~~September 30, 2023, but which were not recognized in the financial statements. The Company has determined that there were no subsequent events which required recognition, adjustment to or disclosure in the financial statements.

~~January Note Exchange Agreement~~ATM Offering
On July 10, 2023, the Company and one of the remaining January Investors entered into a Forbearance Agreement (the “Forbearance Agreement”), which was subsequently amended by a First Amendment to the Forbearance Agreement on July 14, 2023 (the “First Amendment”). As amended by the First Amendment, the Forbearance Agreement provides that such January Investor shall forbear the exercise of its rights and remedies due to certain events of defaults under the January Note, including payment, until December 31, 2023, in exchange for a non-refundable payment of $100,000 in the form of a promissory note due December 31, 2023 (the “New Note”), which the terms of the New Note are under negotiation, and the payment of such January Investor’s attorneys’ fees and related costs up to $20,000. On July, 11, 2023, such January Investor agreed with the Company to accept 152,085 shares of the Company’s common stock as payment in full of their January Note, which such obligations were approximately $931,000.
On July 14, 2023, another of the remaining January Investors agreed with the Company to accept 25,143 shares of common stock as payment in full of their January Note, which such obligations were approximately $132,000.
On August 2, 2023, the Company entered into an exchange agreement with the remaining January Investor to exchange their January Note, with a balance of approximately $52,000, for 12,374 shares of common stock as payment in full of their January Note.
~~Following the above, there are no January Notes outstanding.~~
~~Equity Line of Credit~~
On July 20, 2023, the Company entered into a Common Stock Purchase Agreement (the “ELOC Purchase Agreement”) with a purchaser (the “ELOC Purchaser”), whereby the Company has the right, but not the obligation, to sell to the ELOC Purchaser, and the ELOC Purchaser is obligated to purchase, up to an aggregate of $50 million of newly issued shares (the “ELOC Shares”) of the Company’s common stock.

The purchase price of the shares of common stock that the Company elects to sell to the ELOC Purchaser pursuant to the ELOC Purchase Agreement will be equal to ninety-seven percent (97.0%) of the lower of (i) the lowest intraday sale price of the common stock on the Company’s current trading market on the applicable purchase date and (ii) the arithmetic average of the three (3) lowest closing sale prices during the ten (10) trading days immediately preceding the applicable purchase date. There is no upper limit on the price per share that the ELOC Purchaser could be obligated to pay for the common stock under the ELOC Purchase Agreement.
The Purchase Agreement prohibits the Company from directing the ELOC Purchaser to purchase any shares of our common stock if those shares, when aggregated with all other shares of our common stock then beneficially owned by the ELOC Purchaser (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in the ELOC Purchaser beneficially owning more than 4.99% of the outstanding common stock.
As consideration for the ELOC Purchaser’s irrevocable commitment to purchase shares of common stock upon the terms of and subject to satisfaction of the conditions set forth in the ELOC Purchase Agreement, concurrently with the execution and delivery of the ELOC Purchase Agreement, we agreed to issue to the ELOC Purchaser 21,840 shares of common stock (the “Initial Commitment Shares”) and at the earlier of the date that is thirty days following the closing of the Company’s first public offering of common stock or October 16, 2023, the Company will issue up to an additional 87,417 shares of common stock as additional commitment shares (the “Additional Commitment Shares”).

Subsequent to ~~June~~September 30, 2023, the Company received net proceeds on sales of ~~283,949~~5,456,699 shares of common stock of approximately ~~$0.5~~$1.9 million (after deducting ~~$0.03~~$0.1 million in commissions and expenses) at a weighted average price of ~~$1.81~~$0.36 per ~~share pursuant to the ELOC Purchase Agreement.~~share.

~~ATM Offering~~Delisting Notice

On ~~July 5,~~October 19, 2023, the Company ~~and~~received a letter (the “Nasdaq Staff Deficiency Letter”) from Nasdaq indicating that, for the ~~Sales Agents filed~~last thirty (30) consecutive business days, the ~~second amendment to~~bid price for the ~~Sales Agreement~~Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the ~~“Second Amendment to the Sales Agreement”~~“Bid Price Rule”). ~~Pursuant to the First Amendment to the Sales Agreement,~~
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company ~~may from~~has been provided an initial period of 180 calendar days, or until April 16, 2024, to regain compliance with the Bid Price Rule. The letter states that the Nasdaq staff will provide written notification that the Company has achieved compliance with Bid Price Rule if at any time ~~to time, sell up to $5.1 million in Placement Shares~~before April 16, 2024, the bid price of the Company’s common stock ~~through~~closes at $1.00 per share or more for a minimum of ten (10) consecutive business days. The Nasdaq Staff Deficiency Letter has no immediate effect on the Sales Agents in a continuous At-the-Market Offering (the Amended ATM Offering”). According to the First Amendment to the Sales Agreement, the Company will pay the Sales Agents a commission of up to 3.0%listing or trading of the ~~aggregate gross proceeds~~Company’s common stock.
The Company intends to monitor the ~~Company receives from all sales~~bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the ~~Amended ATM Offering.~~Company regaining compliance with the Bid Price Rule by April 16, 2024.

~~Subsequent to June 30, 2023~~If the Company ~~received net proceeds on sales~~does not regain compliance with the Bid Price Rule by April 16, 2024, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of ~~421,758~~publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of ~~common~~the Bid Price Rule, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, for example, by effecting a reverse stock ~~of approximately $1.59 million (after deducting $0.76 million in commissions and expenses) at a weighted average price of $3.94 per share.~~
~~The additional $2.1 million of combined ATM and ELOC equity offerings have contributed~~split, if necessary. However, if it appears to the Nasdaq staff that the Company ~~maintaining Stockholder equity levels in excess~~will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will notify the Company that its securities will be subject to delisting. In the event of such a notification, the ~~$2.5 million~~Company may appeal the Nasdaq ~~threshold.~~staff’s determination to delist its securities. There can be no assurance that the Company will be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company’s request for continued listing subsequent to any delisting notification.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and related notes thereto included elsewhere in this report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled “Risk Factors” included elsewhere in this report.
As an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, we can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are electing to delay our adoption of such new or revised accounting standards. As a result of this election, our condensed consolidated financial statements may not be comparable to the condensed financial statements of other public companies.
~~Management’s plans and basis of presentation:~~Overview
~~Crown Electrokinetics Corp. was~~We were incorporated in the State of Delaware on April 20, 2015. Effective October 6, 2017, ~~the Company’s~~our name was changed to Crown Electrokinetics Corp. from 3D Nanocolor Corp.
On January 26, 2021, ~~the Company~~we completed ~~its~~our public offering, and ~~its~~our common stock began trading on the Nasdaq Capital Market (Nasdaq) under the symbol CRKN.
~~The Company is commercializing~~We commercialize technology for smart or dynamic glass. ~~The Company’s~~Our electrokinetic glass technology is an advancement on microfluidic technology that was originally developed by HP Inc.
~~Business Combination~~
On December 20, 2022, ~~the Company~~we incorporated Crown Fiber Optics Corp., a Delaware based entity, to own and operate ~~its~~our acquired business from the acquisition of Amerigen 7, LLC (“Amerigen 7)7”) in January 2023. Crown Fiber Optics Corp. ~~will be~~is accounted for as aour wholly- owned ~~subsidiary of Crown Electrokinetics, Corp.~~
On January 3, 2023, the Company acquired certain assets related to the construction of 5G fiber optics infrastructure and distributed antenna systems from Amerigen 7 (the “Business Combination”), for cash consideration of approximately $0.65 million. The Business Combination included approximately 12 employees, customer contracts, and certain operating liabilities. The Business Combination will be accounted for as a business combination in accordance with Accounting Standards Codification 805, Business Combinations. The initial purchase price may be adjusted as needed per the terms of the arrangement agreement. The allocation of purchase price, including any fair value of the assets acquired and liabilities assumed as of the acquisition date has not been completed.
subsidiary.
~~Preferred Stock~~
~~On February 1, 2023 the Company filed the first amendment to its Series D preferred stock, which modifies the conversion price of the Series D preferred stock from $78.00 to $30.00 per share.~~

On February 1, 2023, the Company’s Board of Directors authorized 77,000 shares of Series E preferred stock with a par value of $0.0001 per share. Each share of Series E Preferred Stock is convertible into 16.67 shares of the Company’s common stock at the option of the holders.
On February 2, 2023, as consideration for entering into its Line of Credit (see below), the Company issued 5,000 shares of Series E Preferred Stock as a commitment fee with a fair value of $1.45 million and issued a warrant to purchase 45,000 shares of the Company’s Series E preferred stock. In addition, the Company agreed to issue an additional 5,000 shares of Series E preferred stock on both the first and second anniversary date of the Line of Credit, or 10,000 shares on the first anniversary, if the Company does not elect to extend the maturity date of the Line of Credit. The fair value of the additional 10,000 shares of Series E preferred stock on the issuance date totaled $2.9 million. The Company recorded the total fair value of $4.35 million as additional paid-in capital with the offsetting debit to deferred debt issuance costs. The deferred debt issuance costs will be amortized over the term of the Line of Credit.
The warrant to purchase 45,000 shares of the Company’s Series E preferred stock is exercisable for five years at an exercise price of the greater of $30.00 per share multiplied by 16.67, and subject to adjustment under certain circumstances described in the warrant.
~~Common stock~~
~~Change in Authorized Shares~~
~~On December 22, 2022, the Company’s Board of Directors approved increasing the Company’s authorized shares of common stock from 200,000,000 to 800,000,000 shares.~~
Reverse Stock Split
On August 11, 2023, ~~the Company’s Board~~our board of ~~Directors~~directors authorized a reverse stock split (“(‘Reverse Stock Split”) at an exchange ratio of one (1) share of common stock for every sixty (60) shares of common stock. The Reverse Stock Split was effective on August 15, 2023, such that every sixty (60) shares of common stock have been automatically converted into one (1) share of common stock. The Company did not issue fractional certificates for post-reverse split shares in connection with the Reverse Stock Split. Rather, all shares of common stock that were held by a stockholder were aggregated and each stockholder was entitled to receive the number of whole shares resulting from the combination of the shares so aggregated. Any fractions resulting from the Reverse Stock Split computation were rounded up to the next whole share.
one-for-60 basis. The number of authorized shares and the par value of the common stock was not adjusted as a result of the Reverse Stock Split. In connection with the Reverse Stock Split, the conversion ratio for our outstanding preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. All references to common stock and options to purchase common stock share ~~and~~data, per share data and related information contained in ~~these~~the condensed consolidated financial statements have been ~~retrospectively~~ adjusted to reflect the effect of the Reverse Stock ~~Split~~Split.
Components of Operating Results
Revenue
Revenue include fiber splicing services as required based on short-term work orders assigned by customers. We recognize revenue immediately upon completion of each work order in the amount that reflects the consideration to which we expect to be entitled.
Cost of Revenue
Cost of revenue primarily consists of cost of inventory sold during the period (net of discounts and allowances), storage costs, direct labor, shipping and handling costs, and allocated overhead

Gross Profit
Gross profit have been, and will continue to be, affected by a variety of factors, including those that may affect our revenue set forth above and factors that may affect our cost of revenue.
Operating Expenses
Our operating expenses consist of (i) research and development expenses and (ii) selling, general and administrative expenses.
Research and Development Expenses
Research and development expenses primarily consist of compensation and related costs for ~~all periods presented. The shares~~personnel (including stock-based compensation expenses), materials, supplies, technology and software license amortization and equipment depreciation.
Selling, General and Administrative Expenses
Selling, general and administrative expenses primarily consist of personnel costs, including salaries, bonus and benefit costs, professional fees, stock-based compensation, facility costs (including rent, property taxes, utilities, common ~~stock retain a par~~area maintenance and insurance), audit and compliance expenses, advertising and marketing expenses and other administrative costs.
Other Income (Expense)
Interest Expense
Interest expenses consist primarily of amortization expense from our line of credits. Refer to Note 7 on our condensed consolidated financial statements for additional information.
Loss on Extinguishment of Warrant Liability
Loss on extinguishment of warrant liability relates to the loss recognized on the settlement of our warrant liabilities. Refer to Note 10 on our condensed consolidated financial statements for additional information.
Loss on Extinguishment of Debt
Loss on extinguishment of debt relates to the loss recognized on the settlement of our convertible notes. Refer to Note 9 on our condensed consolidated financial statements for additional information.
Gain on Issuance of Convertible Notes
Gain on issuance of convertible notes relates to the gain recognized due to the change in fair value of ~~$0.0001 per share. Accordingly, an amount equal~~our convertible notes. Refer to ~~the par~~Note 10 on our condensed consolidated financial statements for additional information.
Change in Fair Value of Warrants
Change in fair value of warrants relates to changes in the ~~decreased shares resulting from the Reverse Stock Split was reclassified from common stock~~fair value of our warrants which were remeasured to fair value in each reporting period. Refer to Note 10 on our condensed consolidated financial statements for additional ~~paid-in capital.~~
information.
~~Warrant Exercises~~
Change in Fair Value of Notes
During the six months ended June 30, 2023, the Company issued 106,764 shares of its common stock in connection with the exercise of 106,764 warrants, receiving net proceeds of approximately $2.06 million at a weighted average price of $19.30 per share.
~~During~~Change in fair value of notes relates to changes in the ~~six months ended June 30, 2023, the Company issued 2,488 shares~~fair value of ~~its common stock~~our convertible notes which were remeasured to fair value in ~~connection with the exercise of 2,778 penny warrants.~~each reporting period. Refer to Note 10 on our condensed consolidated financial statements for additional information.

~~ATM Offering~~Change in Fair Value of Derivative Liability
Change in fair value of derivative liability relates to changes in the fair value of our derivative liability which was remeasured to fair value in each reporting period. Refer to Note 11 on our condensed consolidated financial statements for additional information.
Other Expense
Other expenses consist primarily of various other expenses.
Results of Operations for the Three and Nine Months Ended September 30, 2023 Compared to the Three and Nine Months Ended September 30, 2022 (in thousands):
Three Months Ended Nine months Ended
September 30, September 30,
2023 2022 Change 2023 2022 Change
Revenue $ - $ - $ - $ 59 $ - $ 59
Cost of revenue - - - 54 - 54
Gross profit - - - 5 - 5

Operating expenses:
Research and development 492 955 (463 ) 1,523 3,523 (2,000 )
Selling, general and administrative 2,941 2,160 781 10,926 8,634 2,292
Total operating expense 3,433 3,115 318 12,449 12,157 292

Loss from operations (3,433 ) (3,115 ) (318 ) (12,444 ) (12,157 ) (287 )

Other income (expense)
Interest expense (2,445 ) (1 ) (2,444 ) (6,970 ) (6 ) (6,964 )
Loss on extinguishment of warrant liability - - - (504 ) - (504 )
Loss on extinguishment of debt - - - (2,345 ) - (2,345 )
Gain on issuance of convertible notes - - - 64 - 64
Change in fair value of warrants 2,688 - 2,688 10,424 - 10,424
Change in fair value of notes (40 ) - (40 ) (7,040 ) - (7,040 )
Change in fair value of derivative liability 401 401 401 401
Other expense (30 ) - (30 ) (1,264 ) - (1,264 )
Total other income (expense) 574 (1 ) 575 (7,234 ) (6 ) (7,228 )

Loss before income taxes (2,859 ) (3,116 ) 257 (19,678 ) (12,163 ) (7,515 )

Net loss $ (2,859 ) $ (3,116 ) $ 257 $ (19,678 ) $ (12,163 ) $ (7,515 )

Revenue
No revenue was recognized by the Company during the three months ended September 30, 2022 and September 30, 2023. Revenue is generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was $0.1 million for the nine months ended September 30, 2023. No revenue was recognized by the Company during the nine months ended September 30, 2022.
Cost of Revenue
No cost of revenue was recognized by the Company during the three months ended September 30, 2022 and September 30, 2023. Cost of revenue is generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was $0.1 million for the nine months ended September 30, 2023. No cost of revenue was recognized by the Company during the nine months ended September 30, 2022.
Research and Development
Research and development expenses were $0.5 million and $1.0 million for the three months ended September 30, 2023 and 2022, respectively. The decrease of $0.5 million is primarily related to a decrease in salaries and benefits.
Research and development expenses were $1.5 million and $3.5 million for the nine months ended September 30, 2023 and 2022, respectively. The decrease of $2.0 million is primarily related to a decrease in salaries and benefits of $1.9 million and $0.1 million of other expenses.
Selling, General and Administrative
Selling, general and administrative (“SG&A”) expenses were $2.9 million and $2.2 million for the three months ended September 30, 2023 and 2022, respectively. The $0.7 million increase in SG&A expenses is primarily due to an increase in salaries and benefits for Crown Fiber Optics of $0.2 million and $0.5 million in consolidated professional fees.

Selling, general and administrative (“SG&A”) expenses were $10.9 million and $8.6 million for the nine months ended September 30, 2023 and 2022, respectively. The ~~Company entered into~~$2.3 million increase in SG&A expenses is primarily due to an increase in salaries and benefits for Crown Fiber Optics of $2.6 million, partially offset by a ~~Sales Agreement with A.G.P./Alliance Global Partners (the “Sales Agents”) dated March~~decrease in salaries and benefits for Crown Electrokinetics of $0.3 million.
Interest Expense
Interest expenses was $2.5 million for the three months ended September 30, ~~2022 (the “Sales Agreement”), pursuant~~2023 and was immaterial for the three months ended September 30, 2022. Interest expenses for the three months ended September 30, 2023 primarily consisted of amortization expense from our line of credits.
Interest expenses was $7.0 million for the nine months ended September 30, 2023 and was immaterial for the nine months ended September 30, 2022. Interest expenses for the nine months ended September 30, 2023 primarily consisted of amortization expense from our line of credits.

Loss on Extinguishment of Warrant Liability
Loss on extinguishment of warrant liability was $0.5 million for the nine months ended September 30, 2023 and was zero for the nine months ended September 30, 2022. Loss on extinguishment of warrant liability for the nine months ended September 30, 2023 primarily consisted of settlement of our warrant liabilities.
Loss on Extinguishment of Debt
Loss on extinguishment of debt was $2.3 million for the nine months ended September 30, 2023 and was zero for the nine months ended September 30, 2022. Loss on extinguishment of debt for the nine months ended September 30, 2023 primarily consisted of settlement of our convertible notes.
Gain on Issuance of Convertible Notes
Gain on issuance of convertible notes was $0.1 million for the nine months ended September 30, 2023 and was zero for the three months ended September 30, 2022. Gain on issuance of convertible notes for the nine months ended September 30, 2023 was related to ~~which~~ the ~~Company may,~~gain on our 2023 Note.
Change in Fair Value of Warrants
Change in fair value of warrants was $2.7 million for the three months ended September 30, 2023 and was zero for the three months ended September 30, 2022. Change in fair value of warrants for the three months ended September 30, 2023 is related to the fair value gain from ~~time~~the remeasurement of our warrants.
Change in fair value of warrants was $10.4 million for the nine months ended September 30, 2023 and was zero for the nine months ended September 30, 2022. Change in fair value of warrants for the nine months ended September 30, 2023 is related to ~~time, sell up~~the fair value gain from the remeasurement of our warrants.
Change in Fair Value of Notes
Change in fair value of notes was $40,000 for the three months ended September 30, 2023 and was zero for the three months ended September 30, 2022. Change in fair value of notes for the three months ended September 30, 2023 is related to ~~$5.0~~the fair value gain from the remeasurement of our convertible notes.
Change in fair value of notes was $7.0 million for the nine months ended September 30, 2023 and was zero for the nine months ended September 30, 2022. Change in fair value of notes for the nine months ended September 30, 2023 is related to the fair value gain from the remeasurement of our convertible notes.
Change in Fair Value of Derivative Liability
Change in fair value of derivative liability was $0.4 million for the three months ended September 30, 2023 and was zero for the three months ended September 30, 2022. Change in fair value of notes for the three months ended September 30, 2023 is related to the fair value gain from the remeasurement of the derivative liability.
Change in fair value of notes was $0.4 million for the nine months ended September 30, 2023 and was zero for the nine months ended September 30, 2022. Change in fair value of derivative liability for the nine months ended September 30, 2023 is related to the fair value gain from the remeasurement of our derivative liability.

Other Expense
Other expense was $30,000 for the three months ended September 30, 2023 and was zero for the three months ended September 30, 2022. Other expense for the three months ended September 30, 2023 primarily consisted of various other expenses.
Other expense was $1.3 million for the nine months ended September 30, 2023 and was zero for the nine months ended September 30, 2022. Other expense for the nine months ended September 30, 2023 primarily consisted of various other expenses.
Liquidity and Going Concern
September 30, September 30,
2023 2022

Cash and cash equivalents at the beginning of the period $ 821 $ 6,130
Net cash used in operating activities (11,809 ) (8,049 )
Net cash used in investing activities (1,729 ) (339 )
Net cash provided by financing activities 14,773 2,600
Cash and cash equivalents at the end of the period $ 2,056 $ 342
As of September 30, 2023, we had an accumulated deficit of approximately $107.7 million. During the nine months ended September 30, 2023, we incurred net loss of $19.7 million, and used approximately $11.8 million in ~~shares (the “Placement Shares”) of the Company’s common stock through the Sales Agents, acting as the Company’s sales agent and/or principal,~~net cash in a continuous at-the-market offering (the “ATM Offering”). The Company will pay the Sales Agents a commission of up to 3.0% of the aggregate gross proceeds the Company receives from all sales of the Company’s common stock under the Sales Agreement. The Placement Shares will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (Registration No. 333- 262122) and the related base prospectus included in the registration statement, as supplemented by the prospectus supplement dated March 30, 2022.operating activities.
During the ~~six~~nine months ended ~~June~~September 30, 2023, ~~the Company~~we received net proceeds on sales of shares of common stock under the ~~Sales Agreement~~at-the-market offering sales agreement of approximately ~~$2.1~~$3.8 million (after deducting $0.1 million in commissions and expenses) at a weighted average price of ~~$10.38~~$4.98 per share.
~~On July 5,~~During the nine months ended September 30, 2023, in connection with its 2022 Notes, we entered into a warrant inducement and exercise agreement with certain holders. Under the Company and the Sales Agents filed the second amendment to the Sales Agreement (the “Second Amendment to the Sales Agreement”). Pursuant to the First Amendment to the Sales Agreement, the Company may from time to time, sell up to $5.1 million in Placement Sharesterms of the ~~Company’s common stock through~~agreement, the ~~Sales Agents in~~holders exercised 106,764 warrants with a ~~continuous At-the-Market Offering (the Amended ATM Offering”). According~~fair value of approximately $0.8 million and we issued 106,764 new warrants to ~~the First Amendment to the Sales Agreement, the Company will pay the Sales Agents a commission of up to 3.0% of the aggregate gross proceeds the Company receives from all sales~~purchase shares of its common stock inwith a fair value of $1.3 million. We recognized a loss on extinguishment of the ~~Amended ATM Offering.~~
~~Subsequent to June 30, 2023 the Company received net proceeds on sales of 545,100 shares of common stock~~warrants of approximately ~~$1.59~~$0.5 million ~~(after deducting $0.76 million~~which is included in ~~commissions and expenses) at a weighted average price~~other expense on the accompanying condensed consolidated statement of ~~$3.0479 per share.~~
operations.
~~Senior Secured Notes~~
On January 3, 2023, ~~the Company~~we received net proceeds of $1.0 million from the issuance of senior secured notes with a principal balance of $1.2 million and a debt discount of $0.2 million. The notes are non-interest bearing and matured on April 3, 2023 and subsequently were extended to May 23, 2023 incurring an additional 10% on Principal or $120,000. In connection with the senior secured notes, the Company issued 41,667 warrants to purchase shares of the Company’s common stock at an exercise price of $19.32 per share.
On May 8, 2023, the Company entered into a letter agreement (the “Extension Letter”) with the lead noteholder and collateral agent for the January Notes (the “Agent”), pursuant to which we agreed to issue, pending shareholder approval, an aggregate of 11,833 shares of Common Stock to the holders of January Notes in exchange for the extension of the maturity date thereof until May 15, 2023.
On May 15, 2023, the Agent agreed to grant us an additional extension of the maturity date thereof until May 23, 2023 in exchange for the issuance by us to the holders of January Notes, on a pro rata basis, of 66,667 shares of our Common Stock pending shareholder approval.
Subsequently, on May 23, 2023, the Agent agreed to grant us an extension of the maturity date thereof until May 31, 2023 in exchange for the issuance by us to the January Investors, on a pro rata basis, of 25,000 shares of our Common Stock pending shareholder approval.
Thereafter, on May 31, 2023, the Agent for the January Notes agreed to grant us an extension of the maturity date thereof until June 12, 2023 in exchange for the issuance by us to the January Investors, on a pro rata basis, of 100,000 shares of our Common Stock, pending shareholder approval.
With the completion of the Extension Letter and additional extensions, the Company concluded that a troubled debt restructuring did not occur, but an extinguishment of the outstanding senior secured notes occurred. Subsequent to the extinguishment, the Company concluded to account for the senior secured notes using the fair value option. The Company recorded an extinguishment loss of $2.2 million. The loss was comprised of the fair value of the shares of Common Stock on the dates issued to extend the maturity date as discussed above.
On June 4, 2023, $0.2 million of the outstanding senior secured notes was settled as part of the Exchange Agreements described below. The Company accounted for the settlement as an extinguishment that resulted in a gain being recognized of $0.1 million and resulted in $0.1 million being recorded as Series F convertible preferred stock and $0.1 million being recorded as part of the warrant liability.
On June 30, 2023, the Company and the remaining January Investors agreed to extend the maturity date of the January Notes until July 31, 2023, in exchange for 41,667 shares of our Common Stock. The Company recorded a change in fair value adjustment of $0.3 million based on the fair value of the 41,667 shares of Common Stock. As of June 30, 2023, the fair value of the outstanding senior secured notes approximated the principal balance of $1.1 million.

~~Line of Credit~~
On February 2, 2023, the Company entered into a line of credit agreement (the “Line of Credit”) securing a line of credit up to $100.0 million. The Line of Credit will be used to fund expenses related to the fulfillment of contracts with customers of the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation (See Note 1). The Line of Credit expires February 2, 2024, unless the Line of Credit is extended for one or two additional years in accordance with its terms. On February 2, 2023, the Company drew downwe withdrew $2.0 million under the ~~Line~~line of ~~Credit.~~credit. Upon drawing down on the ~~Line~~line of ~~Credit,~~credit, we issued the ~~Company issued a Secured Promissory~~2023 Note ~~(the “2023 Note”)~~ which is due and payable 60 days from the issuance ~~date (See Note 11).~~date.
~~As consideration for entering into the Line of Credit, the Company issued 5,000 shares of Series E preferred stock, and issued~~On April 4^th, 2023, we made a ~~warrant to purchase 45,000 shares of the Company’s Series E preferred stock. Additionally, 5,000 shares of Series E preferred stock will be issued~~$0.3 million payment on the first and second anniversary of the effective date of the Line of Credit. However, if the Company does not elect to extend the Line of Credit for an additional one or two years, the additional 5,000 shares of Series E preferred stock will be issued immediately.note balance.
The warrant to purchase 45,000 shares of the Company’s Series E preferred stock is exercisable for five years at an exercise price of $30.00 per share multiplied by 16.67, and subject to adjustment under certain circumstances described in the warrant.
On April 14, 2023, the Company entered into a First Amendment to the 2023 Note with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note balance until May 1, 2023 in exchange for 33,333 shares of the Company’s common stock. The 2023 Note was further amended to accrue interest at the fifteen percent (15%) per annum from the original funding date of the 2023 Note. The Company recorded a change in fair value adjustment of $0.2 million related to the commitment to issue 33,333 shares of the Company’s common stock.
~~On May 1, 2023, the Company entered into a Second Amendment to the 2023 with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note balance until May 15, 2023.~~
On May 15, 2023, the Company entered into that certain Third Amendment to the 2023 Note with the lender, pursuant to which the lender agreed to extend the maturity date of the 2023 Note until June 7, 2023 in exchange for 4,000 shares of the Company’s Series E Preferred Stock, which are convertible into 66,667 shares of the Company’s common stock. The Company recorded a change in fair value adjustment of $0.7 million related to the commitment to issue 4,000 shares of the Company’s Series E Preferred Stock.
On May 16, 2023, ~~the Company~~we made a second draw of $0.2 million under the ~~Line~~line of ~~Credit.~~credit. Upon drawing down on the ~~Line~~line of ~~Credit, the Company~~credit, we issued a second Secured Promissory Note (the “2^nd 2023 Note”) which is due and payable July 16, 2023. The 2^nd 2023 Note shall accrue interest at the ~~fifteen percent (15%)~~15% per annum from the original funding date of the 2^nd 2023 Note.
On May 26, 2023, ~~the Company~~we made a third ~~draw of $0.15 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company issued a third Secured Promissory Note (the “3~~^rd ~~2023 Note”) which is due and payable June 2, 2023. The 3~~^rd ~~2023 Note included a $200,000 commitment fee and does not bear interest. With the 3~~^rd ~~2023 Note, the Company recorded a change in fair value adjustment of $0.2 million related to the commitment fee.~~
On May 26, 2023, the Company entered into that certain Fourth Amendment to the Convertible Promissory Note with the lender, pursuant to which the Company will issue to Holder a convertible promissory note in the principal amount of $0.15 million due June 2, 2023 in exchange for 4,000 shares of the Company’s Series E Preferred Stock, which are convertible into 66,667 shares of the Company’s common stock. The Company recorded a change in fair value adjustment of $0.6 million related to the commitment to issue 4,000 shares of the Company’s Series E Preferred Stock.

~~On June 13, 2023, the Company partially redeemed the principal of the 2023 Note and fully redeemed the principal of the 2~~^nd ~~2023 Note and the 3~~^rd ~~2023 Note Principals in addition to all accrued interest and commitment fees owing for approximately $2.1 million. With the settlement of the 2~~^nd ~~2023 Note and 3~~^rd~~2023 Note, the Company recorded a change in fair value adjustment of $0.1 million.~~
~~On June 30, 2023, the Company and the LOC Lender agreed to amend the 2~~^nd ~~2023 Note and 3~~^rd2023 Note to extend the maturity dates of each until July 16, 2023. In connection with the amendments, the Company agreed to issue to the LOC Lender: 5,000 shares of the Company’s Series E Preferred Stock, which is convertible into 83,333 shares of the Company’s common stock. Additionally, the Company agreed to issue an additional 8,000 shares of the Company’s Series E Preferred Stock, which is convertible into 133,333 shares of the Company’s common stock, to the LOC Lender for failure to comply with a covenant in the Line of Credit, as amended. The Company recorded a change in fair value adjustment of $2.0 million related to the commitment to issue 13,000 shares of the Company’s Series E Preferred Stock.
~~Demand Notes~~
Between May 17, 2023 and May 18, 2023, the Company issued secured demand promissory notes (the “Demand Notes”) to certain investors (the “Demand Holders”) in an aggregate principal amount equal to $229,877. The Demand Notes are due and payable at any time upon demand by a Demand Holder after the earlier of (i) the consummation of the Company’s first securities offering after the issuance of the Demand Notes and (ii) July 16, 2023. The Demand Notes do not bear interest. In connection with the issuance of the Demand Notes, the Company agreed to issue to the Demand Holders an aggregate of 76,626 shares of the Company’s common stock.
~~On May 30, 2023, the Company issued secured demand promissory notes (the “2~~^nd ~~Demand Notes”) to certain investors (the “2~~^nd ~~Demand Holders”) in an aggregate principal amount equal to $140,804. The 2~~^nd ~~Demand Notes are due and payable at any time upon demand by a 2~~^nd ~~Demand Holder after the earlier of (i) the consummation of the Company’s first securities offering after the issuance of the 2~~^nd ~~Demand Notes and (ii) July 16, 2023. The 2~~^nd ~~Demand Notes do not bear interest. In connection with the issuance of the 2~~^nd ~~Demand Notes, the Company agreed to issue to the 2~~^nd ~~Demand Holders an aggregate of 46,935 shares of the Company’s common stock.~~
To allocate the proceeds to May 2023 issuances, the Company allocated $0.1 million to the secured demand promissory notes and $0.3 million to the Company’s common stock based on the relative fair value of the instruments. The $0.3 million debt discount is amortized over the Demand Notes’ term.
~~October Convertible Note Repricing~~
On October 19, 2022, the Company entered into a Securities Purchase Agreement (the “October Purchase Agreement”) with certain accredited investors as purchasers (the “October Investors”). Pursuant to the October Purchase Agreement, the Company sold, and the October Investors purchased, approximately $5.4 million in principal amount of senior secured convertible notes (the “October Notes”) and warrants (the “October Warrants”).
On May 12, 2023, the Company entered into letter agreements (the “Inducement Agreements”) with certain of the October Investors, pursuant to which such October Investors agreed to reduce the conversion price of October Notes in an aggregate principal amount equal to $1,500,000, to $9.28 per share, which are now convertible into 161,603 shares of the Company’s common stock, representing an increase of 83,849 shares in excess of the number of shares into which such October Notes were convertible prior to the Company’s entry into the Inducement Agreements.
On May 17, 2023, the Company entered into Inducement Agreements with the remaining October Investors, pursuant to which such October Investors agreed to reduce the conversion price of October Notes in an aggregate principal amount equal to $1,392,657, to $10.93 per share, which are now convertible into 127,393 shares of the Company’s common stock, representing an increase of 55,242 shares in excess of the number of shares into which such October Notes were convertible prior to the Company’s entry into the Inducement Agreements.
The Company elected to account for the October Notes under the fair value option. For the Inducement Agreements that were entered into, the Company accounted for the change in the terms through the fair value adjustment of $2.7 million upon the settlement of $0.2 million principal balance of the October Notes on June 4, 2023 as part of the Exchange Agreements and $1.0 million principal balance of October Notes on June 21, 2023 based on the issuance of 248,981 shares of the Company’s common stock.

~~Exchange Agreements~~
On June 4, 2023, the Company entered into Exchange Agreements (the “Exchange Agreements”): (i) with the October Investors for the exchange of October Notes in the aggregate principal amount of $2.6 million for 2,622 shares of the Company’s newly created Series F Convertible Preferred Stock (“Series F Preferred Stock”), in the aggregate; (ii) with the January Investors for the exchange of January Notes in the aggregate principal amount of $0.2 million for 206 shares of Series F Preferred Stock, in the aggregate; (iii) with the Demand Noteholders for the exchange of Demand Notes in the principal amount of $0.6 million for 576 shares of Series F Preferred Stock, in the aggregate; and (iv) with the purchasers of the Company’s Series D Preferred Stock for the exchange of 1,197 shares of Series D Preferred Stock for 1,847 shares of Series F Preferred Stock, in the aggregate.
In addition, in connection with the Exchange Agreements, the Company issued new five-year warrants to purchase an aggregate of 592,129 shares of common stock (the “Exchange Warrants”) to the October Investors, the January Investors, and the purchasers of the Company’s Series D Preferred Stock. The Exchange Warrants are exercisable at an exercise price of $8.868 per share of common stock, subject to certain adjustments as set forth in the Exchange Warrants. The holders may exercise the Exchange Warrants on a cashless basis if the shares of our common stock underlying the Exchange Warrants are not then registered pursuant to an effective registration statement. The Company concluded that the Exchange Warrants are liability classified.
For the October Investors, the total fair value of Series F Preferred Stock and Warrant Liability issued was $1.7 million ($1.1 million for Series F Preferred Stock and $0.6 million for Warrant Liability). For the January Investors, the total fair value of Series F Preferred Stock and Warrant Liability issued was $0.13 million ($0.1 million for Series F Preferred Stock and $0.03 million for the Warrant Liability). For the Demand Note holders, the total fair value of Series F Preferred Stock and Warrant Liability issued was $0.4 million ($0.2 million for Series F Preferred Stock and $0.2 million for the Warrant Liability). For the purchasers of the Company’s Series D Preferred Stock, the Company accounted for the exchange as an extinguishment of the Series D Preferred Stock. The Company recorded the total fair value of Series F Preferred Stock and Warrant Liability of $1.2 million ($0.7 million for Series F Preferred Stock and $0.5 million for the Warrant Liability) and the difference of $0.5 million with the $0.7 million carrying value of the Series D Preferred Stock as a deemed dividend and reduction to additional-paid-in-capital.
~~Series F-1 Preferred Stock Offering~~
On June 13, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which, at the closing of the transactions contemplated by the Purchase Agreement (the “Closing”) the Purchasers agreed to purchase an aggregate of 3,583 shares of the Company’s newly created Series F-1 Convertible Preferred Stock (“Series F-1 Preferred Stock”) for an aggregate purchase price of approximately $2.3 million . In addition, in connection with the issuance of the Series F-1 Preferred Stock, the Purchasers will receive five-year warrants to purchase an aggregate of 398,377 shares of common stock (the “Series F-1 Warrants”). The Warrants will be exercisable at an exercise price of $8.994 per share of the Company’s common stock, subject to certain adjustments as set forth in the Warrants. The holders may exercise the Series F-1 Warrants on a cashless basis if the shares of our Common Stock underlying the Series F-1 Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the Purchasers to consummate the transactions contemplated by the Purchase Agreement are subject to the satisfaction on or prior to the Closing of customary closing conditions.
The Company allocated the proceeds of $2.3 million to the liability classified Series F-1 Warrants with a fair value of $0.9 million and the remaining proceeds of $1.4 million to the Series F-1 Preferred Stock.
~~Series F-2 Preferred Stock Offering~~
On June 14, 2023, the Company entered into a Securities Purchase Agreement (the “F-2 Purchase Agreement”) with certain accredited investors (the “F-2 Purchasers”), pursuant to which, at the closing of the transactions contemplated by the Purchase Agreement (the “F-2 Closing”) the F-2 Purchasers agreed to purchase an aggregate of 1,153 shares of the Company’s newly created Series F-2 Convertible Preferred Stock (“Series F-2 Preferred Stock”) for an aggregate purchase price of approximately $0.7 million. In addition, in connection with the issuance of the Series F-2 Preferred Stock, the F-2 Purchasers will receive five-year warrants to purchase an aggregate of 124,946 shares of common stock (the “F-2 Warrants”). The F-2 Warrants will be exercisable at an exercise price of $9.228 per share of common stock, subject to certain adjustments as set forth in the F-2 Warrants. The holders may exercise the F-2 Warrants on a cashless basis if the shares of our common stock underlying the F-2 Warrants are not then registered pursuant to an effective registration statement. The obligations of the Company and the F-2 Purchasers to consummate the transactions contemplated by the F-2 Purchase Agreement are subject to the satisfaction on or prior to the F-2 Closing of customary closing conditions.
The Company allocated the proceeds of $0.7 million to the liability classified the F-2 Warrants with a fair value of $0.3 million and the remaining proceeds of $0.4 million to the Series F-2 Preferred Stock.

~~Leases~~
Crown’s Research & Development Operation currently occupies 1,700 square feet of space, located on the HP Inc. campus in Corvallis, Oregon in the Advanced Technology and Manufacturing Institute (ATAMI). ATAMI is an academic-industrial research center and business incubator designed to provide an advanced materials development environment to private sector partner tenants performing research and development. The facility includes access to shared state-of-the-art tooling capabilities. ATAMI has grown to 80,000 square feet since its inception in 2004.
~~Hudson 11601 Wilshire, LLC~~
On March 4, 2021, the Company entered into a standard office lease with Hudson 11601 Wilshire, LLC, to lease 3,500 square feet of office space located at 11601 Wilshire Boulevard, Los Angeles, California 90025. The base monthly rent for the first year of the lease is $18,375 per month, which increases to $19,018.13 per month for the second year, $19,683.76 for the third year and $20,372.69 for the final three months of the lease. The lease expires on June 30, 2024.
~~Pacific N.W. Properties, LLC~~
On October 5, 2021, the Company entered into a lease agreement with Pacific N.W. Properties, LLC to lease 26,963 square feet of warehouse, manufacturing, production and office space located in Salem Oregon. The commencement date of the lease is October 1, 2021, the lease term is 62 months and expires on November 30, 2026. On December 9, 2021, the Company entered into the first amendment to its lease agreement with Pacific N.W. Properties, LLC. The lease amendment revises the lease commencement date to December 9, 2021 and the lease expiration date to February 28, 2027.
~~On April 27, 2023 the Company terminated the Pacific NW lease and exited the building on May 10~~^th, 2023. As part of the termination agreement, the Company agreed to pay fees to the landlord for rent in arrears and re-tenanting costs. The fees will be covered by forfeiting Crowns $150,000 security deposit and paying an additional $115,394 for Landlord re-tenanting costs to be paid in three monthly instalments beginning April 30, 2023. As of June 30,2023 these tenanting costs remained outstanding.
~~HP Inc.~~
On May 4, 2021, the Company entered into a lease agreement with HP Inc. to lease office and lab space located in Corvallis, Oregon. The lease term is 5 years, and the lease commencement date is April 1, 2021. The monthly lease expense is $7,388 and increases 3% on each anniversary of the lease commencement date. The Company paid a security deposit totaling $8,315. The Company has the option to extend the lease for an additional 5 years. On January 26, 2022, the Company entered into the first amendment to its lease with HP Inc., which amends the lease commencement date to January 26, 2022 and the lease expiration date to January 31, 2027.
We believe that our facilities are adequate to meet our needs for the immediate future and that, should it be needed, we will be able to secure additional space to accommodate the expansion of our operations. This office space, along with ATAMI, offers Crown all the space requirements it needs for the foreseeable future.
~~Master Supply Agreements~~
As part of the January 4, 2023, Amerigen 7 asset purchase agreement, Crown Fiber Optics acquired an MSA with Charter Spectrum which covered the five Great Lakes states. Subsequent to the acquisition, Crown has now entered into three further MSA’s, with two of the agreements covering the Northwest United States and the other contemplating a Southwest United States footprint. Of the four MSA’s, two are direct agreements with Internet Service Providers (ISP’s) and the others with infrastructure solution providers.
On March 25, 2022, Crown executed a Master Supply Agreement (the “BDN MSA”) with Brandywine Operating Partnerships L.P. to install its Smart Window Inserts powered by DynamicTintTM in Brandywine office buildings. The BDN MSA provides the master terms and conditions under which purchase orders will be executed for Crown to supply units to retrofit windows at certain locations.

On December 27, 2021, Crown executed a Master Supply Agreement (the “HPP MSA”) with Hudson Pacific Properties L.P. for the installation of Crown’s energy saving Smart Window Inserts in several office properties across its West Coast portfolio. The HPP MSA provides the master terms and conditions under which purchase orders will be executed for Crown to supply units to retrofit windows at certain locations.
Prior to this, Crown had entered into a Master Supply Agreement with MetroSpaces Inc., Crown’s first commercial customer, install its Smart Window Inserts in MetroSpaces’ 70,000 square-foot Houston, Texas office building.
Additionally, discussions with multiple other building owners to buy Crown Smart Window Inserts are progressing as the regulatory and consumer pressure to reduce the level of energy consumption and carbon emissions, continues to build.
~~Hudson Purchase Orders~~
On August 12, 2022, the Company entered into two Purchase Orders (PO’s) with Hudson Pacific Properties, L.P. (“Hudson”) for the purchase of the Company’s Smart Window Inserts™ (“Inserts”). Hudson is a unique provider of end-to-end real estate solutions for tech and media tenants. The PO’s have a value of $85,450 and represent the first orders the Company has received prior to the launch of its Inserts. Delivery and installation are expected to begin in in the fourth quarter of 2023.
On August 12, 2022, as additional consideration for the PO’s, the Company issued a warrant to Hudson to purchase 5,000 shares of the Company’s common stock at $45.00 per share. The warrant has a five year life and expires on August 12, 2027.
~~Results of Operations for the three and six months ended June 30, 2023 compared to the three and six months ended June 30, 2022 (in thousands):~~
Three Months Ended Six Months Ended
June 30, June 30,
2023 2022 Change 2023 2022 Change
Revenue $ 37 $ - $ 37 $ 59 $ - $ 59
Cost of revenue 23 - 23 54 - 54
Gross profit 14 - 14 5 - 5

Research and development 490 1,473 (983 ) 1,031 2,568 (1,537 )
Selling, general and administrative 4,409 3,002 1,407 7,985 6,474 1,511
Other (income) expense 9,634 2 9,632 7,808 5 7,803
Net loss $ (14,519 ) $ (4,477 ) $ 10,042 $ (16,819 ) $ (9,047 ) $ 7,772
~~Revenue~~
Revenue is generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was $37,000 for the three months ended June 30, 2023. No revenue was recognized by the Company during the three months ended June 30, 2022.
Revenue is generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was $59,000 for the six months ended June 30, 2023. No revenue was recognized by the Company during the six months ended June 30, 2022.
~~Cost of Revenue~~
Cost of revenue is generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was $23,000 for the three months ended June 30, 2023. No cost of revenue was recognized by the Company during the three months ended June 30, 2022.
Cost of revenue is generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was $54,000 for the six months ended June 30, 2023. No cost of revenue was recognized by the Company during the six months ended June 30, 2022.

~~Research and Development~~
Research and development expenses were $0.5 million and $1.5 million for the three months ended June 30, 2023 and 2022, respectively. The decrease of $1.0 million is primarily related to a decrease in salaries and benefits of $1.0 million.
Research and development expenses were $1.0 million and $2.6 million for the six months ended June 30, 2023 and 2022, respectively. The decrease of $1.6 million is primarily related to a decrease in salaries and benefits of $1.5 million and $0.1 million of various other expenses.
~~Selling, General and Administrative~~
Selling, general and administrative (“SG&A”) expenses were $4.4 million and $3.0 million for the three months ended June 30, 2023 and 2022, respectively. The $1.4 million increase in SG&A expenses is primarily due to an increase in salaries and benefits for Crown Fiber Optics of $0.8 million and $0.6 million in consolidated professional fees.
Selling, general and administrative (“SG&A”) expenses were $8.0 million and $6.5 million for the six months ended June 30, 2023 and 2022, respectively. The $1.5 million increase in SG&A expenses is primarily due to an increase in salaries and benefits for Crown Fiber Optics of $1.8 million and a decrease in salaries and benefits for Crown Electrokinetics of $0.3 million.
~~Other (Income) Expense~~
Other Expense was $9.6 million for the three months ended June 30, 2023 and was immaterial for the three months ended June 30, 2022. Other expense for the three months ended June 30, 2023 primarily consisted of a loss related to change in fair value of notes $6.9 million, interest expense of $2.5 million, and loss on extinguishment of debt of $2.3 million, offset by a $2.1 million gain related to the change in fair value of warrants.
Other Expense was $7.8 million for the six months ended June 30, 2023 and was immaterial for the six months ended June 30, 2022. Other expense for the six months ended June 30, 2023 primarily consisted of a loss related to change in fair value of notes $7.0 million, interest expense of $4.5 million, and loss on extinguishment of debt of $2.3 million, offset by a $7.7 million gain related to the change in fair value of warrants.
~~Liquidity and Going Concern~~
June 30, December 31,
2023 2022

Cash and cash equivalents at the beginning of the period $ 821 $ 6,130
Net cash used in operating activities (8,388 ) (11,140 )
Net cash used in investing activities (1,351 ) (812 )
Net cash provided by financing activities 8,954 6,643
Cash and cash equivalents at the end of the period $ 36 $ 821
The Company had an accumulated deficit of approximately $104.8 million, and a net loss of $16.8 million, and used approximately $8.4 million in net cash in operating activities for the six months ended June 30, 2023. The Company expects to continue to incur ongoing administrative and other expenses, including public company expenses.
During the six months ended June 30, 2023, the Company received net proceeds on sales of shares of common stock under the ATM Sales Agreement of approximately $2.1 million (after deducting $0.1 million in commissions and expenses) at a weighted average price of $10.38 per share.
During the six months ended June 30, 2023, in connection with its 2022 Notes, the Company entered into a warrant inducement and exercise agreement with certain holders. Under the terms of the agreement, the holders exercised 106,764 warrants with a fair value of approximately $0.76 million and the Company issued 106,764 new warrants to purchase shares of its common stock with a fair value of $1.26 million. The Company recognized a loss on extinguishment of the warrants of approximately $0.5 million which is included in other income (expense) on the accompanying condensed statement of operations.
~~On January 3, 2023, the Company received net proceeds of $1.0 million from the issuance of senior secured notes with a principal balance of $1.2 million and a debt discount of $0.2 million.~~

On February 2, 2023, the Company withdrew $2.0 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company issued the 2023 Note which is due and payable 60 days from the issuance date.
~~On April 4~~^th ~~the Company made a $0.3 million payment on the note balance.~~
~~On May 16, 2023, the Company made a second~~ draw of $0.2 million under the ~~Line~~line of ~~Credit.~~credit. Upon drawing down on the ~~Line~~line of ~~Credit, the Company issued a second “Secured Promissory Note (the “2~~^nd ~~2023 Note”) which is due and payable July 16, 2023. The 2~~^nd ~~2023 Note shall accrue interest at the fifteen percent (15%) per annum from the original funding date of the 2~~^nd ~~2023 Note.~~
~~On May 26, 2023, the Company made a third draw of $0.15 million under the Line of Credit. Upon drawing down on the Line of Credit, the Company~~credit, we issued a third “Secured Promissory Note (the “3^rd 2023 Note”) which is due and payable June 2, 2023. The 3^rd 2023 Note included a ~~$200,000 Commitment~~$0.2 million commitment fee and does not bear interest.
On June 13, 2023, ~~the Company~~we partially redeemed the principal of the 2023 Note and fully redeemed the principal of the 2^nd 2023 Note and the 3^rd 2023 Note in addition to all accrued interest and commitment fees owing for approximately $2.1 million.

Between May 17, 2023 and May 18, 2023, ~~the Company~~we issued secured demand promissory notes (the “Demand Notes”) to certain investors (the “Demand Holders”) in an aggregate principal amount equal to ~~$229,877.~~$0.2 million. The Demand Notes are due and payable at any time upon demand by a Demand Holder after the earlier of (i) the consummation of ~~the Company’s~~our first securities offering after the issuance of the Demand Notes and (ii) July 16, 2023. The Demand Notes do not bear interest.
On May 30, 2023, ~~the Company~~we issued secured demand promissory notes (the “2^nd Demand Notes”) to certain investors (the “2^ndDemand Holders”) in an aggregate principal amount equal to ~~$140,804.~~$0.1 million. The 2^nd Demand Notes are due and payable at any time upon demand by a 2^nd Demand Holder after the earlier of (i) the consummation of ~~the Company’s~~our first securities offering after the issuance of the 2^nd Demand Notes and (ii) July 16, 2023. The 2^nd Demand Notes do not bear interest.
On June 13, 2023, ~~the Company~~we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Series F-1 Purchasers”), pursuant to which, at the closing of the transactions contemplated by the Purchase Agreement the Series F-1 Purchasers agreed to purchase an aggregate of 3,583 shares of ~~the Company’s newly created~~our Series F-1 Convertible Preferred Stock (“Series F-1 Preferred Stock”) for an aggregate purchase price of approximately $2.3 million.
On June 14, 2023, ~~the Company~~we entered into a Securities Purchase Agreement (the “Series F-2 Purchase Agreement”) with certain accredited investors (the “Series F-2 Purchasers”), pursuant to which, at the closing of the transactions contemplated by the Purchase Agreement the Series F-2 Purchasers agreed to purchase an aggregate of 1,153 shares of ~~the Company’s newly created~~our Series F-2 Convertible Preferred Stock (“Series F-2 Preferred Stock”) for an aggregate purchase price of approximately $0.7 million, net of $0.1 million in legal fees.
On July 25, 2023, the Company entered into the Demand Secured Promissory Note Agreement (“Q3 Demand Notes”) with two investors for a purchase price of $20,000 each and with an original issue discount of $12,000. Upon settlement, the Company is obligated to pay a total of $0.1 million in principal for the issuance of both notes. The ~~Company will seek to obtain~~Q3 Demand Notes are due and payable at any time upon demand by the holder after the earlier of (i) the consummation of the Company’s first securities offering after the issuance of the Q3 Demand Notes and (ii) January 25, 2024.
We have obtained additional capital through the sale of debt or equity financings or other arrangements including through its existing ~~At-The-Market, $10~~at-the-market offering, $10.0 million ~~Standing Letter~~standing letter of ~~Credit, $100~~credit, $100.0 million ~~Line~~line of ~~Credit,~~credit, and ~~$50~~$50.0 million ~~ELOC~~equity line of credit facilities to fund operations; however, there can be no assurance that ~~the Company~~we will be able to raise needed capital under acceptable terms, if at all. The sale of additional equity may dilute existing stockholders and newly issued shares may contain senior rights and preferences compared to currently outstanding shares of common stock. Issued debt securities may contain covenants and limit ~~the Company’s~~our ability to pay dividends or make other distributions to stockholders. If ~~the Company is~~we are unable to obtain such additional financing, future operations would need to be scaled back or discontinued. Due to the uncertainty in ~~the Company’s~~our ability to raise capital, ~~management believes~~we believe that there is substantial doubt in ~~the Company’s~~our ability to continue as a going concern for twelve months from the issuance of these condensed consolidated financial statements.

Cash Flows
~~Cash Flows~~
Net Cash Used in Operating Activities
For the ~~six~~nine months ended ~~June~~September 30, 2023, net cash used in operating activities was ~~$8.4~~$11.8 million, which primarily consisted of our net loss of ~~$16.8~~$19.7 million, adjusted for non-cash expenses of ~~$9.5~~$8.6 million, which primarily consisted of achange in fair value of warrant liability of $10.4 million, change in fair value of derivative liability of $0.4 million, and gain on issuance of convertible notes of $0.1 million, partially offset by change in fair value of notes $7.0 million, amortization of ~~$5.1~~deferred debt issuance costs of $6.8 million, loss on extinguishment of debt ~~and~~$2.3 million, amortization of right of use assets $1.1 million, loss on extinguishment of warrant ~~liabilities~~liability $0.5 million, stock based compensation expense of ~~$2.8 million, other expenses of $1.2 million primarily consisted of expenses incurred in stock issuance commitments, stock-based compensation of $0.3~~$0.4 million, depreciation and amortization expense of $0.5 million, loss on disposal of equipment $0.4 million, ~~offset by a 0.7 million gain related to the change in fair value~~and other expenses of ~~warrants and debt.~~$0.5 million. The net change in operating assets and liabilities was $1.0 million.

For the ~~six~~nine months ended ~~June~~September 30, 2022, net cash used in operating activities was ~~$5.9~~$8.0 million, which primarily consisted of our net loss of ~~$9.0~~$12.2 million, adjusted for non-cash expenses of ~~$3.1~~$3.8 million which primarily consisted of stock-based compensation expenses totaling ~~$2.5~~$3.0 million, amortization of right of use assets of $0.4 million, and depreciation and amortization of ~~$0.2 million,~~$0.4 million. The net change in operating assets and liabilities was ~~$0.05~~$0.3 million, primarily consisting of ~~an increase~~a decrease in ~~accounts payable of $0.4 million, offset by decreases in accrued expenses of $0.2 million~~prepaid and ~~our lease liability of $0.15 million.~~other current assets.

Net Cash Used in Investing Activities
For the ~~six~~nine months ended ~~June~~September 30, 2023, net cash used in investing activities was approximately ~~$1.4~~$1.7 million, consisting of cash paid for the acquisition of Amerigen 7 of approximately $0.6 million, and purchases of equipment totaling ~~$0.7~~$1.1 million.

For the nine months ended September 30, 2022, net cash was approximately $0.3 million.
Net Cash Provided by Financing Activities
For the ~~six~~nine months ended ~~June 30, 2022, net cash used in investing activities was approximately $1.6 million, consisting of $1.5 million for the purchase of our HP patents and $0.1 million for the purchase of equipment.~~
~~Financing Activities~~
~~For the six months ended June~~September 30, 2023, net cash provided by financing activities was ~~$8.9~~$14.8 million, consisting of net proceed from the issuance of common stock in connection with equity line of credit of $4.5 million, net proceeds received from the issuance of common stock in connection with our ~~ATM agreement~~at-the-market offering totaling ~~$2.2~~$4.0 million, net proceeds from the issuance of our 2023 Note in connection with the line of credit of $2.4 million, net proceeds from issuance of Series F-1 preferred stock of $2.3 million, net proceeds from the exercise of common stock warrants of $2.1 million, net proceeds from the issuance of ~~our 2023 Note (in connection with the Line of Credit) of $2.4 million proceeds from the issuance of~~ senior secured notes of ~~$0.9~~$1.4 million, net proceeds from ~~the~~ issuance of ~~our Demand Notes of $0.4 million, proceeds from the issuance of our Series F-1 preferred stock of $2.3 million, and proceeds from the issuance of our~~ Series F-2 preferred stock of ~~$0.8~~$0.7 million, ~~net~~partially offset by repayment of ~~$0.1~~notes payable $2.3 million ~~fees.~~and offering cost for the issuance of common stock in connection with at-the-market agreement of $0.2 million.
For the ~~six~~nine months ended ~~June~~September 30, 2022, net cash provided by financing activities was ~~$1.1~~$2.6 million, ~~related to~~and consisted of proceeds of the ~~proceeds from a deposit for~~issuance of common stock and warrants of $0.8 million, $1.0 million received in connection with the issuance of our Series D preferred ~~stock.~~stock and $0.7 million received from the issuance of common stock in connection with our at-the-market offering.
~~Off-balance sheet arrangements~~Off-Balance Sheet Arrangements
We did not have any off-balance sheet arrangements during the periods presented, and we do not currently have any off-balance sheet arrangements, as defined in the SEC rules and regulations.
Critical Accounting Policies and Significant Judgments and Estimates

~~Revenue Recognition~~
We adopted the new revenue standard, ASC 606, on March 31, 2019 using the full retrospective approach. The adoption did not have an effect on 2020 or 2019 revenue recognition or a cumulative effect on opening equity, as the timing and measurement of revenue recognition is materially the same as under ASC 605. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:
● ~~Step 1: Identify the contract with the customer~~
● ~~Step 2: Identify the performance obligations in the contract~~
● ~~Step 3: Determine the transaction price~~
● ~~Step 4: Allocate the transaction price to the performance obligations in the contract~~
● ~~Step 5: Recognize revenue when the company satisfies a performance obligation~~

For contracts where the period between when we transfer a promised good or service to the customer and when the customer pays is one year or less, we have elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component.
Our performance obligation is to provide fiber splicing services as required based on short-term work orders as work is assigned by the Customer. We are required to complete the description of work described in the work order and test the service provided prior to any recognition of revenue and invoicing. The short-term work orders are for very specific performance obligations which are performed from start to finish within two weeks or less, and more often, within one week. We are required to adhere to the rules and regulations that are outlined in the Agreement between the Company and the Customer.
Cost for the work performed is outlined in the individual work orders based on the detailed description of work to be performed. All of the revenue is recognized immediately upon completion of the work in each work order. A 5% retainage will be withheld by the Customer upon payment of invoices and will be paid to the Company within one year after termination of the contract. The retainage can be utilized by Customer for any claims that may arise after work is completed up through one year after completion.
Revenue recognized during the six months ended June 30, 2023 was generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was immaterial for the six months ended June 30, 2023. No revenue was recognized by the Company during the six months ended June 30, 2022.
~~Segment and Reporting Unit Information~~
Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is determined to be the CODM. On January 3, 2023 we acquired Crown Fiber Optics, Corp and are currently in the process of integrating this new business line including identifying leadership, and aligning management reporting and allocation methodologies. We are assessing our current segment structure in conjunction with the integration efforts.
~~Business Combinations~~
~~We account for business combinations using the guidance provided by Accounting Standards Codification (“ASC”) 805,~~ ~~Business Combinations~~. ASC 805 requires us to use the acquisition method of accounting by recognizing the identifiable tangible and intangible assets acquired and liabilities assumed, and any non-controlling interest in the acquired business, measured at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the aforementioned amounts.
Accounting for business combinations requires management to make significant estimates and assumptions, especially at the acquisition date, including estimates for intangible assets. Although we believe the assumptions and estimates made have been reasonable and appropriate, they are based in part on historical experience and information obtained from management of the acquired companies and are inherently uncertain. Critical estimates in valuing certain intangible assets we have acquired include future expected cash flows from customer contracts. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates, or actual results. The initial purchase price may be adjusted as needed per the terms of the arrangement agreement. The allocation of purchase price, including any fair value the assets acquired and liabilities assumed as of the acquisition date has not been completed.

~~Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.~~
~~Deferred Debt Issuance Costs~~
We account for debt issuance costs related to our Line of Credit as a deferred asset which is amortized over the life of the Line of Credit. Since we have elected the fair value option for our convertible notes (see below), upon a draw down, a portion of the deferred asset balance will be amortized to other expense. On the issuance date of our Line of Credit, since no loan amounts are drawn down, the issuance of the Series E preferred shares and the warrant to purchase Series E preferred shares are recorded as a deferred asset.
~~Goodwill~~
~~We perform a goodwill impairment analysis on October 1~~^st of each year.  When conducting our annual goodwill impairment assessment, we initially perform a qualitative evaluation to determine if it is more likely than not that the fair value of our reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a two-step goodwill impairment test.
~~Convertible Notes~~
~~In accordance with Accounting Standards Codification 825,~~ ~~Financial Instruments~~ (“ASC 825”), we have elected the fair value option for recognition of our convertible notes. In accordance with ASC 825, we recognize these notes at fair value with changes in fair value recognized in the statements of operations. The fair value option may be applied instrument by instrument, but it is irrevocable. As a result of applying the fair value option, direct costs and fees related to the convertible notes were recognized in other expense. The Company will include the interest expense as a component of the notes fair value.
~~Warrants~~
We account for certain common stock warrants outstanding as a liability at fair value and adjusted the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statements of operations. The fair value of the warrants issued by us has been estimated using the Black Scholes Methodology.
~~Fair Value of Common Stock~~
Stock-based compensation is measured at the grant date for all equity-based awards made to employees and nonemployees based on the estimated fair value of the awards. Stock-based compensation expense is recognized on a straight-line basis over the period the employee or non-employee is required to provide service in exchange for the award, which is generally the vesting period. We recognize forfeitures as they occur.

~~Critical accounting policies and significant judgments and estimates~~
Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates. Our most critical accounting policies are summarized below. See Note 3 to our condensed consolidated financial statements for a description of our other significant accounting policies.
Recent ~~accounting pronouncements~~Accounting Pronouncements
See Note 32 to our condensed consolidated financial statements for a description of recent accounting pronouncements applicable to our financial statements.
JOBS Act Transition Period
As an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, we can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are electing to delay our adoption of such new or revised accounting standards. As a result of this election, our condensed consolidated financial statements may not be comparable to the condensed financial statements of other public companies.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not required for a ~~Smaller Reporting Company.~~smaller reporting company.
Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, to allow timely decisions regarding required disclosure.
The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
With respect to the quarter ended ~~June~~September 30, 2023, under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures. Based upon this evaluation, our Chief Executive Officer has concluded that our disclosure controls and procedures are effective.
Management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.

Changes in Internal Control over Financial ~~Reporting:~~Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended ~~June~~September 30, 2023 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we are also involved in various other claims and legal actions that arise in the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we do not believe that the ultimate resolution of these actions will have a material adverse effect on our financial position, results of operations, liquidity or capital resources.

Future litigation may be necessary to defend ourselves and our partners by determining the scope, enforceability and validity of third party proprietary rights or to establish our proprietary rights. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Other than those previously disclosed by the Company in its current reports on Form 8-K as filed with the SEC, there have been no unregistered sales of the Company’s equity securities during the period covered by this Quarterly Report.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

N/A

Item 5. Other Information

N/A


Item 6. Exhibits
3.1 Certificate of Amendment to Certificate of Incorporation, as amended, filed with the Secretary of State of Delaware (incorporated by reference to Exhibit 3.1 to the registrant’s Form 8-K filed on June 15, 2023).
3.2 Series F-1 Certificate of Designations filed with the Secretary of State of Delaware (incorporated by reference to Exhibit 3.2 to the registrant’s Form 8-K filed on June 15, 2023).
3.3 Series F-2 Certificate of Designations filed with the Secretary of State of Delaware (incorporated by reference to Exhibit 3.3 to the registrant’s Form 8-K filed on June 15, 2023).
3.4 Certificate of Amendment to Amended and Restated Certificate of Incorporation, as amended, filed with the Secretary of State of Delaware on August 11, 2023 (incorporated by reference to Exhibit 3.1 to the registrant’s Form 8-K filed on August 14, 2023).
4.1 Form of Warrant (incorporated by reference to Exhibit 4.1 to the registrant’s Form 8-K filed on June 15, 2023).
4.2 Form of F-2 Warrant (incorporated by reference to Exhibit 4.2 to the registrant’s Form 8-K filed on June 15, 2023).
10.1 Form of Inducement Agreement by and between the Company and the October Investors (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on May 18, 2023).
10.2 Form of LOC Note Amendment by and between the Company and Eleven Advisors LLC (incorporated by reference to Exhibit 10.2 to the registrant’s Form 8-K filed on May 18, 2023).
10.3 Form of Demand Note issued by the Company to the Holder (incorporated by reference to Exhibit 10.3 to the registrant’s Form 8-K filed on May 18, 2023).
10.4 Form of Demand Note issued to the Company to the Demand Holders (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on June 6, 2023).
10.5 Form of May Note issued by the Company to the May Holder (incorporated by reference to Exhibit 10.2 to the registrant’s Form 8-K filed on June 6, 2023).
10.6 Form of Securities Purchase Agreement, dated June 13, 2023, between the Company and the Purchasers (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on June 15, 2023).
10.7 Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the registrant’s Form 8-K filed on June 15, 2023).
10.8 Form of Securities Purchase Agreement, dated June 14, 2023, between the Company and the F-2 Purchasers (incorporated by reference to Exhibit 10.3 to the registrant’s Form 8-K filed on June 15, 2023).
10.9 Forbearance Agreement by and between the Company and a January Investor, dated July 10, 2023 (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on July 14 2023).
10.10 First Amendment to Forbearance Agreement by and between the Company and a January Investor, dated July 14, 2023 (incorporated by reference to Exhibit 10.2 to the registrant’s Form 8-K filed on July 14 2023).
10.11 Common Stock Purchase Agreement by and between the Company and the ELOC Purchaser, dated July 20, 2023 (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on July 24, 2023).
10.12 Registration Rights Agreement by and between the Company and the ELOC Purchaser, dated July 20, 2023 (incorporated by reference to Exhibit 10.2 to the registrant’s Form 8-K filed on July 24, 2023).
10.13 Exchange Agreement by and between the Company and a January Investor, dated August 2, 2023 (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on August 7, 2023).
31.1 Certification of the Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of the Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certifications of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Certifications of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS Inline XBRL Instance Document.
101.SCH Inline XBRL Taxonomy Extension Schema Document.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
Crown Electrokinetics Corp.
Dated: ~~August 24,~~November 14, 2023 /s/ Doug Croxall
Doug Croxall
Chief Executive Officer and
Principal Executive Officer
Dated: ~~August 24,~~November 14, 2023 /s/ Joel Krutz
Joel Krutz
Chief Financial Officer and
Principal Financial Officer
52
40

1554554 3349195 250832 266872 false --12-31 Q3 0001761696 ~~crkn:WarrantsMember 2023-06-30~~ iso4217:USD xbrli:shares

	June 30, 2023			December 31, 2022
	(Unaudited)
ASSETS
Current assets:
Cash	$	36		$	821
Prepaid and other current assets		756			590
Total current assets		792			1,411
Property and equipment, net		2,366			1,409
Intangible assets, net		1,688			1,598
Right of use asset		797			1,842
Goodwill		652			-
Deferred debt issuance costs		5,819			150
Other assets		33			180
TOTAL ASSETS	$	12,147		$	6,590

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	1,822		$	865
Accrued expenses		408			621
Lease liability - current portion		484			574
Warrant liability		2,721			972
Notes payable at fair value		1,470			1,654
Notes payable		330			8
Total current liabilities		7,235			4,694
Lease liability - non-current portion		355			1,366
Total liabilities		7,590			6,060

Commitments and Contingencies (Note 14)

STOCKHOLDERS’ EQUITY:
Preferred stock, par value $0.0001; 50,000,000 shares authorized, no shares outstanding		-			-
Series A preferred stock, par value $0.0001; 300 shares authorized, 251 shares outstanding as of June 30, 2023 and December 31, 2022; liquidation preference $260 as of June 30, 2023 and 0 as of December 31, 2022		-			-
Series B preferred stock, par value $0.0001; 1,500 shares authorized, 1,443 shares outstanding as of June 30, 2023 and December 31, 2022; liquidation preference $1,492 as of June 30, 2023 and 0 as of December 31, 2022		-			-
Series C preferred stock, par value $0.0001; 600,000 shares authorized, 500,756 shares outstanding as of June 30, 2023 and December 31, 2022; liquidation preference $511 as of June 30, 2023 and 0 as of December 31, 2022		-			-
Series D preferred stock, par value $0.0001; 7,000 shares authorized, 0 shares issued and outstanding as of June 30, 2023 and 1,058 as of December 31, 2022; liquidation preference 0 as of June 30, 2023 and $1,113 as of December 31, 2022		-			-
Series E preferred stock, par value $0.0001; 77,000 shares authorized, 21,000 shares committed pending shareholder approval as of June 30, 2023 and no shares outstanding as of December 31, 2022		-			-
Series F preferred stock, par value $0.0001; 9,073 shares authorized, 5,251 shares outstanding as of June 30, 2023 and no shares outstanding as of December 31, 2022		-
Series F-1 preferred stock, par value $0.0001; 9,052 shares authorized, 3,583 shares outstanding as of June 30, 2023 and no shares outstanding as of December 31, 2022.		-
Series F-2 preferred stock, par value $0.0001; 9,052 shares authorized, 1,153 shares outstanding as of June 30, 2023 and no shares outstanding as of December 31, 2022.		-
Common stock, par value $0.0001; 800,000,000 shares authorized; 1,067,341 and 337,392 shares outstanding as of June 30, 2023 and December 31, 2022, respectively		6			2
Additional paid-in capital		109,381			88,533
Accumulated deficit		(104,830	)		(88,005	)
Total stockholders’ equity		4,557			530
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	12,147		$	6,590

	Three Months Ended June 30,						Six months ended June 30,
	2023			2022			2023			2022
Revenue	$	37		$	-		$	59		$	-
Cost of revenue		23			-			54			-
Gross profit		14			-			5			-

Operating expenses:
Research and development		490			1,473			1,031			2,568
Selling, general and administrative		4,409			3,002			7,985			6,474
Total operating expenses		4,899			4,475			9,016			9,042

Loss from operations		(4,885	)		(4,475	)		(9,011	)		(9,042	)

Other income (expense):
Interest expense		(2,508	)		(2	)		(4,525	)		(5	)
Loss on extinguishment of warrant liability		-			-			(504	)		-
Loss on extinguishment of debt		(2,345	)		-			(2,345	)
Gain on issuance of convertible notes		-			-			64			-
Change in fair value of warrants		2,130			-			7,736			-
Change in fair value of notes		(6,883	)		-			(7,000	)		-
Other expense		(28	)		-			(1,234	)		-
Total other income (expense)		(9,634	)		(2	)		(7,808	)		(5	)

Loss before income taxes		(14,519	)		(4,477	)		(16,819	)		(9,047	)

Income tax expense		-			-			-			-

Net loss		(14,519	)		(4,477	)		(16,819	)		(9,047	)
Deemed dividend on Series D preferred stock		-			-			(6	)		-
Cumulative dividends on Series A preferred stock		(5	)		-			(9	)		-
Cumulative dividends on Series B preferred stock		(29	)		-			(49	)		-
Cumulative dividends on Series C preferred stock		(10	)		-			(10	)		-
Cumulative dividends on Series D preferred stock		(53	)		-			(84	)		-
Net loss attributable to common stockholders	$	(14,616	)	$	(4,477	)	$	(16,997	)	$	(9,047	)

Net loss per share attributable to common stockholders	$	(18.02	)	$	(16.35	)	$	(25.96	)	$	(33.62	)

Weighted average shares outstanding, basic and diluted:		810,983			273,767			653,848			269,094

	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Series D Preferred Stock					Series E Preferred Stock					Series F Preferred Stock				Series F-1 Preferred Stock				Series F-2 Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Number		Amount		Number		Amount		Number		Amount		Number			Amount		Number			Amount		Number		Amount		Number		Amount		Number		Amount		Number		Amount		Capital			Deficit			Equity
Balance as of December 31, 2022		251	$	-		1,443	$	-		500,756	$	-		1,058		$	-		-		$	-		-	$	-		-	$	-		-	$	-		338,033	$	2	$	88,533		$	(88,005	)	$	530
Exercise of common stock warrants		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		109,257		1		2,061			-			2,062
Issuance of common stock in connection with conversion of notes		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		31,466		-		516			-			516
Issuance of common stock/At-the-market offering, net of offering costs		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		211,667		1		2,106			-			2,107
Issuance of Series E preferred stock in connection with LOC		-		-		-		-		-		-		-			-		5,000			-		-		-		-		-		-		-		-		-		4,350			-			4,350
Deemed dividend for repricing of Series D preferred stock		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		-		-		6			(6	)		-
Commitment to issue shares of common stock in connection with March waiver agreement		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		-		-		298			-			298
Issuance of common stock in connection with Series A and Series B Dividends		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		6,921		-		-			-			-
Issuance of common stock upon the conversion of Series E preferred stock		-		-		-		-		-		-		-			-		(5,000	)		-		-		-		-		-		-		-		83,334		1		-			-			1
Issuance of common stock in connection with conversion of October Notes		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		248,984		1		2,165			-			2,166
Dividends paid in shares of Series D preferred stock		-		-		-		-		-		-		139			-		-			-		-		-		-		-		-		-		-		-		-			-			-
Series D preferred stock exchanged for Series F preferred stock in connection with Exchange Agreements		-		-		-		-		-		-		(1,197	)		-		-			-		1,847		-		-		-		-		-		-		-		(450	)		-			(450	)
Conversion of Demand Notes and October Notes into Series F preferred stock in connection with Exchange Agreements		-		-		-		-		-		-		-			-		-			-		3,198		-		-		-		-		-		-		-		1,276			-			1,276
Conversion of January Notes into Series F preferred stock in connection with Exchange Agreements		-		-		-		-		-		-		-			-		-			-		206		-		-		-		-		-		-		-		82			-			82
Issuance of Series F-1 preferred stock		-		-		-		-		-		-		-			-		-			-		-		-		3,583		-		-		-		-		-		1,372			-			1,372
Issuance of Series F-2 preferred stock		-		-		-		-		-		-		-			-		-			-		-		-		-		-		1,153		-		-		-		464			-			464
Commitment to issue shares of common stock in connection with January Notes		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		-		-		2,410			-			2,410
Commitment to issue shares of common stock in connection with LOC Notes		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		-		-		230			-			230
Commitment to issue shares of Series E preferred stock in connection with LOC Notes		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		-		-		3,363			-			3,363
Commitment to issue shares of common stock in connection with Demand Notes		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		-		-		286			-			286
Stock-based compensation		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		38,335		-		313			-			313
Net loss		-		-		-		-		-		-		-			-		-			-		-		-		-		-		-		-		-		-		-			(16,819	)		(16,819	)
Balance as of June 30, 2023 (unaudited)		251		-		1,443		-		500,756		-		-			-		-			-		5,251		-		3,583		-		1,153		-		1,067,997		6	$	109,381		$	(104,830	)	$	4,557

	Three Months Ended September 30,						Nine months ended September 30,
	2023			2022			2023			2022
Revenue	$	-		$	-		$	59		$	-
Cost of revenue		-			-			54			-
Gross profit		-			-			5			-

Operating expenses:
Research and development		492			955			1,523			3,523
Selling, general and administrative		2,941			2,160			10,926			8,634
Total operating expenses		3,433			3,115			12,449			12,157

Loss from operations		(3,433	)		(3,115	)		(12,444	)		(12,157	)

Other income (expense):
Interest expense		(2,445	)		(1	)		(6,970	)		(6	)
Loss on extinguishment of warrant liability		-			-			(504	)		-
Loss on extinguishment of debt		-			-			(2,345	)
Gain on issuance of convertible notes		-			-			64			-
Change in fair value of warrants		2,688			-			10,424			-
Change in fair value of notes		(40	)		-			(7,040	)		-
Change in fair value of derivative liability		401						401
Other expense		(30	)		-			(1,264	)		-
Total other income (expense)		574			(1	)		(7,234	)		(6	)

Loss before income taxes		(2,859	)		(3,116	)		(19,678	)		(12,163	)

Income tax expense		-			-			-			-

Net loss		(2,859	)		(3,116	)		(19,678	)		(12,163	)
Deemed dividend on Series D preferred stock		-			-			(6	)		-
Cumulative dividends on Series A preferred stock		(5	)		-			(14	)		-
Cumulative dividends on Series B preferred stock		(29	)		-			(78	)		-
Cumulative dividends on Series C preferred stock		(10	)		-			(20	)		-
Cumulative dividends on Series D preferred stock		-			(23	)		(53	)		(23	)
Cumulative dividends on Series F preferred stock		(144	)					(190	)
Cumulative dividends on Series F-1 preferred stock		(51	)					(71	)
Cumulative dividends on Series F-2 preferred stock		(44	)					(44	)
Net loss attributable to common stockholders	$	(3,142	)	$	(3,139	)	$	(20,154	)	$	(12,186	)

Net loss per share attributable to common stockholders	$	(0.94	)	$	(11.76	)	$	(12.96	)	$	(48.58	)

Weighted average shares outstanding, basic and diluted:		3,349,195			266,872			1,554,554			250,832

	June 30,
	2023		2022

Series A preferred stock		3,146		3,146
Series B preferred stock		33,883		33,883
Series C preferred stock		9,346		9,346
Series F preferred stock		592,130		-
Series F-1 preferred stock		398,377		-
Series F-2 preferred stock		124,946		-
Convertible notes		11,667		-
Warrants to purchase common stock (excluding penny warrants)		1,760,095		78,787
Warrants to purchase Series E preferred stock		750,000		-
Options to purchase common stock		157,779		151,892
Unvested restricted stock units		7,139		8,613
Commitment shares		783,806		-
		4,632,314		285,667

	September 30,
	2023		2022

Series A preferred stock		3,146		3,146
Series B preferred stock		33,883		33,883
Series C preferred stock		9,346		9,346
Series D preferred stock		-		35,278
Series F preferred stock		501,579		-
Series F-1 preferred stock		72,631		-
Series F-2 preferred stock		124,946		-
Warrants to purchase common stock (excluding penny warrants)		1,760,095		98,402
Warrants to purchase Series E preferred stock		750,000		-
Options to purchase common stock		157,779		164,996
Unvested restricted stock units		7,139		14,796
Commitment shares		200,205		-
Total		3,620,749		359,847

Property and equipment	$	655
Intangible assets		200
Security deposits		5
Accrued expenses		(529	)
Notes payable		(338	)
Total identifiable assets and liabilities acquired		(7	)
Goodwill		652
Total purchase consideration	$	645

	June 30,			December 31,
	2023			2022

Equipment	$	2,456		$	1,457
Leasehold improvements		362			362
Vehicles		159			-
Computers		55			52
Other		44			-
Total		3,076			1,871
Less accumulated depreciation and amortization		(710	)		(462	)
Property and equipment, net	$	2,366		$	1,409

	Estimated Amortization Expense		Estimated Amortization Expense

Six months ended December 31, 2023	$	121
Nine months ended December 31, 2023			$	66
Year ended December 31, 2024		235		235
Year ended December 31, 2025		234		234
Year ended December 31, 2026		197		197
Year ended December 31, 2027 and thereafter		901		901
Total	$	1,688	$	1,633

	June 30, 2023			December 31, 2022
SLOC	$	150		$	223
Line of Credit	$	9,943			-
Total		10,093			223
Accumulated amortization		(4,274	)		(73	)
Deferred debt issuance costs, net	$	5,819		$	150

	September 30, 2023			December 31, 2022
Standing letter of credit	$	150		$	223
Equity letter of credit		555
Line of credit	$	9,943			-
Total		10,648			223
Accumulated amortization		(6,801	)		(73	)
Deferred debt issuance costs	$	3,847		$	150

	September 30, 2023		December 31, 2022

Payroll and related expenses	$	115	$	-
Bonus		-		510
Taxes		49		-
Insurance		-		104
Other expenses		11		7
Total	$	175	$	621

	Fair value measured at June 30, 2023								Fair value measured at September 30, 2023
	Total carrying value at June 30, 2023		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total carrying value		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Liabilities:
Convertible notes	$	1,470	$	-	$	-	$	1,470
Warrant liability	$	2,721	$	-	$	-	$	2,721	$	34	$	-	$	-	$	34

	Fair value measured at December 31, 2022								Fair value measured at December 31, 2022
	Total carrying value at December 31, 2022		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total carrying value		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Liabilities:
Convertible notes	$	1,654	$	-	$	-	$	1,654	$	1,654	$	-	$	-	$	1,654
Warrant liability	$	972	$	-	$	-	$	972	$	972	$	-	$	-	$	972

	Convertible Notes			Warrant Liability
Balance at December 31, 2022	$	1,654		$	972
Conversion of October convertible notes		(516	)
Issuance of convertible note in connection with Line of Credit		2,000
Change in fair value of convertible notes in connection with March waiver agreement		368
Gain on issuance of convertible note		(64	)
January Notes - reclass to fair value option		1,117
Settlement in Connection with October Note		(2,166	)
Conversion of October Notes		(1,685	)
Settlement in Connection with LOC		(5,893	)
LOC Note issuance		350
Warrants issued in connection with January promissory note					157
Warrants issued in connection with Line of Credit					5,593
Warrants issued in connection with inducement agreement					760
Warrants issued in connection with February waiver agreement					711
Fair value of warrants exercised					(759	)
Other income (expense):					504
Warrants Issued in connection with Demand Notes Series F Exchange					140
Warrants Issued in connection with January Notes Series F Exchange					50
Warrants Issued in connection with October Notes Series F Exchange					639
Warrants Issued in connection with Series D to Series F Exchange					450
Warrants Issued in connection with Series F-1					956
Warrants Issued in connection with Series F-2					285
Change in fair value		6,305			(7,737	)
Balance at June 30, 2023	$	1,470		$	2,721

	Series F / F-1 / F-2		2022 Notes		Warrants - January Note		Warrants - Series E - LOC		December 31, 2022
Date	6/4/2023		6/30/2023		6/30/2023		6/30/2023		12/31/2022
Dividend yield		0.0%		0.0%		0.0%		0.0%		0%
Expected price volatility		50.0%		50.0%		50.0%		50.0%		48.7%
Risk free interest rate		3.8% - 4.1%		4.19% - 4.26%		4.22%		4.20%		4.74%
Expected term (in years)		5.0		4.3 - 4.7		4.5		4.6		0.8

	Series F / F-1 / F-2	2022 Notes	Warrants - Senior Secured Note	Warrants - Series E - Line of Credit	December 31, 2022
Date	9/30/2023	9/30/2023	9/30/2023	9/30/2023	12/31/2022
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%
Expected price volatility	70.0%	65.0%	65.0%	65.0%	48.7%
Risk free interest rate	4.63%	4.69%	4.22%	4.67%	4.74%
Expected term (in years)	4.7	4.1	4.3	4.3	0.8

	Shares Underlying Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding at December 31, 2021
Granted
Canceled
Forfeited
Outstanding at December 31, 2022		159,295		$	153.35		6.5	$	26,188
Forfeited		(1,516	)	$	196.86		-
Outstanding at June 30, 2023		157,779		$	157.47		6.0	$	-

Exercisable at June 30, 2023		142,884		$	167.85		5.7	$	-

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at December 21, 2022		10,483		$	82.02
Vested		(3,344	)	$	104.04
Unvested at June 30, 2023		7,139		$	71.68

	Shares Underlying Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value		Shares Underlying Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding at December 31, 2022		461,066		$	44.88		4.5	$	-		461,066		$	44.88		4.5	$	-
Issued		1,405,797		$	11.42		4.7				1,405,797		$	11.42		4.6		-
Exercised		(106,768	)	$	19.20		-				(106,768	)	$	19.20		-		-
Outstanding at June 30, 2023		1,760,095		$	18.96		4.7	$	-
Outstanding at September 30, 2023											1,760,095		$	18.96		4.4	$	-

●	~~Months 1-12~~	-	~~$18,375~~
●	~~Months 13-24~~	-	~~$19,018~~
●	~~Months 25-36~~	-	~~$19,683~~
●	~~Months 37-39~~	-	~~$20,372~~

	Operating
	Leases
Six months ended December 31, 2023	$	392
Year ended December 31, 2024		405
Year ended December 31, 2025		194
Year ended December 31, 2026		100
Year ended December 31, 2027		9
Total		1,100
Less present value discount		(261	)
Operating lease liabilities	$	839

	Operating
	Leases
Three months ended December 31, 2023	$	133
Year ended December 31, 2024		417
Year ended December 31, 2025		194
Year ended December 31, 2026		100
Year ended December 31, 2027		9
Total		853
Less present value discount		(113	)
Operating lease liabilities	$	740

	Three Months Ended									Nine months Ended
	September 30,									September 30,
	2023			2022			Change			2023			2022			Change
Revenue	$	-		$	-		$	-		$	59		$	-		$	59
Cost of revenue		-			-			-			54			-			54
Gross profit		-			-			-			5			-			5

Operating expenses:
Research and development		492			955			(463	)		1,523			3,523			(2,000	)
Selling, general and administrative		2,941			2,160			781			10,926			8,634			2,292
Total operating expense		3,433			3,115			318			12,449			12,157			292

Loss from operations		(3,433	)		(3,115	)		(318	)		(12,444	)		(12,157	)		(287	)

Other income (expense)
Interest expense		(2,445	)		(1	)		(2,444	)		(6,970	)		(6	)		(6,964	)
Loss on extinguishment of warrant liability		-			-			-			(504	)		-			(504	)
Loss on extinguishment of debt		-			-			-			(2,345	)		-			(2,345	)
Gain on issuance of convertible notes		-			-			-			64			-			64
Change in fair value of warrants		2,688			-			2,688			10,424			-			10,424
Change in fair value of notes		(40	)		-			(40	)		(7,040	)		-			(7,040	)
Change in fair value of derivative liability		401						401			401						401
Other expense		(30	)		-			(30	)		(1,264	)		-			(1,264	)
Total other income (expense)		574			(1	)		575			(7,234	)		(6	)		(7,228	)

Loss before income taxes		(2,859	)		(3,116	)		257			(19,678	)		(12,163	)		(7,515	)

Net loss	$	(2,859	)	$	(3,116	)	$	257		$	(19,678	)	$	(12,163	)	$	(7,515	)

	Three Months Ended									Six Months Ended
	June 30,									June 30,
	2023			2022			Change			2023			2022			Change
Revenue	$	37		$	-		$	37		$	59		$	-		$	59
Cost of revenue		23			-			23			54			-			54
Gross profit		14			-			14			5			-			5

Research and development		490			1,473			(983	)		1,031			2,568			(1,537	)
Selling, general and administrative		4,409			3,002			1,407			7,985			6,474			1,511
Other (income) expense		9,634			2			9,632			7,808			5			7,803
Net loss	$	(14,519	)	$	(4,477	)	$	10,042		$	(16,819	)	$	(9,047	)	$	7,772

3.1		Certificate of Amendment to Certificate of Incorporation, as amended, filed with the Secretary of State of Delaware (incorporated by reference to Exhibit 3.1 to the registrant’s Form 8-K filed on June 15, 2023).
3.2		Series F-1 Certificate of Designations filed with the Secretary of State of Delaware (incorporated by reference to Exhibit 3.2 to the registrant’s Form 8-K filed on June 15, 2023).
3.3		Series F-2 Certificate of Designations filed with the Secretary of State of Delaware (incorporated by reference to Exhibit 3.3 to the registrant’s Form 8-K filed on June 15, 2023).
3.4		Certificate of Amendment to Amended and Restated Certificate of Incorporation, as amended, filed with the Secretary of State of Delaware on August 11, 2023 (incorporated by reference to Exhibit 3.1 to the registrant’s Form 8-K filed on August 14, 2023).
4.1		Form of Warrant (incorporated by reference to Exhibit 4.1 to the registrant’s Form 8-K filed on June 15, 2023).
4.2		Form of F-2 Warrant (incorporated by reference to Exhibit 4.2 to the registrant’s Form 8-K filed on June 15, 2023).
10.1		Form of Inducement Agreement by and between the Company and the October Investors (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on May 18, 2023).
10.2		Form of LOC Note Amendment by and between the Company and Eleven Advisors LLC (incorporated by reference to Exhibit 10.2 to the registrant’s Form 8-K filed on May 18, 2023).
10.3		Form of Demand Note issued by the Company to the Holder (incorporated by reference to Exhibit 10.3 to the registrant’s Form 8-K filed on May 18, 2023).
10.4		Form of Demand Note issued to the Company to the Demand Holders (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on June 6, 2023).
10.5		Form of May Note issued by the Company to the May Holder (incorporated by reference to Exhibit 10.2 to the registrant’s Form 8-K filed on June 6, 2023).
10.6		Form of Securities Purchase Agreement, dated June 13, 2023, between the Company and the Purchasers (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on June 15, 2023).
10.7		Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the registrant’s Form 8-K filed on June 15, 2023).
10.8		Form of Securities Purchase Agreement, dated June 14, 2023, between the Company and the F-2 Purchasers (incorporated by reference to Exhibit 10.3 to the registrant’s Form 8-K filed on June 15, 2023).
10.9		Forbearance Agreement by and between the Company and a January Investor, dated July 10, 2023 (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on July 14 2023).
10.10		First Amendment to Forbearance Agreement by and between the Company and a January Investor, dated July 14, 2023 (incorporated by reference to Exhibit 10.2 to the registrant’s Form 8-K filed on July 14 2023).
10.11		Common Stock Purchase Agreement by and between the Company and the ELOC Purchaser, dated July 20, 2023 (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on July 24, 2023).
10.12		Registration Rights Agreement by and between the Company and the ELOC Purchaser, dated July 20, 2023 (incorporated by reference to Exhibit 10.2 to the registrant’s Form 8-K filed on July 24, 2023).
10.13		Exchange Agreement by and between the Company and a January Investor, dated August 2, 2023 (incorporated by reference to Exhibit 10.1 to the registrant’s Form 8-K filed on August 7, 2023).
31.1		Certification of the Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of the Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certifications of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certifications of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

	Crown Electrokinetics Corp.

Dated: ~~August 24,~~November 14, 2023	/s/ Doug Croxall
	Doug Croxall
	Chief Executive Officer and
	Principal Executive Officer

Dated: ~~August 24,~~November 14, 2023	/s/ Joel Krutz
	Joel Krutz
	Chief Financial Officer and
	Principal Financial Officer